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Resumen - Abstract  
   
  
La Deficiencia de Adhesión Leucocitaria Tipo I (DAL-I) es una inmunodeficiencia primaria 
producida por mutaciones en el gen ITGB2, que codifica para la proteína CD18 o subunidad β2. Esta 
proteína se asocia con diferentes subunidades CD11 para formar las integrinas β2, las cuales se 
expresan en la membrana de los leucocitos y les permiten adherirse al endotelio como paso previo a la 
extravasación. Las mutaciones en el gen ITGB2 producen una reducida, ausente o aberrante expresión 
de CD18, lo que se traduce en la ausencia de integrinas β2 en la membrana leucocitaria. Los leucocitos 
de estos pacientes, principalmente los neutrófilos, son incapaces de abandonar el torrente sanguíneo y 
combatir las infecciones que se producen en los diferentes tejidos. Así, estos pacientes sufren 
infecciones bacterianas graves y recurrentes que pueden conducir a su muerte. 
En la presente tesis doctoral nos propusimos inicialmente caracterizar una cepa de ratón que 
presenta una mutación hipomórfica en el gen itgb2 (CD18HYP) para su posterior uso como modelo 
animal de DAL-I. Estos ratones mostraban una expresión baja pero detectable de integrinas β2 en 
células linfoides y mieloides y presentaban leucocitosis y defectos en la migración de neutrófilos en 
respuesta a agentes inflamatorios. Sorprendentemente, la médula ósea (MO) de estos ratones 
presentaba un mayor contenido de células madre hematopoyéticas (CMHs). Además, las células de MO 
de los ratones CD18HYP presentaban una mayor capacidad de repoblación competitiva que las de un 
ratón WT. A través de diferentes experimentos in vivo observamos que la ausencia de CD18 conduce a 
la expansión del compartimento de CMHs incluso en presencia de un ambiente hematopoyético WT, lo 
que demuestra por primera vez el papel de CD18 en la regulación del nicho hematopoyético. 
Al tratarse de una enfermedad hematopoyética monogénica, DAL-I es una enfermedad idónea 
para ser tratada mediante terapia génica (TG) ex vivo. Por ello, generamos cuatro vectores lentivirales 
(VLs) autoinactivantes en los que la expresión del gen ITGB2 está controlada por diferentes promotores, 
tanto ubicuos (PGK y UCOE) como mieloides (Chim y MIM). Estos VLs demostraron su eficacia para 
recuperar la expresión de integrinas β2 y corregir el fenotipo en dos modelos in vitro: una línea 
linfoblastoide derivada de un paciente con DAL-I y CMHs sanas interferidas para la expresión de CD18 
(mediante la utilización de un VL que expresa un RNAsh capaz de reconocer el RNAm de CD18).   
Finalmente, pasamos a realizar experimentos de TG ex vivo en los ratones CD18HYP. Los ratones 
tratados por TG presentaban células en sangre periférica y en MO que expresaban la proteína humana 
CD18 (hCD18). Además, estas células presentaban una mayor expresión de la proteína endógena CD11a 
(mCD11a) en comparación con ratones no tratados, lo que indicaba que la expresión ectópica de hCD18 
rescataba la expresión de las integrinas β2 de ratón. La expresión de hCD18 en todos los grupos tratados 
siempre fue mayor en neutrófilos que en linfocitos, aunque fueron aquellos ratones tratados con el 
vector LV:Chim.hCD18 en los que el ratio entre la expresión mieloide y la expresión linfoide fue mayor. 
Al retransplantar la MO de estos ratones, se observaron células hCD18+ con expresión incrementada de 
mCD11a en los receptores secundarios, lo que indicaba que los VLs-hCD18 eran capaces de transducir 
CMHs con capacidad de repoblación a largo plazo. La recuperación de valores normales de leucocitos 
en la sangre y el restablecimiento de la capacidad de extravasación de los neutrófilos corroboraron la 
eficacia terapéutica de estos vectores. 
 Aunque se obtuvieron resultados muy similares con todos los VLs, el promotor ideal para la TG 
de DAL-I sería aquel que expresase hCD18 en todas las células hematopoyéticas y que dirija una alta 
expresión en el linaje mieloide, puesto que es el tipo celular más afectado por la deficiencia en esta 
proteína. Por eso, y en base a los resultados obtenidos, proponemos el uso del vector LV.Chim.hCD18 
para un futuro ensayo de terapia génica en pacientes con DAL-I.  
  
Leukocyte Adhesion Deficiency Type I (LAD-I) is a primary immunodeficiency caused by 
mutations in ITGB2 gene, encoding for CD18 protein (also known as β2 subunit). This protein binds to 
different CD11 subunits to form β2 integrins, which are expressed in the leukocyte membrane and allow 
leukocytes to firmly adhere to the endothelium as a previous step to the extravasation. In LAD-I 
patients, ITGB2 mutations lead to absent, low or aberrant CD18 expression, which results in absent or 
low β2 integrin expression on the leukocyte membrane. CD18 deficient leukocytes, especially 
neutrophils, fail to extravasate from the bloodstream to infected tissues. LAD-I patients suffer from 
recurrent and severe infections leading normally to death. 
In the present doctoral thesis, we initially aimed to characterize a mouse strain presenting an 
hypomorphic mutation in the itgb2 gene (CD18HYP), which would be later used as a LAD-I animal model. 
These mice displayed low but still present β2 integrin expression in lymphoid and myeloid cells and 
showed leukocytosis and defects in neutrophil extravasation capacity in response to different 
inflammatory stimuli. Surprisingly, CD18HYP bone marrow (BM) showed enrichment in haematopoietic 
stem cells (HSCs). Moreover, BM cells from CD18HYP mice presented a higher competitive repopulation 
ability compared to WT cells. Through different in vivo experiments, we demonstrated that CD18 
deficiency lead to the expansion of HSCs even in the presence of a WT haematopoietic environment, 
which pointed out the role of CD18 in the regulation of the haematopoietic niche for the first time. 
As a monogenic haematopoietic disorder, LAD-I is a good candidate for ex vivo haematopoietic 
gene therapy (GT). For this, we generated four lentiviral vectors (LVs) in which ITGB2 gene is expressed 
under ubiquitous (UCOE and PGK) or myeloid (Chim and MIM) promoters. These LVs succeeded in the 
CD18 expression and phenotype restoration in two different in vitro models: a lymphoblastic cell line 
derived from a LAD-I patient and in CD18-interferred healthy HSCs (generated by the use of a LV 
expressing a shRNA against the CD18 mRNA). 
Finally, we carried our GT experiments in CD18HYP mice. GT-treated CD18HYP mice showed 
peripheral blood and BM cells expressing hCD18 protein, which in addition showed higher expression of 
mCD11a subunit in comparison with untreated mice. This indicated that ectopic hCD18 expression 
restores murine β2 integrins. hCD18 expression was always higher in myeloid than in lymphoid cells in 
all treated groups, although LV.Chim.hCD18-treated animals showed the highest ratio between myeloid 
and lymphoid expression. When BM from these animals was re-transplanted into secondary recipients, 
hCD18+ cells with increased mCD11a expression could be observed, indicating that all CD18-LVs were 
able to transduce true and long-term HSCs. The recovery of normal number of leukocytes and the 
reestablishment of inflammation-mediated neutrophil extravasation capacity supported the 
therapeutic effect of these LVs 
Although similar results were obtained with all the hCD18-LVs, the ideal promoter for the GT of 
LAD-I would be the one driving a high expression of CD18 in the myeloid lineage but also expressing at a 
low level in other haematopoietic cells. For this reason, and on the basis of these results, we propose 
the use of LV.Chim.hCD18 for a future LAD-I GT clinical trial. 
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 Hypomorphic CD18 mice 
CD18
KO
 Null CD18 mice 
cDNA Complementary DNA 
CDS Coding DNA sequence 
CFU Colony forming unit 
CGD Chronic granulomatous disease 
CLAD Canine leukocyte adhesion deficiency 
CMC  Carboxymethylcellulose 
CMH Célula madre hematopoyética 
CMP Common myeloid progenitor 
cPPT Central polipurine tract 
CR Complement receptor 
CRA Competitive repopulation assay 
Ct Cycle threshold values 
CXCL12 C-X-C motif ligand 12 
DAG Diacylglycerol 
DAL-I Deficiencia de adhesión leucocitaria tipo I 
DiD 2-[5-(3,3-dimethyl-1-octadecyl-1,3-dihydro-2H-indol-2-ylidene)penta-1,3-dien-1-
yl]-3,3-dimethyl-1-octadecyl-3H-indolium perchlorate 
DOCK2 Dedicator of cytokinesis 2 
ECM Extracellular matrix 
EF1α  Elongation factor 1 alpha 
ESL-1 E-Selectin ligand 1 
Fc Fragment crystallizable 
FcR Fc Receptor 
FIS Foamyviral insertion site 
Flt3L  FMS-like tyrosine kinase 3 ligand 
FV Foamyviral vector 
GALV Gibbon ape leukaemia virus 
G-CSF Granulocyte colony-stimulating factor 
gDNA  Genomic DNA 
GEF Guanine-nucleotide-exchange factor 
GMP Granulocyte/monocytic progenitor 
GOI Gene of interest 
GT Gene therapy 
h  Human 
HEK Human embryonic kidney 
HIV-1 Human immunodeficiency virus type 1 
HSC Haematopoietic stem cell 
HSCT Haematopoietic stem cell transplantation  
HUVEC Human umbilical vein endothelial cells 
iC3b Inactive complement component 3b 
ICAM Intercellular adhesion molecule 
IP3 Inositol triphosphate 
JAM Junctional adhesion molecule 
LAC Leukocyte adhesion cascade 
LAD Leukocyte adhesion deficiency 
LCL Lymphoblastoid cell line 
LDA Limiting dilution assay 
LFA-1 Lymphocyte function-associated antigen 1 
Lin
-
 Lineage negative 
LSK Lin
-
Sca
+
Ckit
+
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LT-HSC Long-Term haematopoietic stem cell 
LV Lentiviral vector 
m Murine 
Mac-1 Macrophage 1 antigen 
MACS Magnetic-activated cell sorting 
MDS Myelodysplastic syndrome 
MEP Megakaryotic/erythroid progenitor 
MFI  Mean fluorescent intensity 
MIDAS Metal-ion-dependent adhesion site 
miRNA Micro RNA 
MLD Metachromatic leukodystrophy 
MOI Multiplicity of infection 
MPP Multipotent progenitor 
MSCV Murine stem cell virus 
NK Natural killer 
O/N  Overnight 
P/S Penicillin/Streptomycin 
PB Peripheral blood 
PBE PBS with BSA and EDTA 
PBL Peripheral blood leukocyte 
PBS Primer binding site 
PECAM1  Platelet endothelial cell adhesion molecule 
PGK  Phosphoglycerate kinase 
PID Primary immunodeficiency 
PLC Phospoholipase C 
PMA  Phorbol 12-myristate 13-acetate 
PPT Polypurine tract 
PSGL-1 P-selectin glycoprotein ligand-1 
Q-PCR Quantitative PCR 
Rap1 Ras-related protein 1 
RIAM1 Rap1 GTP-interacting adaptor molecule 
RIC Reduced intensity conditioning 
RIS Retroviral insertion site 
RISC RNA Induced Silencing Complex 
RN Retronectin 
RRE Rev responsive element 
SAE Serious adverse effect 
SCF Stem cell factor 
shSCR Scrambled shRNA 
sICAM-1 Soluble ICAM-1 
SIN Self-Inactivating 
SRC SCID Repopulating Cells 
ST-HSC Short-term haematopoietic stem cell 
T-ALL  T-cell acute lymphoblastic leukaemia 
TBI Total body irradiation 
TCR  T Cell receptor 
TG Terapia génica 
TPO Thrombopoietin 
VCAM1 Vascular cell adhesion molecule 1 
VCN  Vector copy number 
VL Vector lentiviral 
VLA-4 Very late antigen-4 
VSV-G  Glycoprotein of the vesicular stomatitis virus 
WAS Wiskott-Aldrich syndrome 
wPRE Post-transcriptional regulatory element of the Woodchuck hepatitis B virus 
wPRE* Mutated wPRE 
X-SCID X-linked SCID 
γRV γ-retroviral vector 
ΔhCD4 Truncated human CD4 
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1. Haematopoietic system 
The haematopoietic system is responsible for the production, maturation and recycling of the 
cellular components of blood. The organs and tissues of the haematopoietic system include blood, bone 
marrow (BM), liver, spleen, thymus, lymph nodes and accessory lymphoid tissues.  
Blood cells belong to two main lineages: lymphoid and myeloid. The lymphoid lineage consists 
of T, B, and natural killer (NK) cells, which perform adaptive and innate immune responses. The myeloid 
lineage includes very different cell types including granulocytes (neutrophils, eosinophils, mast cells, 
and basophils), monocytes, erythrocytes, and megakaryocytes/platelets; which play many different 
roles including innate immune response, oxygen transport and haemostasis. 
Blood is one of the most highly regenerative tissues, with around one trillion mature cells being 
produced daily in adult human BM. Location of haematopoiesis changes throughout development, from 
the aorta-gonad-mesonephros1 to foetal liver, spleen and finally to BM2,3.  Haematopoiesis is mainly 
supported by the BM in healthy human adults, while spleen significantly contributes to the 
haematopoiesis in mice4,5.  
1.1. Organization of the haematopoiesis 
Haematopoiesis follows a hierarchical organization as can be observed in Figure 1, where a 
small number of very primitive cells are able to generate a huge number of different mature cells. 
The haematopoietic stem cells (HSCs) are the most primitive cells in the haematopoietic system 
and support all the haematopoiesis. As stem cells, they are characterized by their ability to generate 
different cell types (multipotency) and by their capability to self-renew.  
The haematopoietic committed progenitors arise from the HSCs, but they have different 
properties: They have a higher proliferation activity than HSCs at the expense of having a reduced 
ability of self-renewal, and they are committed to produce a limited number of cell types.  
Finally, cells with a recognizable morphology, either cells in maturation or mature and 
functional cells, complete the pyramid. These cells present a low or null capacity of proliferation and 
self-renewal, but carry out a variety of functions including immune defence, nutrient transport and 
blood clotting among others. 
Haematopoiesis has to be tightly regulated since the requirements of the production of each 
cell type could change. This regulation is dependent on exogenous factors (endocrine and paracrine 
soluble mediators), cell-cell interactions with different components of the haematopoietic niche and 
neuroendocrine factors released by the nerve endings innervating the BM. On the other hand, there is 
an important regulation dependent on intrinsic factors of the HSCs like the greater or lesser expression 
of different transcription factors or epigenetic modifications6. 
1.2. Haematopoietic stem cells in mice 
Mouse haematopoietic progenitors are defined as a heterogeneous population with short and 
long-term repopulation ability that do not express typical lineage markers expressed by blood cells so 
they are often defined as lineage negative (lin-) cells. The Lin- cell fraction contains a population of cells 
expressing Sca1 and c-kit markers known as LSK (Lin-, Sca1+ and c-Kit+) cells corresponding to the true 
mouse HSCs. The LSK population represents a very low percentage of the BM cellularity, and only 100 
LSK cells are sufficient to repopulate all the lineages of a mouse in the long term4,7. Additional markers 
can be used to define 3 different subpopulations of LSK cells8: 
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• Haematopoietic stem cells with the ability of self-renewal in the long-term (LT-HSC; 
LSK/Flk2−/CD34−/CD150+) 
• Haematopoietic stem cells with the ability of self-renewal in the short-term (ST-HSC; 
LSK/Flk2−/CD34+/CD150-) 
• Multipotent progenitors (MPP; LSK/IL7Rα−/ Flk2+), which no longer possess self-renewal 
ability yet keeping full-lineage differentiation potential. 
1.3. Haematopoietic stem cells in humans 
Xenotransplant models, where human cells are transplanted into immunodeficient mice, are 
typically used to define human HSCs. Human cells with the capacity to reconstitute a multilineage 
haematopoiesis in SCID mice are called SCID repopulating cells (SRCs)9,10. The CD34 marker was defined 
as a very important indicator of these SRCs11,12. Subsequent studies have identified other populations 
with higher SRC capacity, CD34+CD38- and lin-CD34+CD38- cells13, the latter being the more primitive 
among all of them. A more in-depth study identified two populations of cells with SRC capacity: cells 
with capacity to repopulate in the short term (short term SRCs) or in the long term (long term SRCs)14. 
 
Figure 1. Current models of the haematopoietic system and lineage determination in the adult mouse and human. Modified 
from Doulatov et al
15
. 
1.4. Haematopoietic stem cells niche 
The BM microenvironment appears to be uniquely adapted to support key properties of HSCs 
like multipotency, self-renewal and quiescence. The hypothesis of the HSC niche was first proposed by 
Schofield16 and suggested that specialized niche cells in the BM are physically associated with HSCs and 
provide specific signals that help to maintain their function. Cell components of this HSC niche can be 
from haematopoietic and non-haematopoietic origin. A general model for the murine HSC niche (Figure 
2) has been recently established supporting a perivascular location for most HSCs, with a preference for 
the endosteal region. Key components of the perivascular niche comprise endothelial cells, 
mesenchymal stromal cells and C-X-C motif Ligand 12 (CXCL12) expressing stromal cells, including 
CXCL12-abundant reticular (CAR) cells, leptin receptor+ cells and nestin-GFP+ cells17. All these cells 
provide signals, including CXCL12, Stem Cell Factor (SCF), and angiopoietin, that maintain the HSC 
function.  
Monocytes/macrophages in the BM provide signals that support CXCL12 production from BM 
stromal cells and possibly act directly upon HSCs.  Recently it has been described that circadian rhythms 
of neutrophil release from and migration back to the BM are able to modulate HSC niche. PB aged 
neutrophils (Ly6G+/CD62-/CXCR4Low) migrate back to the BM where they are engulfed by BM-resident 
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macrophages. This process finally results in a reduction of the number of CAR cells and in the levels of 
CXCL1218.  
All these cellular components can also be regulated by physiological stimuli, such as 
sympathetic innervation, circadian rhythms and hormonal signals19. 
  
Figure 2. General Model for the mouse HSCs niche. Modified from Anthony et al17. 
2. Leukocyte adhesion cascade 
Leukocytes or white blood cells are the cells of the immune system involved in defending the 
body against both infectious diseases and foreign materials. Leukocytes are classified into different 
groups according to morphological characteristics: granulocytes or polimorphonuclear leukocytes 
(including neutrophils, basophils and eosinophils) and agranulocytes or mononuclear leukocytes 
(including lymphocytes and monocytes). Leukocytes normally circulate in the blood but carry out most 
of their immune functions in tissues. Thus, leukocytes have to extravasate from circulation towards the 
site of tissue damage or infection in a multistep process known as leukocyte adhesion cascade (LAC) 
that is very similar for the different leukocyte subpopulations. In an inflammatory setting, recruitment 
of leukocytes occurs mainly in postcapillary venules beneath low haemodynamic shear forces. LAC 
implicates a large variety of cell-cell and cell-extracellular matrix (ECM) interactions. These interactions 
are mediated by a group of proteins known as adhesion molecules and their specific ligands. Integrins 
are some of these important adhesion molecules.  
2.1. Integrins 
Integrins are heterodimeric adhesion molecules that mediate cell-cell and cell-ECM interactions 
and also induce bidirectional signalling across the cell membrane. They are involved in important 
processes like immunity, wound healing and haemostasis and are able to regulate cell proliferation, 
activation, migration and homeostasis20,21. 
2.1.1. Structure 
Twenty four different integrins can be found in humans and mice. They are formed by specific 
non-covalent associations of eighteen different α subunits and eight different β subunits (Figure 3). 
Both α and β subunits have a large extracellular region, a transmembrane domain and a short 
cytoplasmic tail. Nine of the eighteen α subunits contain an inserted or I domain with a Rossmann 
nucleotide-binding fold22. It is also known as αA domain because of its homology with the A domain of 
von Willebrand factor23. β subunits also contain an I-like domain (also known as βA domain) and their 
cytoplasmic tails share sequence homology (except for β4 and β8 subunits) including two very preserved 
NxxY/F motifs (where x could be any other amino-acid).  
10 │ INTRODUCTION 
 Integrins contain many different ion-binding sites because adhesion processes are dependent 
on bivalent cations. A metal-ion-dependent adhesion site (MIDAS) can be found in α subunits and it is 
the primary ligand-binding site in those integrins that contain an αA domain. Three different sites for 
ion-binding sites can be found in the βA domain of the β subunits. A pocket formed by these sites and 
the β-propeller of α subunits represents the major ligand-binding site in those integrins lacking the αA 
domain.   
 
Figure 3. Integrins as a model of adhesion molecules. A) Combinatory scheme of human and mouse integrins. β subunits 
appear as dark blue circles and α subunits are represented as light blue circles. The lines represent the heterodimerization of 
an α and a β subunit to form an integrin. B) Conformational changes during integrin activation. Modified from Tan
24
. 
2.1.2. Signalling and conformational changes 
Integrins transmit signals bidirectionally. They are able to respond to both intracellular and 
extracellular stimuli with conformational changes in their structure. Intracellular signals start the inside-
out signalling leading to the activation of the integrins. When integrins are activated, they are able to 
recognize and bind their ligands. Ligand binding induce structural changes or clustering of integrins 
initiating different intracellular signalling cascades (outside-in signalling). This way cells are capable to 
sense the extracellular environment and react correspondingly25. 
A general model of the integrins activation is described in Figure 3 (Panel B). In their basal state, 
the extracellular region of the integrins adopts a bent conformation while cytoplasmic tails and 
transmembrane domains are strongly attached. The joining of a cytosolic activator results in the 
disruption of that attachment, allowing the extension of the extracellular regions. In this extended 
conformation, the headpiece is still closed and shows intermediate-affinity for the specific ligand. 
Tensile forces exerted by the cytoskeleton on the intracellular domain produce conformational changes 
along the entire length of the integrin thus integrins adopt the high-affinity ligand-binding 
conformation24. 
2.1.3. β2 integrins  
The β2 integrins are those formed by the β2 subunit and different I domain-containing α 
subunits. Its expression is restricted to the haematopoietic system. This integrin subfamily includes four 
members, with different patterns of expression and functions (Table 1) 
All types of leukocytes express lymphocyte function-associated antigen 1 (LFA-1) on their 
surface. Six ligands have been described for integrin LFA-1, all belonging to the immunoglobulin 
superfamily. LFA-1 has been shown to bind its ligands through a conserved glutamate residue with 
different affinity for each one depending on the presence of different numbers of hydrophilic residues 
surrounding the acidic glutamate residue24. LFA-1 is mainly involved in the LAC, where its activation and 
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transition to the high affinity state allow its binding to intercellular adhesion molecule (ICAM) ligands 
and thus, the leukocyte firm adhesion to the endothelium. Transendothelial migration is also 
dependent on the interactions between LFA1 and endothelial ICAM-1 and junctional adhesion molecule 
1 (JAM-1). LFA-1 is also involved in immune synapse formation between T cells and antigen-presenting 
cells (APCs). It is essential for maintaining a sustained contact between naïve T cells and APCs and for 
lowering the threshold of T cell activation by inducing a high level phosphorylation of ERK1/2 and IL-2 
production in naïve T cells. Additional functions of LFA-1 include the mediation of cytolitic functions of 
cytotoxic T cells and NK cells. 
Macrophage-1 antigen (Mac-1) binds a variety of ligands that do not share canonical binding 
sequences. This may be attributed to ligand-binding sites other than its αA domain24. It is mainly 
expressed in the myeloid lineage, where it mediates a range of functions like phagocytosis, degradation 
and remodelling of the ECM. Neutrophils use LFA-1 to attach to the vasculature and Mac-1 to crawl to 
an endothelial junction thus eventually leading to migration26. Mac-1-mediated outside-in signalling 
regulate neutrophil survival and apoptosis. Finally, Mac-1 has been implicated in immune tolerance in 
macrophages, dendritic cells and NK cells.  
Integrin p150,95 shares many ligands with Mac-1. It is expressed in myeloid cells, dendritic cells, 
NK cells and populations of activated T and B cells. The differential expression of p150,95 serves as a 
marker to distinguish mature from immature dendritic cells. It also mediates phagocytosis of inactive 
complement component 3b (iC3b)-opsonized particles and it is involved in the adhesion of monocytes 
to endothelial cells. 
Integrin αDβ2 is expressed at a basal level on the surface of most leukocytes and it is upregulated 
on phagocytic leukocytes present in regions of local inflammation. Although its specific role on 
leukocyte function remains unknown, αDβ2 has been implicated in eosinophil, neutrophil, and 
macrophage activation, lung inflammation, T cell proliferation and leukocyte infiltration into inflamed 
tissues27,28.  
Integrin β subunit α subunit Ligands Expression Pattern 
LFA-1 
β2-CD18 
(ITGB2 
gene) 
αL-CD11a 
(ITGAL gene) 
ICAM1-5, JAM-1, Type I collagen 
T cell, B cell, 
monocyte/macrophages, NK cell, 
dendritic cell, neutrophil, 
eosinophil 
Mac-1 
(CR3) 
αM-CD11b 
(ITGAM gene) 
ICAM1, ICAM2, ICAM4, iC3b, fibrinogen, 
factor X, heparin, laminin, LPS, zymosan, 
oligodexosynucleotide, collagen, ellastase 
Monocyte/macrophages, NK cell, 
neutrophil, eosinophil 
p150.95 
(CR4) 
αX-CD11c 
(ITGAX gene) 
C3bi, fibrinogen, collagen, CD23, heparin, 
LPS 
Monocyte/macrophage, 
neutrophil, NK cell, dendritic cell 
αDβ2 
αD-CD11d 
(ITGAD gene) 
ICAM3, VCAM1 
Monocytes/macrophages, 
eosinophils, 
neutrophils 
Table 1. The β2 subfamily of integrins: names, location and ligands. LFA-1 (Lymphocyte function-associated antigen 1), Mac-1 
(Macrophage-1 antigen), CR (Complement receptor), ICAM (Intercellular adhesion molecule), JAM-1 (Junctional adhesion 
molecule 1), C3bi (Inactive complement component 3b), VCAM1 (Vascular cell adhesion molecule 1). Modified from Tan
29
. 
2.2. Phases of leukocyte adhesion cascade 
The LAC (Figure 4) starts with the capture and rolling of free flowing leukocytes on the 
endothelium, which is mediated by the interaction between selectins and their glycosylated ligands. 
This initial contact slows down the velocity of the leukocytes and exposes them to signals coming from 
the inflamed endothelium, finally resulting in full integrins activation and firm adhesion to their ligands 
expressed by endothelial cells. This is followed by post -arrest modifications of leukocytes including 
reorganization of their cytoskeleton, cell spreading and intraluminal crawling. These modifications are 
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important for finding the optimal spot to pass through the endothelial lining either via the paracellular 
(between cells) or, more rarely, via the transcellular route (through cells). 
 
Figure 4. Phases of the leukocyte adhesion cascade (LAC). 
2.2.1. Rolling 
Leukocyte initial capture and rolling on the endothelium are mediated by the interaction 
between selectins and their glycosylated ligands. During this initial contact between endothelium and 
leukocytes, there is a continuous binding and release between selectins and their counter ligands30,31. 
Three members of the selectin family have been reported with different locations and functions. P-
selectin is stored in Webel-Palade bodies of endothelial cells and is exposed in the membrane when 
these granules fuse to the cell membrane after cell activation by different stimuli. E-Selectin is 
constitutively expressed in skin microvessels. However, its expression can be rapidly induced by 
inflammatory cytokines such as TNFα and IL1b on endothelial cells. Basal levels of L-Selectin are 
expressed in most leukocytes. While E- and P-Selectin expressed by endothelial cells are considered as 
the most important rolling molecules, L-selectin is important for the lymphocyte homing to secondary 
lymphatic tissues30. 
Selectins are members of the C-type lectin family. As other members of this family, they are 
able to bind specific carbohydrate ligands. The minimal glycan determinant for selectin binding is Sialyl 
Lewis X, which can be found in different cell surface glycolipids and glycoproteins32. The best 
characterized ligand for selectins is P-selectin glycoprotein ligand-1 (PSGL-1), which is a mucin-type 
glycoprotein that can bind to all three selectins in an inflammatory environment. While P-Selectin 
interacts mainly with PSGL-1, E-Selectin has been shown to additionally use E-Selectin Ligand 1 (ESL-1) 
and CD44 as ligands. Selectin binding to PSGL-1 is critical for tethering and rolling of leukocytes on 
endothelial cells. In the case of E-Selectin, binding to PSGL-1 mediates initial leukocyte capturing while 
binding to ESL-1 and CD44 facilitates the characteristic E-selectin-mediated slow rolling of 
leukocytes30,31. L-selectin directs the migration of naive and central memory T cells to lymph nodes 
through recognition of glycoproteins expressed on the luminal surface of high endothelial venules32. 
Besides mediating leukocyte firm adhesion, α4 integrins such as α4β1 (Very late antigen-4, VLA4) 
and α4β7 can mediate selectin-independent rolling. Although the role of LFA-1 and Mac-1 to mediate 
selectin-independent rolling is controversial, LFA-1 in its intermediate affinity conformation has been 
shown to be able to slow down the velocity of leukocytes rolling on selectins30. 
2.2.2. Integrin activation and firm adhesion 
Integrins need to achieve a high-affinity ligand-binding state to mediate the leukocyte arrest 
and firm adhesion to the inflamed endothelium. During the rolling on the inflamed endothelium, 
chemokines, chemoattractants and selectin-initiated signaling pathways participates in fully integrin 
activation. The most relevant integrins for this process belong to the β1 and β2 integrin subfamilies, and, 
among them, the most studied are VLA-4 and LFA-1. These leukocyte integrins bind to immunoglobulin 
superfamily members such as vascular cell adhesion molecule 1 (VCAM-1) and ICAM-1, both expressed 
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by Inflammation-activated endothelial cells31  
Integrin activation (Figure 5) is initiated when chemokines bind to their counterpart G-protein-
coupled receptors leading to phospholipase C (PLC) activation and results in the cleavage of 
phosphatidylinositol 4,5-bisphosphate into inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 is a 
soluble mediator able to initiate intracellular Ca2+ release. Both Ca2+ and DAG are able to activate 
guanine-nucleotide-exchange factors (GEFs) which activate the small GTPase Ras-related protein 1 
(Rap1). Activated Rap1 forms a complex with Rap1 GTP-interacting adaptor molecule (RIAM1). RIAM1 
acts as a scaffold to connect the membrane targeting sequences in Rap1 to talin, thereby recruiting 
talin to the plasma membrane33. Talin is a large cytoskeletal protein that binds to the membrane 
proximal NxxY/F moiety in the β tail and disrupts the interaction between the α and the β chains. Thus, 
talins initiate conformational changes leading to integrin activation. Kindlins are proteins able to bind 
the membrane distal NxxY/F motif of the β tails and have been proposed to modulate talin-mediated 
activation although the mechanism is still not completely understood34. 
  
Figure 5. General mechanism for β2 integrin activation. 
2.2.3. Crawling and transendothelial migration 
Adherent leukocytes crawl to nearby endothelial borders seeking for preferred sites of 
transmigration. Neutrophils and Monocytes intraluminal crawling is mediated by Mac-1 and ICAM-1 
interactions35.  Transendothelial migration, also known as diapedesis, is the point of no return in the 
LAC. Leukocytes cross the endothelium at the cell borders (paracellular route) or directly through 
endothelial cells (transcellular route). In addition to the heterophilic interactions mediated by β1 and β2 
integrins and their ligands (ICAMs, VCAM-1 and JAMs), diapedesis requires homophilic adhesion of one 
leukocyte molecule interacting with the same molecule expressed by the endothelial cell. Among these 
molecules, platelet endothelial cell adhesion molecule (PECAM-1) and CD99 seem to be the most 
important36.  
3. Leukocyte adhesion deficiencies 
Defects in the LAC lead to a number of primary immunodeficiencies (PID) known as leukocyte 
adhesion deficiencies (LAD). In LAD patients, leukocytes are unable to extravasate from blood to the 
infection sites. They are classified as defects in the myeloid  function as neutrophils and monocytes are 
the most affected cells37. Three different types of LAD have been described according to which phase of 
the cascade is impaired. Table 2 summarizes the characteristics of each disease.  
3.1. LAD-I 
LAD-I is an autosomal recessive PID caused by the deficient cell surface expression of β2 
integrins. As a consequence neutrophils fail to firmly adhere to the inflamed endothelium. The 
PIP2
IP3 DAG
Ca2+
Rap1
Rap1
RIAM
Talin1
β
α
Kindlin3
Chemokines
GPCRs
PLC
GEF
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molecular basis underlying LAD-I are mutations in the ITGB2 gene located at 21q22.3 (OMIM*600065) 
that encodes the β2 common integrin subunit (CD18). More than 80 different mutations have been 
described in the ITGB2 gene in LAD-I patients38 including deletions, insertions, nonsense, splice site and 
missense mutations. Most of these mutations lead to null or reduced expression of β2 integrins in the 
leukocyte surface, although in some cases they can lead to an aberrant and non-functional CD18 
protein expressed at normal levels39. Although there is no hotspot for ITGB2 mutations, most of the 
point mutations take place within the 5 and 9 introns, which encode for the βA domain38. βA domain 
seems to be implicated in the association and successful biosynthesis of integrins before been 
transported to the membrane40. 
  LAD-I LAD-II LAD-III 
Aetiology 
Gene ITGB2 SLC35C1 FERMT3 
Protein CD18 SLC35C1 KINDLIN-3 
Phase of LAC Firm Adhesion Rolling Integrin Activation 
Clinical 
Manifestations 
Recurrent Severe Infections +++ + +++ 
Skin Infection ++ + ++ 
Delayed separation of the 
Umbilical cord 
+++ - +++ 
Periodontitis ++ ++ ? 
Developmental abnormalities - +++ -/? 
Bleeding tendency - - +++ 
Table 2. Principal Characteristics of the three Leukocyte adhesion deficiency syndromes. Modified from Eztioni40. 
Neutrophil adhesion defects are the functional abnormality responsible for the clinical picture in 
LAD-I patients, although β2 integrins are deficient in all of their leukocytes
41. This is likely because 
neutrophils are mainly dependent on the CD18 integrin expression for firm adhesion, while 
lymphocytes have redundant adhesion cascades42. CD18-deficient lymphocytes show decreased in vitro 
blastogenesis and proliferation. However, the clinical significance of these findings remains to be 
determined as LAD-I patients have no increased susceptibility to viral infections43. 
The severity of LAD-I is strictly related to the degree of CD18 deficiency40. Thus, two different 
phenotypes of LAD-I have been described according to the clinical manifestations and the levels of 
CD18 expression44: 
• Severe Phenotype, when levels of CD18 expression are <2% of the normal levels. 
• Moderate Phenotype, when levels of CD18 expression are 2-30% of the normal levels. 
LAD-I patients suffer from recurrent and life-threatening infections in the skin, mucosa surface 
and digestive and respiratory tracts, that are usually indolent and necrotic and tend to lead to 
secondary bacteraemia. These infections appear in the childhood, when omphalitis and delayed 
umbilical cord separation are also very characteristic. Absence of pus formation is considered as a 
pathognomonic symptom45,46. Staphylococcusaureus, Pseudomonas spp. and gram-negative 
enterobacteria are the microorganisms leading to most of the infections, although mycoses caused by 
Candida albicans are also frequent47,48. Those patients surviving till the adulthood normally develop 
severe gingivitis and periodontitis49.  Impaired healing of traumatic or surgical wounds is also very 
characteristic of LAD-I. These patients show moderate neutrophilia in the absence of apparent 
infections. As a consequence of acute infections, circulating granulocytes could reach levels of 105 / µL 
of blood45,46. Similar infections take place in patients with the moderate phenotype, although they are 
less frequent and severe39. 
3.1.1. Prevalence 
LAD-I is considered as a rare disease due to the limited number of patients that have been 
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diagnosed all over the world. There are no available data of prevalence for LAD-I. The following table 
(Table 3) summarizes the number of LAD-I patients that have been reported in the literature in different 
geographic areas. As other PIDs, LAD-I seems to be more prevalent in Africa and Middle East because of 
the high rate of consanguinity, which reach more than 50% in some places50,51. 
Area Organism Patients Observations 
USA Medscape <400 75% with severe phenotype 
Europe52 Orphanet <350  
South-America53 Latin American Group for PID 7 All patients were diagnosed in Argentina 
Iran54 Iranian PID Registry 37  
North-Africa55  33 
Patients were diagnosed for LAD, but not for which type 
of LAD 
India56  13 These patients were diagnosed in the same centre 
Table 3. Reported cases of LAD-I in different geographic areas.  
3.1.2. Diagnosis 
According to the current diagnostic criteria of the European Society for Immunodeficiencies, 
LAD-I should be suspected in those children with soft-tissues recurrent infections and increased white 
blood cell count, even more if there is delayed umbilical cord separation. LAD-I diagnosis has to be 
confirmed by the analysis of CD18 and CD11 subunits expression by flow cytometry, although definitive 
criteria is the determination of CD18 mRNA levels or the identification of ITGB2 mutations. Functional 
adhesion experiments are not necessary for the diagnosis and they are only performed for research57. 
Leukocytes express CD18 in their surface since week 20 of gestation allowing an early prenatal 
diagnosis in those families with a known history of LAD-I40. A procedure for preimplantation genetic 
diagnosis in human embryos generated by in vitro fertilization has been also developed 58. 
3.1.3. Treatment 
3.1.3.1. Symptomatic treatment 
Those patients with the moderate form of LAD-I normally respond to conservative therapy 
based on the immediate use of antibiotics during acute infectious episodes and surgical debridement of 
wounds. Prophylactic antibacterial and/or antifungal may be used to reduce the risk of infections40,59. 
Although granulocyte transfusions may be useful to treat infections otherwise unresponsive to 
antibiotherapy60, their use is limited because of difficulties in supply of daily donors and immune 
reactions to the allogeneic leukocytes40. 
3.1.3.2. Haematopoietic stem cell transplantation 
Allogeneic haematopoietic stem cell transplantation (HSCT) is the only curative treatment for 
LAD-I and should be considered early in the course of the disease in patients with severe LAD-I 
phenotype59. Four large retrospective or prospective studies have been reported so far regarding HSCT 
for LAD-I patients (Table 4).  
Time Period Number of centres Number of Patients Overall Survival Reference 
1981-1993 2 14 71% Thomas et al61 
1993-2007 14 36 75% Qasim et al62 
1991-2008 1 11 91% Al Dhekri et al51 
2007-2009 1 10 80% Hamidieh et al63 
Table 4. HSCT in LAD-I patients. 
From the published studies, a survival rate from 71 to 91 % can be achieved with HSCT in LAD-I 
patients. HLA-matched donors, both related or not, appear to be more suitable candidates for HSCT in 
LAD-I patients than haploidentical or mismatched related donors. The use of umbilical cord blood-
derived HSC from mismatched unrelated donors has been lately introduced but appears as a very 
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promising alternative for those patients without a suitable donor. Full donor chimerism is not required, 
as mixed chimerism seems to be sufficient to maintain patients free of disease. This is in concordance 
with results from HSCT in Canine Leukocyte Adhesion (CLAD) affected dogs, where a reduced number of 
CD18+ neutrophils is enough to correct the phenotype64-66. 
3.1.4. Somatic mosaicism 
Five cases of somatic mosaicism have been detected in LAD-I patients67-69. All these patients 
presented a small subpopulation of CD8+ T cells expressing normal levels of CD18. These cells presented 
revertant mutations leading to the WT sequence or to new functional CD18 variants. It remains unclear 
whether this revertant T cell population arises as a consequence of the survival of the patients into 
adulthood or, otherwise, it plays an active role in patient long-term survival. Furthermore, no 
reversions in progenitor or myeloid cells were observed suggesting that CD18 revertant mutations do 
not confer proliferative advantage outside the T-cell lineage. This phenomenon could be related to the 
role of LFA-1 as a costimulatory molecule during T-Cell Receptor (TCR)-mediated T cell activation70. 
Interestingly, it is very common the incidence of inflammatory bowel disease in this LAD-I mosaic 
patients69. 
3.1.5. LAD-I animal models 
3.1.5.1. Canine leukocyte adhesion deficiency  
CLAD is a lethal immunodeficiency typical of Irish (white and red) setter dogs. Symptoms appear 
from the early beginning, with omphalitis, following with severe and frequent bacterial infections 
accompanied by fever41,71. Afterwards, clinic progression is very homogenous with leukocytosis, severe 
gingivitis, lymphadenopathy, wound-healing delay and infectious episodes with pyrexia and cachexia. 
Skin lesions are also frequent in CLAD-affected dogs41.  
CLAD was first described in a dog with a clinical picture very similar to the one of LAD-I 
patients72. Flow cytometry analyses revealed an absent expression of CD18 and CD11b leukocyte 
integrins in the neutrophil surface73. Functional studies disclosed severe defects in adhesion-dependent 
functions of affected granulocytes. A mutation in the ITGB2 gene was lately discovered as the cause of 
CLAD74. All the studied dogs were homozygous for a point mutation in the ITGB2 gene (G107C) resulting 
in a substitution of a cysteine for a serine at position 36 (C36S) in the amino-terminal end of the CD18 
protein. This cysteine is highly conserved among different species (human, dog, pig and mice) and its 
substitution for a serine likely leads to the disruption of a disulphide bridge and the alteration of the 
tertiary structure abrogating the correct dimerization of CD18 and CD11 subunits41. 
3.1.5.2. LAD-I mouse models 
As mice with naturally occurring mutations in Itgb2 have not been described, two transgenic 
models have been generated. 
• Hypomorphic CD18 mouse model (CD18HYP) was generated by homologous recombination 
of an integration-type gene targeting vector containing a neomycin resistance cassette75. The plasmid 
was linearized and electroporated into embryonic stem cells. Although the intention was to produce a 
null mutation, the presence of a cryptic promoter derived from the plasmid backbone finally resulted in 
an hypomorphic mutation, leading to a decreased but not absent expression of CD18, resembling the 
characteristics of the moderate LAD-I phenotype. Homozygous mutant mice presented mild 
leukocytosis, minimal to mild hyperplasia in spleen and BM, impaired inflammatory response assessed 
using a chemical peritonitis model (thioglycollate intraperitoneal injection) and delayed transplantation 
rejection of allografted neonatal hearts. These mice were originally generated in a mixed background 
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C57BL6/J and 129/Sv and then backcrossed for more than 10 generations to the C57BL/6J inbred strain.  
• Null CD18 mouse model (CD18KO) was generated by homologous recombination using the 
same gene targeting vector. However, the vector was used as a replacement-type vector in this case76. 
These animals display a phenotype very close to that observed in patients with the severe form of LAD-
I: leukocytosis, spontaneous skin infections, impaired migration of neutrophils at infection sites and 
defective T cell function. 
Previous studies have shown enrichment of LSK cells in the BM of CD18KO mice77,78. Similarly, 
when CD18KO foetal liver cells were used in competitive transplant assays against WT foetal liver cells, 
the proportion of CD18KO haematopoietic cells in recipient mice was always higher than expected77,79. 
Although these studies suggested a role of CD18 in HSC regulation, this need to be deeply studied. 
3.1.5.3. Other models 
Bovine Leukocyte Adhesion Deficiency (BLAD) is the bovine analogue of human LAD-I that 
affects Holstein-Friesian cattle worldwide80. It is an autosomal recessive congenital disease 
characterized by recurrent bacterial infections, persistent neutrophilia, delayed wound healing and 
retarded growth. BLAD is caused by a single point mutation A383G in the ITGB2 gene, leading to the 
substitution of glycine for aspartic acid at 128 (D128G) in the CD18 protein. BLAD-affected calves have a 
severe deficiency in β2 integrin expression on the leukocytes surface and aberrations in several 
adherence dependent functions of leukocytes41. 
4. Ex vivo haematopoietic stem cell gene therapy 
Gene therapy (GT) and cell therapy are overlapping fields of biomedical research with the 
purpose of repairing the origin of genetic diseases or re-establishing the normal equilibrium in acquired 
diseases. GT is defined as the introduction of nucleic acids with the help of a vector into cells with the 
objective of modifying gene expression to prevent or reverse a specific disease. This new therapeutic 
approach can be carried out in three different ways: gene addition, gene correction/alteration and gene 
knockdown. On the other hand, cell therapy is based on the ability to isolate stem, progenitor or 
mature cells from a patient or a normal donor, expand them ex vivo and infuse them back into the 
patient to establish a short-lived or stable graft of the infused cells and their progeny.  
In many diseases, gene and cell therapy have been used in combination to develop promising 
therapies. The best example of this combination is the GT through autologous transplantation of gene-
modified HSCs. Thanks to the well-established knowledge and clinical application of HSCT, ex vivo gene 
transfer techniques have been applied to standard HSCT procedures and have reached rapid clinical 
translation. The key point of this combination of gene and cell therapy is that gene-modified autologous 
HSCs can be used for HSCT in the absence of a suitable donor for an allogeneic HSCT. Nowadays, 
autologous HSC GT represents an emerging therapeutic option for several monogenic diseases.  
 
Figure 6. GT through autologous transplantation of gene-modified HSCs. 
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The biology of HSCs makes them amenable to be isolated ex vivo, genetically modified and 
transplanted by intravenous infusion. Prior to transplantation, patients could be conditioned or not. 
Once genetically modified HSCs have engrafted the recipient BM, they can produce new blood cells of 
all lineages for the whole life of the recipient, producing a long lasting effect (Figure 6). Autologous HSC 
GT has been successfully used in clinical trials since the Nineties (Table 5). Haematological disorders are 
the main indication, but not the unique, of this promising therapeutic approach, including PIDs such as 
SCID due to adenosine deaminase deficiency (ADA-SCID), X-linked SCID (X-SCID), chronic granulomatous 
disease (CGD) and Wiskott-Aldrich syndrome (WAS); erythroid diseases like β-thalassemia and HSC 
diseases like Fanconi anaemia. Storage disorders like metachromatic leukodystrophy (MLD) and 
adrenoleukodystrophy (ALD) can be also treated by autologous HSC GT because of the ability of 
haematopoietic cells to deliver the therapeutic enzyme to the nervous system. 
 
Target 
Cells 
Treated 
Patients 
Vector SAE Efficacy 
Haematological disorders 
ADA-SCID81-83 
Lymphoid 
cells 
40 γ-RV expressing ADA None 
Long-term cure 
comparable to HSCT 
ADA-SCID84 
Lymphoid 
cells 
 
SIN LV expressing ADA 
from EF1α promoter 
- - 
X- SCID85,86 
Lymphoid 
cells 
24 γ-RV expressing IL2RG 
5 cases of T-
ALL 
Long-term cure 
comparable to HSCT 
X- SCID84,87 
Lymphoid 
cells 
9 
SIN γ-RV expressing  
IL2RG from EF1α 
promoter 
- 
Recovery of PB T cells that 
were functional and led to 
resolution of infections 
CGD88 Myeloid cells 13 
γ-RV expressing 
gp91
phox
 
3 cases of 
MDS / 
Transgene 
silencing 
Transient or no clinical 
benefit. 
Long- term efficacy only in 
the 3 cases of clonal 
expansion 
CGD 
(Personal 
Communication) 
Myeloid cells On Going 
SIN LV expressing  
gp91
phox
 from a myeloid 
promoter 
- - 
WAS89 Multi-lineage 10 γ-RV expressing WAS 
4 cases of T-
ALL 
Clear benefit at 2 year 
follow-up 
WAS90 Multi-lineage On Going 
SIN LV expressing WAS 
from WAS promoter 
- 
Improvements in platelet 
counts, immune functions, 
and clinical scores 
β-thalassemia91 
Erythroid 
Cells 
On Going 
SIN LV; large LCR 
expressing β-globin and 
cHS4 insulator 
Clonal 
Expansion 
Transfusion independence 
Fanconi 
anaemia92,93 
Stem Cells  
γ-RV expressing FANCC 
or FANCA 
- No clinical benefit 
Fanconi anaemia94-
96 
Stem Cells On Going 
SIN LV expressing 
FANC-A from PGK 
promoter 
- - 
Storage Disorders 
ALD97 
Macrophages 
and microglia 
On Going 
SIN LV expressing 
ABCD1 from MND 
promoter 
- 
Clear therapeutic benefit 
comparable to HSCT 
MLD98 
Macrophages 
and microglia 
On Going 
SIN LV expressing ARSA 
from PGK promoter 
- 
The disease did not 
manifest or progress 
beyond the predicted age 
of symptom onset 
Table 5. Ex vivo HSC GT Clinical Trials. Serious adverse effect (SAE), T-cell acute lymphoblastic leukaemia (T-ALL), 
myelodysplastic syndrome (MDS), locus control region (LCR), phosphoglycerate kinase (PGK), aryl sulfatase A (ARSA), 
elongation factor 1α (EF1α), ATP-binding cassette sub-family D member 1 (ABCD1), interleukin 2 receptor, gamma chain 
(IL2RG). Modified from Naldini
99
 and Fischer et al
84
. 
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4.1. Retrovirus 
Viral vector-mediated gene transfer protocols have concentrated most of the efforts on 
developing clinical GT trials, taking advantage of the fact that viruses have naturally evolved to insert 
genetic information into target cells100. Concerning ex vivo HSC GT, retroviruses have been the most 
frequently used vectors. Retroviridae is a family of enveloped virus containing their genetic information 
in the form of RNA genome. The viral envelope is composed by the membrane of the host cell and 
glycoproteins encoded by the virus itself. Retroviruses are able to convert RNA into double-stranded 
DNA in a process known as retrotranscription. This DNA molecule is then integrated in the genome of 
the host cell allowing the replication of the virus. Retroviruses can be classified according to the 
complexity of their genome into two groups: simple and complex. Simple retroviruses contain only 
essential genetic information while complex ones also codify for additional regulatory proteins. A more 
detailed classification divides retroviruses into 7 genera (Table 6). 
Genus Subfamily Representative species Genome 
Alpharetrovirus 
Orthoretrovirinae 
Avian sarcoma leukosis virus, Rous sarcoma virus Simple 
Betaretrovirus Mouse mammary tumour virus Simple 
Deltaretrovirus Bovine leukemia virus, human T-lymphotropic virus Complex 
Epsilonretrovirus Walleye dermal sarcoma virus Simple 
Gammaretrovirus 
Moloney murine leukemia virus (Mo-MLV), gibbon ape leukemia 
virus (GALV), Abelson murine leukemia virus, spleen focus-
forming virus (SFFV) 
Simple 
Lentivirus HumaniImmunodeficiency virus 1 (HIV-1) Complex 
Spumavirus Spumaretrovirinae Human foamy virus Complex 
Table 6. Genera belonging to the Retroviridae family. 
4.1.1. Retroviral genome and virion structure 
Retroviral genome (Figure 7) consists of two single-stranded positive RNA molecules with an 
equivalent structure to an mRNA (contain a 5' cap and 3' polyA tail) that bind each other by hydrogen 
bonds to form a dimer. Retroviral genome has a variable size between 8 and 12 kb and contains at least 
three genes in an invariable order 5’-gag-pol-env-3’101: 
• Gag, encoding capsid, matrix and nucleocapside proteins, which protect the viral genome. 
• Pol, encoding the viral enzymes: RT, protease and integrase. 
• Env, encoding the proteins of the viral envelope (surface and transmembrane proteins). 
 
Figure 7. A) General structure of the retroviral virion. B) WT Retroviral RNA genome. 
In addition to these major proteins, complex lentiviral genomes also codify for regulatory 
proteins such as Tat, which activates viral transcription, and Rev, involved in the control of splicing and 
nuclear export of viral transcripts102. Some of them also have accessory proteins such as Vif, Vpr, Vpu 
and Nef, whose combined action regulates viral gene expression, assembly and replication103. 
The retroviral RNA 5' end includes four regions, which are R, U5, primer binding site (PBS) and L.  
• R is a short repeated sequence at each end of the genome used during the reverse 
transcription to ensure correct end-to-end transfer in the growing chain.  
• U5 contains sequences important for polyadenylation and gives rise to the provirus 3’ end 
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• PBS consists of 18 nucleotides complementary to 3' end of the specific tRNA primer, which 
and provides -OH group for initiation of reverse transcription. 
• L is an untranslated region that contains the signal for packaging of the RNA genome (Ψ) and 
binding sites for transcription factors.  
The 3' end includes 3 regions, which are PPT (polypurine tract), U3, and R.  
• PPT is a short and purine-rich sequence used to initiate the plus-strand DNA synthesis during 
reverse transcription.  
• U3 is a sequence between PPT and R and that give rise to the provirus 5’ end contains 
promoter elements responsible for the transcription of the provirus. Att site is located in U3 and it is 
essential for the integration in the genome. 
4.1.2. Retrovirus life cycle 
A general scheme for the retrovirus life cycle can be found in Figure 8. The envelope proteins 
present in the viral membrane are able to bind receptor proteins in the membrane of the host cell (step 
1). This step allows the viral membrane to fuse with the cell membrane (step 2) and proteins and RNA 
strands contained inside the virion can be released inside the cytoplasm (step 3). Within the cell, the 
retroviral RNA is reverse transcribed into double stranded DNA (step 4), which is transported to the 
nucleus (step 5) and integrated into the host cell genome with the help of the integrase (provirus, step 
6). Proviral DNA is stable integrated so it can be replicated within the whole genome and transferred to 
the daughter cells. Proviral DNA is transcribed into RNA (step 7), which is spliced (step 8), transported 
to the cytoplasm (step 9) and used to synthesize the viral proteins (step 10). Full-length viral RNA and 
viral proteins are then assembled together (step 11) and a new viral particle escapes from the cell (step 
12). 
 
Figure 8. General Scheme of retrovirus life cycle. 
As a consequence of the reverse transcription process, LTRs are generated on each end of the 
provirus. LTRs are sequences between 300 and 1800 nucleotides that are formed by U3-R-U5 regions 
and contain important transcriptional signals, including a cleavage/polyadenylation site in the R region 
and a promoter and enhancers in U3. Transcription is initiated at the U3-R boundary in the upstream 
LTR, and cleavage/polyadenylation takes place at the R-U5 boundary in the downstream LTR101. 
1. Binding to specific receptors
2. Membranes Fusion
3. Particle Internalization
5. Nuclear Import
4. Retrotranscription
6. Integration
7. Transcription
8. Splicing
9. Export
10. Translation
11. Viral Particle Assembly
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4.1.3. Lentiviral vectors  
Lentiviral vectors (LVs) are lentiviruses that have been modified to be replication defective so 
once they are integrated, they cannot generate new replication-competent particles. That way, LVs are 
able to transduce the target cell and integrate an exogenous gene in its genome, but unable to 
propagate to other cells. These vectors are generated by the elimination of viral genes, which are 
replaced by a therapeutic transgene. Those viral genes that are essential are provided in trans during LV 
production. 
Human immunodeficiency virus type 1 (HIV-1)-based LVs are currently commonly used in the 
HSC GT field. LVs have some characteristics that make them more suitable as vectors than classical γ-
retroviral vectors (γRVs): 
• Larger transgene capacity (up to 10 kb). 
• Capability of transducing non-dividing cells. 
• Safer integration profile.  
Production of LVs is accomplished by the co-transfection in human embryonic kidney (HEK) 
293T cells of a plasmid containing the modified lentiviral backbone, known as transfer plasmid, and 
other plasmids that supply in trans the elements that have been removed from the retroviral backbone 
and that are required for the production of the vectors (Figure 9)104. These plasmids are: 
• Envelope plasmid: it contains the envelope protein. The properties of LVs can be modified 
supplying envelope proteins different from the WT one. This process is called pseudotyping. The most 
commonly used LV envelope is the G glycoprotein of the vesicular stomatitis virus (VSV-G) (Figure 9B), 
which allows the production of high-titer vectors105. Several studies have shown their ability to package 
LVs that are able to efficiently transduce different cellular types including HSCs from different species 
such as dog106, mouse107, non-human primates108 and humans109,110. 
• Packaging plasmid: it contains the genes required for the viral cycle. Accessory viral genes 
(vif, vpr, vpu and nef) were removed as they are not required for the packaging of the vector111 (second 
generation plasmids, Figure 9C). In third generation packaging plasmids, tat has been removed (as it 
was shown not to be required for the generation of functional vectors) and gag-pol and rev have been 
split into two plasmids104. 
 
Figure 9. Split Packaging system for LV production. A) Transfer Plasmid B) Envelope Plasmid C) 2nd Generation Helper Plasmid. 
• Transfer plasmid (Figure 9A): it encloses the therapeutical transgene and the lentiviral 
sequences that have to be supplied in cis to obtain a functional lentiviral particle (LTRs, PBS, Ψ signal, 
Δgag and att integration sites). Δgag is a non-coding residual element of gag gene giving rise to a 
secondary structure (SL4) that is required for the packaging112. The U3 region of the 5’ LTR has been 
substituted for CMV or RSV promoters (among others) to enable an improved and TAT-independent 
RNA transcription104. None of these modifications are present in the transcribed RNA neither in the 
transduced cells.  
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Some additional modifications have been introduced to improve the safety of the lentiviral 
vectors. Among them, Self-inactivating (SIN) configuration is worthy of mention113. This modification 
implies a deletion of 400 bp within U3 region (including strong enhancer elements like CAAT and TATA 
boxes) making LTRs of the integrated provirus less likely to initiate any proto-oncogene activation (see 
section 1.4.2.). 
SIN LVs require an internal promoter to drive the expression of the therapeutic transgene. The 
level of gene expression required for a specific application can be regulated by choosing a strong or a 
week promoter. Cellular and physiological promoters such as EF1α, PGK and VAV are weaker trans-
activators as compared to viral promoters (such as CMV or SFFV)114 so they are preferred when medium 
to low expression levels are required. Other promoters, such as inducible promoters, or lineage specific 
promoters (such as Cathepsin G/c-Fes Chimeric promoter115) can be incorporated in order to tightly 
regulate gene expression. 
Some sequences have been incorporated into lentiviral backbones to increase both titers and 
gene expression: 
• Post-transcriptional regulatory element of the woodchuck hepatitis B virus (wPRE): enhances 
the stability of viral RNA116. This sequence contains an open-reading frame (ORF) encoding a truncated 
peptide of the woodchuck hepatitis virus X protein, which has been related with hepatocarcinomas. For 
this reason, most of pre-clinical and clinical LVs include a version of the wPRE sequence where the ORF 
translation start codon was mutated (wPRE*)117.               
• The central polipurine tract (cPPT) facilitates the transport of the pre-integration complex to 
the nucleus118,119.  
• The central terminal sequence (CTS) is involved in the separation of reverse transcriptase118. 
• dNEF/PPT is essential for reverse transcription. 
• The Rev responsive element (RRE) facilitates the transport of the viral RNA to the nucleus. 
4.2. Safety of gene therapy 
Genetic modification of HSCs using retroviral vectors has brought encouraging results in the 
correction of genetic diseases, but genotoxicity due to insertional oncogenesis is a risk that has to be 
taken in consideration. Several cases of haematological malignancies were described in the first γRV-
based GT clinical trials. T-ALL cases described in SCID-X1 and WAS patients have been associated with 
LTR-mediated up-regulation of proto-oncogene, in most vases LMO2120-122, while clonal dominance and 
MDSs described in γRV-treated CGD patients occurs by up-regulation of myeloproliferative genes like 
MECOM, PRDM16 or SETBP1
88. Since then, research was focused on improving the safety of GT 
protocols through new vector designs and minimizing the ex vivo manipulation of HSCs.  
Retroviral integration within or near a proto-oncogene could lead to its activation by different 
mechanisms. As mentioned before, the two LTRs contain strong enhancers and promoter elements in 
the U3 region, which can upregulate proto-oncogene transcription from its cellular promoter. 
Additionally, both LTRs could initiate the transcription originating a chimeric transcript encoding an N-
terminally truncated form of the oncogene with constitutive activity and transforming potential. These 
LTR-dependent events are abrogated by the use of SIN RVs, where U3 regions are deleted from both 
LTRs during the transduction process and the vector expresses the therapeutic gene from an internal 
promoter. These internal promoters might also mediate upregulation of proto-oncogene transcription 
from its cellular promoter. However, the use of weak exogenous promoters results in lower proto-
oncogene expression99.  
Retroviral vectors differ in their integration profile. γRVs show a strong preference for 
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integration close to transcription start sites and CpG islands while LVs prefer to integrate inside 
transcription units of actively transcribed genes that cluster in mega-base-wide chromosomal regions. 
On the other hand, vectors derived from foamy viruses and α-retroviruses show a largely random and 
uniform integration pattern123.   
Insertions of γRVs into gene regulatory elements make them more prone to induce insertional 
oncogenesis, while lentiviral integration pattern appears to be safer. However, lentiviral characteristic 
integration into transcribed genes can also deregulate gene expression on post transcriptional levels 
through the generation of chimeric transcripts. This phenomenon occurs when transcripts originated 
from upstream cellular promoters are spliced into provirus-derived RNAs through the use of 
constitutive and cryptic splice sites124. It has been recently described a clonal dominance in a LV-treated 
β-thalassemia patient as a consequence of a truncated HMGA2 transcript that escaped regulation by a 
miRNA directed at the 3′ end of the full-length mRNA91. 
5. Alternative tools for genetic engineering: RNA interference 
RNA interference is a mechanism of gene silencing produced by small non-coding RNAs, which 
include endogenous miRNA and exogenous siRNA or shRNA. This mechanism is deeply conserved 
during evolution and highly dependent on gene sequence. The process starts when a double-stranded 
small RNA is incorporated into the RNA induced silencing  complex (RISC).  The anti-sense strand guides 
RISC to the complementary or near-complementary region of the target mRNA leading to its cleavage 
(by the endonuclease Ago2) or to translation inhibition respectively125.  
miRNAs are non-coding RNAs encoded in the genome that help to regulate gene expression. 
They are expressed as a longer transcript, known as pri-miRNA which is processed in the nucleus to a 
stem-loop structure called a pre-miRNA by the microprocessor complex. Pre-miRNA is transported to 
the cytoplasm where it is cleaved by Dicer to produce a mature miRNA that can be incorporated into 
RISC 126. A shRNA is a sequence of RNA emulating the pre-miRNA structure that can be used to stably 
silence target gene expression by its delivery through viral vectors127. This sequence is normally 
incorporated into a lentiviral backbone although, in some cases, a piggyback transposon has been 
used128. When the lentivirus is integrated into the genome, shRNA can be expressed by the internal 
promoter leading to the silencing of the desired gene (Figure 10). 
 
Figure 10. General mechanism for shRNA lentiviruses-mediated gene silencing. 
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Due to its strength and specificity, RNA interference-mediated gene silencing has been used in 
basic research to study the function of specific genes and in translational investigation to generate 
models of monogenic diseases such as Fanconi Anaemia129 or CGD130 in which it is possible to study new 
therapeutic approaches like GT. 
6. Gene therapy for LAD-I 
6.1. γ-retroviral vectors 
GT for LAD-I was first attempted using γRVs expressing hCD18 from the LTR. These vectors were 
used to transduce a WT murine lymphoblastoid cell line (LCL)131. Transduced cells expressed the hCD18 
protein in the cell surface as a chimeric heterodimer with the mCD11a protein and membrane 
expression of hCD18 was restricted to those cells expressing CD11 subunits. hCD18-γRVs were also used 
to transduce WT murine BM cells which were then transplanted into lethally irradiated recipients132. 
Expression of hCD18 could be detected in granulocytes 2 weeks after transplantation, but levels of 
expression decreased after 4 weeks.  
γRVs expressing hCD18 from an internal promoter were also designed133. Sequences from the 
chicken ACTB gene and enhancer sequences derived from the immediate early gene of CMV were 
located internally into the viral transcription unit. This vector was used to transduce WT mouse BM cells 
that were infused back into lethally irradiated mice. 42% of surviving transplanted mice displayed 
expression of hCD18 in granulocytes at 6 weeks after transplantation and the number of hCD18-
expressing granulocytes ranged from undetectable to 70% and was maintained for 6 months. hCD18 
expression was always lower in lymphoid cells than in myeloid cells. hCD18 expression showed post-
transcriptional regulation as it was upregulated after in vitro exposure of granulocytes to phorbol-12-
myristate-13-acetate (PMA). 
hCD18-γRVs pseudotyped with either A-MLV132,134,135 or GALV135 envelopes were used to 
transduce a LCL derived from a severe LAD-I patient with no detectable expression of either hCD18 or 
hCD11 subunits. hCD18-expressing LCLs recovered the ability to aggregate in the presence of PMA. This 
aggregation was CD18-dependent as it could be abrogated using an anti-CD18 blocking antibody. 
The GALV-pseudotyped γRV mentioned above was used to transduce BM CD34+ cells from a 
LAD-I patient. 31% of transduction was achieved in the presence of retronectin (RN). Corrected cells 
recovered mainly hCD11a expression while hCD11b and hCD11c expression were only detected upon 
expansion and differentiation. Corrected cells were assessed for functionality after sorting and myeloid 
differentiation. Corrected LAD-I neutrophils displayed increased binding to human umbilical vein 
endothelial cells (HUVEC)  and underwent partially respiratory burst in response to opsonized zymosan, 
a stimulant that requires hCD11b/hCD18 expression. Based on these results, a phase-I GT clinical trial 
for human LAD-I was conducted in which 2 patients were enrolled136,137. Mobilized CD34+ HSCs were 
collected from peripheral blood (PB), transduced with the γRV and infused back into the patients 
without any conditioning. A small percentage of corrected myeloid cells (up to 0.04%) were detected in 
PB at 2 and 4 weeks after transplantation but no corrected cells were detected by PCR 2 months after 
transplantation. 
The failure observed in this clinical trial and in other similar phagocyte disorders138 to achieve 
therapeutic levels of gene-corrected cells in vivo, despite high levels of transduction observed in vitro, 
suggested that conditioning was required in these cases to allow transduced CD34+ cells to engraft. 
A new γRV was designed, in which the canine CD18 (cCD18) was expressed from an internal 
murine stem cell virus (MSCV) LTR promoter/enhancer sequence139. This vector was evaluated for its 
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efficacy in the CLAD model. CLAD-affected dogs received a non-myeloablative conditioning with either 
200 cGy total body irradiation (TBI) or busulfan prior to the administration of the gene-corrected CD34+ 
cells (Figure 11). Both reduced-intensity conditioning (RIC) regimens resulted in low but detectable and 
long-term levels of cCD18+ cells in PB with reversal or marked improvement of the CLAD clinical 
phenotype in 6 out of the 11 treated pups. Integration site analysis was performed on the 6 surviving 
dogs revealing the presence of 40 retroviral insertion sites (RIS) near oncogenes and 52 RIS near active 
genes out of a total of 321. Nevertheless, no evidence of vector-mediated transformation has been 
reported to date140. 
 
Figure 11. Ex vivo GT protocol in CLAD dogs. 
6.2. Foamyviral vectors 
New viral vectors have been developed to overcome the problems associated with γRV. A 
foamyviral vector (FV) expressing cCD18 from the MSCV LTR promoter/enhancer was used to conduct 
ex vivo GT experiments in 5 CLAD dogs after non-myeloablative conditioning141. Four dogs underwent 
complete reversal of the CLAD phenotype, which was sustained more than 4 years with no evidences of 
leukemia or MDS, as demonstrated by normal leukocytes counts, normal T-cell subsets and normal tri-
lineage haematopoiesis in BM biopsies. Integration sites from early and late time-points were analysed 
in PB leukocytes142. cCD18-FVs integrated less close to oncogenes compared to cCD18-RVs and their 
integration pattern was very similar to computer-generated random sites. No foamyviral insertion sites 
(FIS) were found in oncogenes previously described as RIS in human GT clinical trials for CGD and X1-
SCID like PRDM16, SETBP1 and LMO2 and only 6 FIS were found in the MECOM gene out of a total of 
1528 unique FIS. 
A FV incorporating a PGK promoter was also designed143. This vector was able to express cCD18 
in canine neutrophils and CD34+ cells after in vitro transduction. Nonetheless, CLAD dogs that received 
HSCs transduced with this vector did not experiment any clinical benefit and some of them died 
because of the disease.  
6.3. Lentiviral vectors 
SIN LVs for ex vivo LAD-I GT have been extensively studied in the CLAD model. Different internal 
promoters were used to drive the expression of the cCD18 cDNA (Table 7).  
The use of a strong promoter–enhancer in a LV resulted in the successful correction of the 
typical CLAD phenotype in the two treated dogs, which became long-survivors in contrast to non-
treated CLAD dogs, which normally die within the first 6 months of life. The outcome was not so 
conclusive when more physiological and weaker promoters were used. In vitro transduction of CLAD 
CD34+ cells with the EF1α-LV resulted in similar cCD18 expression levels compared to that seen in CD34+ 
cells from healthy dogs. Despite this fact, after transplantation of EF1α-LV-corrected CD34+ cells, none 
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of the treated four CLAD dogs showed higher than 0.3% of CD18+ PBLs and all died around 9 months 
after the procedure. EF1α promoter silencing was proposed as the reason of the failure of these 
experiments 144. As shown in Table 7, only one dog survived after transplantation of PGK-LV-corrected 
CD34+ cells. The surviving dog presented only 0.6% CD18+ neutrophils in PB after 1 year, although a 
19.2% of these positive neutrophils expressed cCD18 at normal levels. PGK and EF1α promoters in 
these particular settings (low multiplicity of infection (MOI), no CD34+ cells pre-stimulation and reduced 
conditioning regimen) were not able to drive therapeutic levels of cCD18 expression.  
Alternative physiological promoters were investigated. Different fragments of hCD18 and 
hCD11b promoters were cloned into LVs and checked for their ability to express cCD18 in CLAD CD34+ 
cells145. Selected hCD18 and hCD11b LVs were assayed in ex vivo CLAD GT experiments resulting in 3 
surviving dogs out of 4 treated dogs. Percentages of cCD18+ PB neutrophils ranged from 0.7 to 1.5 % 
and expressed cCD18 from 12 to 24.3 % of normal levels. This study showed for the first time that 
lentiviral-mediated GT could be successful for LAD-I treatment. 
Promoter Reference Free-disease Survival CLAD-dogs 
MSCV LTR Hunter et al146 2/2 
EF1α Nelson et al147 0/4 
hPGK Hunter et al146 1/4 
hCD11b Hunter et al145 1/2 
hCD18 Hunter et al145 2/2 
Table 7. LV-based ex vivo GT studies conducted in CLAD-affected dogs. 
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LAD-I is an autosomal recessive disorder caused by mutations in the ITGB2 gene resulting in null, 
low or aberrant expression of CD18. These defects affect the ability of the leukocytes to extravasate 
from the blood to the sites of infection. LAD-I symptomatology depends on the CD18 expression levels, 
resulting in a moderate or a severe phenotype, but in all cases it includes a high susceptibility to 
bacterial infections, neutrophilia and delayed wound healing. Patients with severe LAD-I normally die in 
the first years of life, while patient with the moderate phenotype can survive into the adulthood.  
 
The standard treatment of these patients normally includes intensive antibiotherapy and even 
granulocyte transfusions, but the only current curative therapy is the allogeneic HSCT. However, the 
availability of HLA-compatible donors limits the number of patients that can benefit from this 
treatment. Additionally, HSCT complications can be very severe. As other monogenic PIDs, LAD-I is a 
good candidate to be treated by ex vivo HSC GT. The transplantation of autologous corrected HSCs 
could be available for all LAD-I patients and would limit the side effects associated with the allogeneic 
HSCT. 
 
In order to develop new strategies of GT for LAD-I, we considered the following aims: 
 
1. To study and characterize the HSC phenotype of the CD18 hypomorphic mouse model  
 
2. To develop clinically applicable lentiviral vectors expressing hCD18 from ubiquitous and 
myeloid promoters.  
 
3. To perform preclinical GT studies in different human and mouse in vitro and in vivo LAD-I 
models. 
 
   
Materials and methods 
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1. Animal experimentation 
All experimental procedures were carried out according to Spanish and European regulations 
(Spanish Royal Decree 53/2013 and Law 6/2013, which translate and comply with the European 
Directive 2010/63/UE about the use and protection of vertebrate mammals used for experimentation 
and other scientific purposes). Mice were maintained at the CIEMAT animal facility (registration 
number ES280790000183) under high standard conditions in line with FELASA recommendations: 
• High-efficiency particulate air-filtered air with an exchange rate of 16–20 changes per hour. 
• Regulated temperature of 20±2°C. 
• Relative humidity of 55±10%. 
• Light/dark cycle of 13/11 h with lights on at 07:00 h. 
• 20 Gy-irradiated standard diet and ultraviolated-irradiated water ad libitum. 
• Routinely pathogen screening. 
1.1. Mouse strains 
C57BL/6J (B6, stock number 000664), B6.SJL-Ptprca/bPep3b/BoyJ (P3B, stock number 002014) 
and B6.129S7-Itgb2tm1Bay/J (CD18 hypomorphic mice, CD18HYP, stock number 002128) colony founders 
were obtained from the Jackson Laboratory (Bar Harbor, USA).  
B6 mice were used as WT controls in most of the experiments. P3B is a B6 congenic strain 
because it carries the differential B cell antigen designated CD45.1 (Ptprca allele), while the b allele 
(CD45.2) is present in the C57BL inbred strain.  
Strain Type Background CD45 ΔhCD4 Experiments 
B6 
C57BL/6J 
Inbred  CD45.2 - 
• Analysis of LAD-I classical phenotype: CD18WT 
controls. 
• LSK cells determination, flow cytometry 
analysis and clonogenic assays: CD18WT controls. 
• Limiting dilution assays: CD18WT donor. 
• GT experiments: CD18WT controls. 
P3B
148
 
B6.SJL-Ptprca Pep3b/BoyJ 
Inbred C57BL/6J CD45.1 - 
• Competitive repopulation experiments: 
recipients. 
• Limiting dilution assays: recipients and 
radioprotective donors. 
• Neutrophil donor in neutrophil transfer 
experiments. 
CD18
HYP 75
 
B6.129S7-Itgb2tm1Bay/J 
Inbred 
Targeted 
Mutation 
C57BL/6J CD45.2 - 
• Analysis of LAD-I classical phenotype. 
• LSK cells determination, flow citometry 
analysis and clonogenic assays. 
• Competitive repopulation experiments and 
limiting dilution assays 
• GT experiments: LAD-I model. 
P3B-ΔhCD4
149
 
vavHS21/45hCD4 
Inbred 
Targeted 
Mutation 
C57BL/6J CD45.1 + 
• Competitive repopulation experiments: 
CD18WT donor 
PEdKO
150
 
B6.129S2-Seletm1Hyn 
Selp
tm1Hyn/J 
Inbred 
Targeted 
Mutation 
C57BL/6 CD45.2 - • Study of aged neutrophils 
Table 8. Mouse Strains: pan-leukocyte markers expression and experiments in which they have been used. 
CD18HYP mice contain the Itgb2tm1Bay allele which is a hypomorphic mutation leading to the 
expression of low levels of mCD18. These animals were handled under sterile conditions and 
maintained in micro-isolators. 
P3B-ΔhCD4 mice were previously generated in the laboratory149. Briefly, a vector consisting of a 
modified human CD4 gene (ΔhCD4, incapable of intracellular signalling and association with the MHC 
34 │ MATERIALS AND METHODS  
class II) driven by the HS21/45 vav promoter (a kind gift from Jerry M. Adams, Walter and Eliza Hall 
Institute of Medical Research, Parkville, Australia) was linearized and microinjected into P3B eggs and 
then transferred into B6D2F1 pseudo pregnant females. These mice express the marker ΔhCD4 in all 
cells of the haematopoietic system. 
PEdKO mice contain Seletm1Hyn and Selptm1Hyn alleles leading to absent E- and P-selectin 
expression respectively. These mice were kindly provided by Dr. Andrés Hidalgo (CNIC, Madrid, Spain). 
1.2. Haematological sampling 
Routine bleeding for PB collection of experimental mice was carried out by lateral tail vein 
sampling. A maximum volume of 200 µL was collected. PB was mixed with 20 µL of EDTA to prevent 
blood coagulation. Terminal blood collection was performed by cardiac puncture after CO2 mice 
treatment. A maximum volume of 1 mL was collected. For haematological counts, 50 µl of EDTA-
anticoagulated PB were analysed using an ABACUS Junior Vet Haematological Analyzer (Practice CVM, 
Tudela, Spain). 
For BM collection, animals were sacrificed by cervical dislocation. Both tibiae and femora were 
surgically extracted and BM was harvested by flushing them under sterile conditions with DMEM + 
GlutaMAX (Gibco/Life Technologies/Thermo Fisher Scientific, Waltham, USA) and washed twice with 
PBE buffer (PBS + 0.5% BSA + 1mM EDTA, MACS/Miltenyi Biotec, Bergisch Gladbach, Germany). 
Cellularity was determined in the Neubauer chamber by diluting the sample in Türk solution (Merck 
KGaA, Darmstadt, Germany). 
1.3. Transplantation experiments 
1.3.1. Haematopoietic progenitors purification  
Mouse haematopoietic progenitors, both Lin- and LSK cells, were purified from femora and 
tibiae BM samples by FACS. BM cells (BMCs) were stained for LSK or Lin- phenotype using a panel of 
monoclonal antibodies (Table S1) and FACS-sorted using a BD INFLUX (BD/Becton, Dickinson and 
Company, New Jersey, USA). FACS analysis of representative pre and post sorting BM samples from 
CD18HYP mouse are represented in Figure 12. 
 
Figure 12. Representative flow cytometry analysis of a pre and post sorting BM sample.  
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1.3.2. Haematopoietic stem cell limiting dilution assay  
BM single cell suspensions were obtained from CD18HYP, CD18WT and P3B wild type mice (8 to 12 
week old). Lethally irradiated (4.75 Gy + 4.75 Gy) recipient mice were competitively reconstituted by 
retro-orbital venous sinus injection with five different doses (5×105 cells, 1.5×105 cells, 5×104, 2.5x104 
cells) of whole BMCs from test mice (CD18HYP or CD18WT) and a radioprotective dose of 3×105 BMCs 
from P3B mice. Mice were bled at 3 months post transplantation (mpt) and analysed for the percentage 
of donor-reconstituted animals on each group. We considered as repopulated by donor cells those mice 
that had more than 1% donor-derived (CD45.2+) cells in both lymphoid (CD3+ and B220+) and myeloid 
(Gr-1+ and CD11b+) subpopulations. Frequency of reconstituting haematopoietic stem cells from these 
limiting dilution experiments was calculated using ELDA software151. 
 
Figure 13. HSC limiting dilution assays. A) Experimental protocol. B) Groups of animals according to the dose of cells from each 
of the tested strains. C) Criteria used to determine if an animal had been reconstituted with donor cells. 
1.3.3. Competitive repopulation assay 
Competitive repopulation assays (CRAs) were conducted by mixing hematopoietic repopulating 
cells from male CD18HYP and P3B-ΔhCD4 mice (CD18WT), that were subsequently intravenously 
transplanted into myeloablated P3B female mice that had received two doses of 4.75 Gy, spaced 24 
hours apart, with x-ray equipment MG324 (300 kV, 12.8 mA, Philips, Hamburg, Germany). Proportion of 
both populations in the mixture was checked by flow cytometry prior to transplantation.  
The percentage of cells derived from the transplanted competitor populations and from the 
endogenous BM was deduced from CD45.1, CD45.2 and ΔhCD4 FACS analyses carried out every 30 
days. At 4 mpt, animals were culled and BMCs were harvested. BMCs and CFUs-derived cells were 
analysed for population content (CD45.1, CD45.2 and ΔhCD4). In addition, harvested BMCs were 
intravenously infused into myeloablated P3B secondary recipients, whose PB cells were periodically 
analysed for population content (CD45.1, CD45.2 and ΔhCD4). Two CRAs were performed with total 
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BMCs: one in which CD18HYP and CD18WT cells were mixed at the same proportion (1x106 cells of each 
stain) and other in which cells were mixed at 3:1 proportion CD18HYP / CD18WT (5x105 and 1,5x106 cells 
respectively). CRA was also conducted with MACS-sorted lin- cells. In this case 2x105 cells of both 
competitor populations were mixed and transplanted into the recipients (Figure 14). 
 
Figure 14. General protocol for CRAs. Population analysis was based on the determination by flow cytometry of pan-leukocyte 
markers CD45.1, CD45.2 and ΔhCD4. 
1.3.4. Homing experiments 
FACS-Sorted BM-derived LSK cells from 6 week old CD18HYP and CD18WT mice were washed with 
PBS (Sigma-Aldrich, St. Louis, USA) and resuspended at a density of 1 × 106 cells/mL. This suspension 
was incubated with 5 μl/ml of Vybrant® DiD cell-labelling solution (Molecular Probes/Life 
Technologies/Thermo Fisher Scientific, Waltham, USA) during 20 min at 37 ºC. After washing, LSK cells 
were resuspended and intravenously infused into myeloablated female B6 mice recipients. 6x104 LSK 
cells were administered to each mouse. At 14 h after transplantation recipients were culled and BMCs 
were harvested from the femora and tibiae and analysed for the presence of homed DiD+ cells (Figure 
15). A minimum of 5x105 viable cells were acquired. 
 
Figure 15. Protocol followed in LSK homing experiments. 
Homing efficiency was calculated as published before152. Briefly, to determine the seeding 
efficiency to the BM we assumed that the two femora and tibiae contain approximately 20% of the 
total BM cellularity153. The seeding efficiency was calculated then on the basis of the total LSK cells 
retrieved related to the total LSK cells injected (all of them DID+ as confirmed after the staining). The 
number of total homed LSK cells analysed (DID+) was corrected for the total BMCs obtained from the 2 
femora and tibiae.  
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1.3.5. Ex vivo gene therapy experiments 
For ex vivo GT experiments, O/N transduced lin- cells were collected, washed and suspended in 
PBS at a density of 1.5 – 2.5x106 cell/mL. 200 µL of this cellular suspension (3 – 5x105 cells) were 
intravenously administered into lethally irradiated female CD18HYP mice. These mice received a 
conditioning regimen consisting of two consecutive doses of irradiation (4.75 Gy + 4.75 Gy) the day 
before and the same day of the transplantation. 
Transplanted mice were monthly followed-up for 4 months. Each month animals were bled. 
Collected PB was analysed by flow cytometry for the expression of hCD18 and the different murine 
CD11 subunits. 100 µL of PB were lysed and cells spun down. Genomic DNA (gDNA) was extracted from 
these pellets and used for vector copy number (VCN) determination (see section 5). 3 months after 
transplantation, animals were analysed by flow cytometry for hCD18 expression in different leukocytes 
subpopulations (T-Cells, B-cells and granulocytes) using specific markers (CD3, CD45R and Gr-1).  
Transplanted mice were culled by cervical dislocation at 4 mpt. BMCs were harvested and 
analysed by flow cytometry. 3x106 of these BMCs were transplanted mouse to mouse into 
myeloablated secondary recipients. Two animals were transplanted with a pool of 3x106 BMCs from 
different animals. 
Secondary recipients were similarly followed-up for 9 months. At the end of the experiments, 
mice were sacrificed by cervical dislocation. BM was subsequently harvested and analysed by flow 
cytometry. 
  
Figure 16. Ex vivo GT protocol in CD18HYP mice. 
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1.4. Neutrophil transference 
P3B mice were sacrificed and BMCs were collected by flushing both femora and tibiae with 
DMEM. Neutrophils were purified using Percoll 62% (GE Healthcare, Farfield, USA) (Figure 17) and 
erythrocytes lysed using a hypotonic buffer. Purities of 83-90% were achieved using this method. To 
induce senescence, neutrophils were cultured for 6 hours in RPMI 1640 (Roswell Park Memorial 
Institute) 1640 medium + GlutaMAX (Gibco/Life Technologies/Thermo Fisher Scientific, Waltham, USA) 
supplemented with 10% HyClone (GE Healthcare, Fairfield, USA) and 1% penicillin/streptomycin (P/S). 
4-7x106 BM-derived ex vivo-senesced neutrophils were intravenously transferred into CD18HYP mice 
each 24 hours for 5 days. At day 6, mice were sacrificed and BMCs were collected and analysed for LSK 
cell content. PBS-treated CD18HYP mice and untreated CD18HYP and CD18WT mice were used as controls. 
 
Figure 17. Representative example of the purity of Percoll (62%)-purified BM neutrophils from P3B mice. 
1.5. Inflammation models 
Two different models of local inflammation were performed to evaluate the capacity of 
neutrophils to extravasate from PB in two different anatomical locations: lung and subcutaneous air 
pouch. 
1.5.1 Lipopolysaccharides-induced asthma model 
Mice were administered intranasaly with 50 µL of 0.3 µg/µL LPS (from Escherichia coli 0111:B4, 
Sigma-Aldrich, St. Louis, USA) or PBS under isoflurane anaesthesia. 24 hours after LPS/PBS 
administration, bronchoalveolar lavages (BALs) were performed. BAL removes non-adherent cells and 
lung lining fluid from the mucosal surface so this technique allows sampling of innate, cellular and 
humoral responses within the lung. Mice were expired immediately prior to lavage by lethal injection of 
avertin (synthetized in the laboratory from 2,2,2-tribromoethanol and 2-methyl-2-butanol, both from 
Sigma-Aldrich, St. Louis, USA) and exsanguinated from both femoral arteries. Then, a small incision was 
made in the animal skin at the abdomen, skin around entire body was torn and skin upwards was 
peeled to expose thoracic cage and neck. Tissue from neck was dissected to expose trachea. A small 
incision in the trachea was performed taking care of not cutting the trachea all the way through and an 
18G blunt fill needle (BD, 305180) was inserted through the incision. The needle and the trachea were 
stabilized with a bulldog serrefine. Utilizing 1 mL syringes, 3 lavages with 700 µL of PBS were performed 
and collected together. BAL samples were pulled down and resuspended into 200 µL of fresh PBS. Cell 
number was determined diluting these samples with trypan blue (Sigma-Aldrich, St. Louis, USA) and 50 
µL of the suspension were used for FACS analysis (Ly6G/CD11c). Absolute numbers of neutrophils were 
determined as following: 
 
Absolute numbers of migrating neutrophils were normalized to the values obtained in the 
CD18HYP animals. 
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1.5.2. Air-pouch inflammation model 
The air pouch (AP) was generated by the dorsal subcutaneous injection of 5 ml of air on day 0 
under isoflurane anaesthesia. On day 3 the pouches were reinflated with 3 ml of air and, on day 5, 40 
ng of mouse recombinant TNF-α in PBS with 0.5% carboxymethylcellulose (CMC) as inert carrier were 
injected into the matured pouches. 4 hours after TNF-α administration, mice were sacrificed by CO2 
inhalation and PB collected by heart puncture and total leukocytes and neutrophils number counted 
using an ABACUS Junior Vet Haematological Analyser. The APs were then flushed with 8 ml of PBS and 
the collected cells centrifuged at 500g for 10min. The cells were resuspended in 0.5 ml of PBS and total 
leukocytes and neutrophils number in the AP were also counted using the haematological analyser. 
Emigration ratio for total leukocytes or neutrophils was calculated with the following equation: 
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In the case of GT-treated animals, hCD18+ or GFP+ cells were determined in PB and in the AP and 
emigration ratio was calculated as following: 
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2. Cell culture 
2.1. Cell lines  
The different cell lines used in the present work are summarized in Table 9. 
Cell Line Organism Cell Type Tissue Disease Growth Origin Purpose 
293T 
Human 
Epithelial 
Embryonic 
kidney 
- Adherence ATCC -  CRL-3216™ 
Production 
of LVs 
HT1080 Epithelial 
Connective 
tissue 
Fibrosarcoma Adherence ATCC -  CCL-121™ 
Titration of 
LVs 
ZJ B cell Blood LAD-I Suspension 
Kindly provided by Dr. 
Hickstein (NIH) 
In vitro 
LAD-I 
experiments 
MARK B cell Blood - Suspension 
Kindly provided by Dr 
Regueiro (CIEMAT) 
GUS-1  B cell Blood - Suspension 
Kindly provided by Dr 
Regueiro (UCM) 
Table 9. Cell lines used for the in vitro experiments. 
293T cell line, also known as HEK293T, is a cell line derived from human embryonic kidney cells 
and contains the SV40 (Simian vacuolating Virus 40) large T-antigen, which owes its transformation 
activity to the inhibition of the retinoblastoma and p53 tumour suppressor proteins. This allows for 
episomal replication of transfected plasmids containing the SV40 origin of replication. 293T cells are 
routinely used for LV production because of being easily grown and transfected154.  
HT1080 cell line was generated from tissue taken in a biopsy of a fibrosarcoma present in a 35 
year old human male who died without having been treated with chemotherapy or radiotherapy155. 
HT1080 cells were widely used for LV titration. 
ZJ cell line is a lymphoblastoid cell line (LCL) that was obtained by Epstein Barr virus infection of 
B cells from a LAD-I patient. This cell line expresses no detectable CD18 mRNA or protein levels156. ZJ 
cells have been widely used for in vitro transference of CD18 as a proof of concept for LAD-I GT75,134. 
MARK and GUS-1 LCLs were generated in Dr. Regueiro’s laboratory from healthy samples and they were 
used as a CD18WT controls in these experiments. 
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2.1.1. Culture of adherent cells 
HT1080 and 293T cells were cultured in complete medium based on DMEM + GlutaMAX 
supplemented with 10% Hyclone and 0.5% P/S. Cells were cultured in polystyrene cell culture flasks 
(Corning, New York, USA). Adherent cells were diluted using Trypsin-EDTA 1% (Sigma-Aldrich, St Louis, 
USA). 
2.1.2. Culture of suspension cells 
ZJ, GUS-1 and MARK cells were cultured in complete medium based on PRMI 1640 + GlutaMAX 
supplemented with 10% Hyclone and 0.5% P/S. 
2.1.3. Transduction of lymphoblastoid cell lines 
2.5x105 cells were normally transduced on RN (Takara Bio, Otsu, Japan)-coated 24-well non-
treated tissue plates. Cells were O/N transduced with lentiviral supernatants at the desired MOI. The 
next day, cells were collected, washed and resuspended in fresh medium. The amount of viral 
supernatant was calculated as following: 
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For the preparation of RN-coated plates, 500 µL of 19 µL/mL RN in PBS were added to each well 
(5 µg/cm2). Plates were allowed to stand for 2 hours at room temperature or at 4℃ overnight. After 
that, RN solution was removed and wells were washed once with PBS. 
2.1.4. CD18-dependent functional assays in lymphoblastoid cells  
2.1.4.1. PMA-induced aggregation 
The aggregation assay was carried out as previously described157. Cells were washed two times 
and suspended in RPMI 1640 medium + GlutaMAX with 10% HyClone at a concentration of 2×106 
cells/ml and added to a flat-bottomed 96-well plate. Then, 50 µl of PBS or 1 µg/ml PMA solution (Sigma-
Aldrich, St. Louis, USA) were added to each well and cells were incubated for one hour at 37ºC. An 
inverted microscope was used to view the aggregation. In blocking studies, a mouse monoclonal 
antibody against hCD18 (LEAFTM purified anti-human CD18, Clone TS1/18, BioLegend, San Diego, USA) 
was added at a final concentration of 7 µg/ml to the cell suspension 5 min before the addition of the 
PMA stimulus. 
2.1.4.2. Soluble ICAM-1 binding assay 
sICAM-1 binding assay was performed as formerly described158. sICAM-1 was prepared by 
incubating 20 µg/ml recombinant human ICAM-1/Fc ( Chimera (R&D System, Minneapolis) with 100 
µg/ml polyclonal PE-conjugated rabbit anti-human IgG Fc antibody (eBioscience, San Diego, USA) in 50 
µl of RPMI 1640 medium + GlutaMAX containing 5% HyClone and HEPES 10 mM (Gibco/Life 
Technologies/Thermo Fisher Scientific, Waltham, USA) for 30 min at room temperature. 2x105 cells 
were resuspended in the sICAM mixture with or without β2-activating agents (10 mM MgCl2 and 3 mM 
EGTA) for 30 min at 37 °C. Cells were washed with RPMI 1640 medium + GlutaMAX and analysed by 
flow cytometry. 
2.2. Primary cells  
2.2.1. Mouse lineage negative cells 
2.2.1.1. Methyl-cellulose culture 
1.5x104 BMCs or 103 BM-derived lin- cells were seeded in methylcellulose-based medium with 
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recombinant cytokines including mSCF, mIL-3 and mIL-6 (Methocult M3534, StemCell Technologies, 
Vancouver, Canada). The number of CFUs was scored on day 7 under an inverted microscope. 
2.2.1.2. Lin- cell transduction and liquid culture 
Mouse haematopoietic progenitors were transduced with hCD18-LVs and eGFP-LV at different 
MOIs (20 – 50) using an O/N protocol. Freshly isolated lin- cells were resuspended in StemSpan medium 
(StemCell Technologies, Vancouver, Canada) containing 100 ng/mL hIL-11 and 100 ng/mL mSCF 
(Eurobiosciences, Friesoythe, Germany) and the required amount of lentiviral supernatant was added 
(calculated using the formula described in section 2.1.3 of Material and Methods). Next day cells were 
washed and either resuspended in fresh medium for their expansion in liquid culture or resuspended in 
PBS to be used in GT ex vivo experiments (see section 1.3.5). Lin- cells were allowed to grow in liquid 
culture for 7 days for flow cytometry analysis and VCN determination. 
2.2.2. Human CD34+ cells 
2.2.2.1. Purification of cord blood CD34+ cells 
Cord blood samples from healthy donors were obtained from the Madrid Community 
Transfusion Centre. Mononuclear cells were purified by Ficoll-Paque PLUS (GE Healthcare, Fairfield, 
USA) density gradient centrifugation. Then, CD34+ cells were selected using CD34 MicroBead Kit. 
Magnetic-labelled cells were positive selected firstly with a LS column and then with a MS column in 
QuadroMACS™ and OctoMACS™ separators respectively (All from MACS, Miltenyi Biotec, Bergisch 
Gladbach, Germany). Purified CD34+ were then evaluated for their purity by flow cytometry. Purities 
from 80-95% were routinely obtained. 
2.2.2.2. Transduction of human CD34+ cells and neutrophil differentiation 
Freshly isolated CD34+ cells were cultured for 2 days in StemSpam medium supplemented with 
human cytokines including SCF (300 ng/ml), thrombopoietin (TPO, 100 ng/ml) and FMS-like tyrosine 
kinase 3 ligand (Flt3l, 100 ng/ml), and 1% P/S. Cells were collected at day 2 and O/N transduced with 
shRNA-LVs at a MOI of 100 vp/cell on non-treated retronectin-coated 24-multiwell plates. The following 
day, cells were washed and resuspended in fresh medium.  
In the case of lentiviral correction, interfered-CD34+ cells were allowed to grow for 3 additional 
days and then GFP+ cells were FACS-sorted and resuspended in fresh medium. The next day, cells were 
collected and transduced with hCD18-LVs at a MOI of 100 vp/cell. The day after transduction cells were 
washed and resuspended in neutrophil differentiation medium (IMDM supplemented with 20% 
Hyclone, 1% P/S and human cytokines including IL-3 (20 ng/ml), SCF (20 ng/ml) and G-CSF (100 ng/ml) 
and allowed to proliferate for 12 days. These 12-day differentiated neutrophils were used in different 
functional assays described below (Figure 18). 
 
Figure 18. Transduction and differentiation of cord blood CD34+ cells from healthy human donors.  
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2.2.2.3. Soluble ICAM-1 binding assay 
This assay was performed similarly as described for LCLs in 2.1.4.2. section, but with one 
exception; cells were incubated with 1 µL of Fc receptor (FcR) blocking reagent (MACS, Miltenyi Biotec, 
Bergisch Gladbach, Germany) for 20’ at 4 ºC and then washed prior to the incubation with the ICAM-1-
Fc reagent. This step was performed in order to avoid the recognition of the ICAM-1-Fc reagent by the 
FcR typically expressed by myeloid cells. 
2.2.2.4. Flow chamber assay 
Flow chamber assays were performed as previously described159. 1x105 twelve-day 
differentiated neutrophils  were mixed with 1x105 control untransduced neutrophils and resuspended 
in 500 µL of RPMI 1640 medium + GlutaMAX with 10% Hyclone. Plastic slides were coated with 
fibrinogen (2.5 mg/ml) for one hour at 37 ºC. Flow chambers (Department of Medical Engineering, 
Imperial College School of Medicine, London, United Kingdom) were assembled with 0.2-mm spacers, 
pre-coated slides, and an exit tubing (Medex/Smiths Medical, London, United Kingdom). Four 50 ml 
syringes were filled with PBS and connected to the chamber using tubing (Medex/Smiths Medical, 
London, United Kingdom), a three-way tap (BD/Becton, Dickinson and Company, New Jersey, USA), and 
Y-connectors (Alaris/CareFusion, San Diego, USA). The tubing and chambers were primed to eliminate 
bubbles and mounted on a microscope stage inside of an environmental chamber (37 ºC). Syringes 
were assembled on a BS-9000-6 multi-syringe programmable syringe pump with flow-rate control 
(Braintree Scientific, Braintree, United Kingdom). Cells were injected through the three-way tap and 
passed into the chamber with about 1 ml PBS from the syringes. After 10 min adherence, PBS was 
pumped into the chamber at low flow (1 dyn/cm2/min) for 1 min to remove non-adherent cells. 
Afterwards, flow rates were augmented in 10–20 dyn/cm2 increments in 1-min intervals to a maximum 
sheer stress of 80 dyn/cm2. Images of bright field and eGFP fluorescence were acquired after each flow 
rate increment using Zeiss Axiovert 135 microscope with a 10X phase contrast lens (Zeiss, Oberkochen, 
Germany), a digital camera (Hamamatsu Photonics, Hamamatsu, Japan) and Volocity 4.2 software 
(PerkinElmer, Waltham, USA).  
The shear stress for each flow rate was calculated from the following formula: 
Shear	stress	  	 6	 ∗ 	flow	rate ∗ 	viscositychannel	width ∗ $channel	height&2 
Where: shear stress is expressed in dyn/cm2, flow rate is expressed in ml/sec, viscosity of PBS is 
0.0076 Poise, channel height = chamber width = 0.7 cm and channel height = spacer height = 0.02 cm. 
The number of cells detaching at each increment of shear stress was calculated and expressed 
as a percentage of the total number of adherent cells in the same field immediately after the low flow 
wash. eGFP+ cells correspond to the LV:shSCR and LV:sh10-transduced cells and eGFP- cells correspond 
to the untransduced cells. 
2.2.2.5. Chemiluminescence assay of neutrophil respiratory burst 
12-day in vitro differentiated neutrophils were compared in a chemiluminescence assay of 
respiratory burst activity in response to complement-opsonized zymosan. Activation of the respiratory 
burst in response to C3bi-opsonized zymosan has been shown to be a CD11/CD18-mediated function 
activity160,161. Luminol-enhanced chemiluminescence was used as a sensitive measure of the respiratory 
burst of human phagocytes as previously described162. 1x105 cells were preincubated for 15 min in a 
160 µL of RPMI 1640 medium + GlutaMAX with 15 μg/mL human serum albumin at room temperature 
in an Isoplate-96 Microplate White Frame Clear Well (PerkinElmer, Waltham, USA). At the beginning of 
the assay, 10 μmol/L luminol (Sigma-Aldrich, St. Louis, USA) and 1 mg/mL opsonized zymosan were 
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added to the reaction mixture. Luminol-enhanced chemiluminescence was read for 10-second intervals 
at the designated time points with a Genios Pro reader (Tecan, Männedorf, Switzerland). The assay was 
performed at room temperature and chemiluminescence was reported as relative light units (RLU)/106 
cells/10 s.  
Zymosan (Sigma-Aldrich, St. Louis, USA) was opsonized with human serum as previously 
described163. Briefly, Zymosan was resuspended in PBS at 20 mg/mL, heated and shaken at 100 ºC for 
20 minutes, sonicated for 60 s and washed in PBS by centrifugation (300g, 2 min). Finally Zymosan was 
resuspended in fresh PBS at 20 mg/mL and incubated with an equal volume of pooled human serum. 
The mixture was incubated at 37 ºC for 1 hour (keeping Zymosan in suspension). Opsonized Zymosan 
was washed twice in PBS by centrifugation (300g, 2 min), resuspended in PBS at 10 mg/mL and stored 
at –80°C. 
3. Flow cytometry analyses 
Flow cytometry analyses were performed in the LSRFortessa cell analyser (BD/Becton, Dickinson 
and Company, New Jersey, USA). Off-line analysis was performed with the FLowJo Software v7.6.5. 
(Tree star, Ashland, USA).  
A minimum of 104–105 viable cells were normally acquired. Samples were always resuspended 
in flow cytometry buffer (PBS containing 0.5% BSA and 0.05% sodium azide) containing 1 μg/ml DAPI as 
a viability marker. In the case of PB and BM samples, erythrocytes were lysed in ammonium chloride 
lysis solution (0.155 mM NH4Cl, 0.01 mM KHCO3, 10
−4 mM EDTA) before antibody staining. Table S1 
summarize all the labelled antibodies used in the different experiments. Fluorochrome-conjugated 
streptavidins were used as a second step reagent to detect biotinylated primary antibodies. 
Mean fluorescent intensity (MFI) was used to determine the surface expression of antigens 
detected by fluorescent-labelled antibodies. In those cases where relative surface expression was used, 
this was calculated by normalizing the MFI value from the sample to that of a control as following: 
"	!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3.1. Haematopoietic progenitor population study 
For haematopoietic progenitor population studies, harvested BMCs from 6 week old CD18HYP 
and CD18WT mice were stained with the cocktail of monoclonal antibodies listed on Table S1. Cell-
surface markers for the harvested haematopoietic populations are summarized as indicated in Table 10. 
 Positive Negative 
Long-term haematopoietic stem  cells (LT-
HSC) 
ckit, Sca1, CD150 CD3, B220, Gr1, Mac1, Ter119, Flk2, CD34 
Short-term haematopoietic stem cells (ST-
HSC) 
ckit, Sca1, CD34 CD3, B220, Gr1, Mac1, Ter119, Flk2, CD150 
Multipotent progenitor (MPP) ckit, Sca1, Flk2 CD3, B220, Gr1, Mac1, Ter119 
Megakaryotic/erythroid progenitor (MEP) Ckit, CD3, B220, Gr1, Mac1, Ter119, Sca1, CD34, FcγR 
Granulocyte/monocytic progenitor (GMP) ckit, CD34, FcγR CD3, B220, Gr1, Mac1, Ter119, Sca1, 
Common myeloid progenitor (CMP) Ckit, CD34 CD3, B220, Gr1, Mac1, Ter119, Sca1, FcγR 
Table 10. Subpopulation of BM haematopoietic progenitors identified on the basis of FACS-detection of surface markers.   
3.2. LSK cell cycle analysis 
For the LSK cell cycle status and apoptosis analysis, 5x105 BM-derived MACS-sorted lineage 
negative cells from 6 week old CD18HYP and CD18WT mice were resuspended in Hoesch binding buffer 
(Hank’s balanced salt solution containing 20 mM HEPES, 5.5 mM Glucose and 10% HyClone) and stained 
for DNA and RNA using Hoechst 33342 (Sigma-Aldrich, St. Louis, USA) and Pyronin Y (Sigma-Aldrich, St. 
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Louis, USA). These cells were then labelled for LSK phenotype analyses using a cocktail of monoclonal 
antibodies listed on Table S1. Cells were analysed by flow cytometry in the Influx cell sorter (BD/Becton, 
Dickinson and Company, New Jersey, USA). 
3.3. Annexin V apoptosis study 
Apoptosis was studied in Gr1+ BMCs using FITC apoptosis detection Kit I (BD 
Pharmingen/Becton, Dickinson and Company, New Jersey, USA). 2x105 fresh isolated BMCs were first 
stained with a Gr1-PE antibody. Then cells were resuspended in 200 µL of binding buffer at 106 
cells/mL. 100 µL were stained with 5 µL of FITC-annexin V (AV). Cells were gently vortexed and 
incubated for 15 min at RT in the dark. Finally, 400 µL of binding buffer containing DAPI were added to 
the cells. The samples were immediately analysed by flow cytometry. Cells in early apoptosis were 
identified as the AV+ DAPI- population. In contrast, cells in late apoptosis or already dead were 
identified as AV+ DAPI+ population.  
4. Lentiviral vectors 
4.1. Plasmids 
 Bacterial plasmids containing the different lentiviral constructs used were generated using 
typical procedures of molecular biology. All the enzymes used during the cloning such as restriction 
enzymes, ligases, polymerases, kinases and phosphatases were obtained from New England Biolabs 
(Ipswich, USA). After each ligation, the resulting products were transformed in TOP10 bacteria 
(Invitrogen/Life Technologies/Thermo Fisher Scientific, Waltham, USA). Plasmid DNA was purified from 
selected colonies and analysed by restriction analysis. 
4.1.1. CD18-LV cloning 
Four different promoters were selected to drive the expression of the human CD18 cDNA 
(hCD18). Two of them are ubiquitous promoters, PGK and UCOE, and the other two are myeloid 
promoters, chimeric promoter (Chim) and MIM.  
Chim promoter is a fusion of the FES and the CTSG minimal 5′-flanking regions (where the TATA 
box of the CTSG promoter is mutated in order to limit transcriptional initiation to the FES minimal 
promoter only). CTSG gene encodes a protein known as cathepsin G, which is a serine protease 
expressed during neutrophil maturation. FES gene codifies for a protein known as tyrosine-protein 
kinase Fes/Fps, which is implicated in the normal development of macrophages and neutrophils. Chim 
promoter drives a specific myeloid expression both in human cell lines and in mice, where the highest 
levels of expression are seen in Gr-1+ and CD41+ cells. A SIN LV expressing gp91Phox protein under the 
control of the Chim promoter has been successfully used for haematopoietic ex vivo GT in a mouse 
model of X-CGD115 and has been proposed for a future clinical trial. 
MIM promoter is a fusion of the promoter and the enhancer sequences of the chicken LECT2 
gene, containing several C/EBP-beta binding sites164.  This gene encodes for a protein known as myeloid 
protein 1 (MIM-1), implicated in granulocytic differentiation. In a xenotransplantation model, where 
human CD34+ cells were transduced with a lentiviral vector expressing GFP under the control of the 
MIM promoter, the highest levels of expression were observed in CD15+CD33- and CD15+CD14- 
neutrophils (Personal communication). 
Ubiquitin chromatin opening elements (UCOEs) consist of methylation-free CpG islands 
surrounding dual divergently transcribed promoters of housekeeping genes165. These genetic elements 
have some characteristics that make them suitable for GT such as resistance to transcriptional silencing 
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and consistent and stable transgene expression in tissue culture systems166. The UCOE from the human 
HNRPA2B1-CBX3 locus (A2UCOE) have been successfully used within the context of a SIN LV to drive the 
expression of IL2GR for ex vivo GT experiments in a mouse model of X1-SCID167. The A2UCOE promoter 
displays little or no methylation both in vivo and in vitro and can provide protection from methylation 
to other promoters when linked upstream168-170.  
The plasmids containing Chim, MIM and A2UCOE promoters, pCCL.Chim.GFP.Wpre*115, 
pCCL.mim.gp91.Wpre* (data not published) and pHR’.A2UCOE.GFP167  plasmid were kindly provided by 
Dr. Adrian Thrasher and Dr. Giorgia Santilli (Institute of Child Health – University College of London, 
London, United Kingdom). The plasmid containing the hCD18 (HsCD00044736) was obtained from 
Harvard PlasmID (Harvard Medical School, Boston, USA).  
An ampicylin-resistant plasmid containing the pCCL SIN lentiviral backbone with an internal PGK 
promoter and the Wpre* sequence (pCCL.PGK.eGFP.Wpre*), kindly provided by Dr. Luigi Naldini (San 
Raffaele-Telethon Institute for Gene Therapy, Milan, Italy),  was used to clone the four hCD18-LVs.  
4.1.1.1. pCCL.PGK.CD18.Wpre* plasmid 
A fragment containing the lentiviral backbone and the PGK promoter (7181 bp) was obtained by 
digestion of pCCL.PGK.eGFP.Wpre* plasmid (7929 bp) with BamHI. The generated overhang ends were 
blunted using a T4 DNA polymerase. This fragment was treated with Antarctic phosphatase to prevent 
self-ligation. HsCD00044736 plasmid (4854 bp) was digested with PsiI to generate a blunt fragment 
containing the hCD18 (2370 bp). Both fragments were ligated with the T4 DNA Ligase and transformed 
in TOP10 bacteria to obtain the pCCL.PGK.CD18.Wpre* plasmid (Figure S1).   
4.1.1.2. pCCL.Chim.CD18.Wpre* plasmid 
Lentiviral backbone lacking the cPPT sequence (6500 bp) was obtained by digestion of 
pCCL.PGK.eGFP.Wpre* plasmid (7929 bp) with HpaI and BamHI restriction enzymes. On the other hand, 
a fragment containing Chim promoter together with the cPPT sequence (1021 bp) was obtained from 
the pCCL.Chim.GFP.Wpre* plasmid (8109 bp) by digestion with the same restriction enzymes. Both 
fragments were ligated with the T4 DNA Ligase and transformed in TOP10 bacteria to obtain the 
intermediate plasmid pCCL.Chim.Wpre*. This plasmid was digested with PstI, and treated with Antarctic 
phosphatase to remove the 5´ phosphate and thus avoid self-ligation. HsCD00044736 plasmid (4854 bp) 
was digested with PsiI to generate a blunt fragment containing the hCD18 (2370 bp). Both fragments 
were ligated with the T4 ligase and transformed in TOP10 bacteria to obtain the 
pCCL.Chim.CD18.Wpre* plasmid (Figure S2).   
4.1.1.3. pCCL.MIM.CD18.Wpre* plasmid 
Lentiviral backbone lacking cPPT sequence (6500 bp) was obtained by digestion of 
pCCL.PGK.eGFP.Wpre* plasmid (7929 bp) with HpaI and BamHI restriction enzymes. On the other hand, 
a fragment containing MIM promoter together with the cPPT sequence (1283 bp) was obtained from 
the pCCL.mim.gp91.Wpre* plasmid (9486 bp) by digestion with the same restriction enzymes. Both 
fragments were ligated with the T4 DNA Ligase and transformed in TOP10 bacteria to obtain the 
intermediate plasmid pCCL.MIM.Wpre*. This plasmid was digested with SmaI to generate two blunt 
ends between the promoter and the Wpre* sequence. This fragment containing the lentiviral backbone 
and the promoter was then treated with Antarctic phosphatase. HsCD00044736 plasmid (4854 bp) was 
digested with PsiI to generate a blunt fragment containing the hCD18 (2370 bp). Both fragments were 
ligated with the T4 ligase and transformed in TOP10 bacteria to obtain the pCCL.MIM.CD18.Wpre* 
plasmid (Figure S3).   
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4.1.1.4. pCCL.A2UCOE.CD18.Wpre* plasmid 
Lentiviral backbone (6648 bp) was obtained by sequential digestion of pCCL.PGK.eGFP.Wpre* 
plasmid (7929 bp) with EcoRV and XmaI restriction enzymes. On the other hand, a fragment containing 
A2UCOE promoter (2653 bp) was obtained from the pHR’.A2UCOE.GFP plasmid (11156 bp) following 
three steps: Digestion with EcoRI, generation of blunt ends with T4 DNA polymerase and digestion with 
AgeI. XmaI and AgeI are restriction enzymes that generate compatible cohesive ends. Both lentiviral 
backbone and promoter fragments were ligated with the T4 DNA Ligase and transformed in TOP10 
bacteria to obtain the intermediate plasmid pCCL.A2UCOE.Wpre*. This plasmid was digested with 
EcoRV to generate two blunt ends and then treated with Antarctic phosphatase. HsCD00044736 
plasmid (4854 bp) was digested with PsiI to generate a blunt fragment containing the hCD18 (2370 bp). 
Both fragments were ligated with the T4 ligase and transformed in TOP10 bacteria to obtain the 
pCCL.A2UCOE.CD18.Wpre* plasmid (Figure S4).   
4.1.2. shRNA-LV cloning 
Seven different shRNAs were designed against different regions of the human CD18 mRNA, 
including the coding DNA sequence (CDS) and the 3’ UTR (Figure 19). A scrambled shRNA (shSCR) was 
previously generated in the laboratory that did not recognize any sequence in the human 
transcriptome. This sequence was obtained from the plasmid pSilencer 3.1-H1 puro (Ambion/Life 
Technologies/Thermo Fisher Scientific, Waltham, USA). 
 
Figure 19. shRNA designed to recognised human CD18 mRNA. Nucleotides corresponding to the restriction sites used for 
cloning into the LVTHM backbone (MluI and ClaI) are marked in brown and nucleotides corresponding to the central loop are 
marked in orange. The shSCR was designed not to recognize any sequence of the human transcriptome so it could be used as a 
negative control. 
All the designed shRNAs were cloned into the LVTHM plasmid171,172. This plasmid contains a 
lentiviral backbone where the shRNA expression cassette is incorporated into the 3’ LTR. In this 
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cassette, the expression of the shRNA is driven by an H1 promoter and the presence of a TetO operator 
allows the regulation of the shRNA expression if desired. It also includes an EF1α promoter driving the 
expression of the eGFP reporter protein that allows an easy detection of the transduced cells (Figure 
20). 
 
Figure 20. LVTHM Lentiviral Backbone containing an shRNA expression cassete in the 3’ LTR 
First of all, double-stranded DNA sequences (as described in Figure 19) were generated by using 
complementary oligonucleotides that were flanked by MluI and ClaI restriction sites. For that, oligos 
were mixed in annealing buffer (100 mM KCH3COO; 30 mM HEPES pH7.4; 2 mM Mg(CH3COO)2 ) and 
hybridized at 95ºC for 4 min and then at 70ºC for 10 min. T4 polynucleotide kinase was subsequently 
used to transfer a Pi from the γ position of ATP to the 5´-hydroxyl terminus of the double-stranded DNA. 
Reaction was carried out at 37 ºC for 30 min and then the enzyme was inactivated at 70ºC for 10 min. 
LVTHM plasmid was digested with MluI and ClaI and then dephosphorylated using Antarctic 
Phosphatase. Digested LVTHM and double-stranded inserts were ligated by the use of T4 DNA ligase 
(Figure S5).  
4.2. Production of lentiviral vectors 
All SIN LVs were generated by a second generation packaging system in which 293T cells were 
transiently transfected with the transfer, helper (pCMVdR8.74) and envelope (pMD2.VSVg) plasmids, 
obtaining VSV-G-pseudotyped lentiviral particles (Figure 21). The pMD2.VSVg and pCMVdR8.74 
plasmids used were obtained from PlasmidFactory (Bielefeld, Germany). Transfections were performed 
on 293T cells at 70-80 % confluence in 150 mm diameter plates following the CaCl2 DNA precipitation 
method previously described104,173. Briefly, culture medium was replaced for Iscove's Modified 
Dulbecco's Medium + GlutaMAX (IMDM, Gibco/Life Technologies/Thermo Fisher Scientific, Waltham, 
USA) supplemented with 10% Hyclone and 0.5% P/S one hour before transfection.  
 
Figure 21. Second generation packaging strategy for lentiviral vector production. 
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The amounts described below correspond to one plate of 293T cells. Mixtures of the three 
plasmids were prepared freshly containing 40 µg of the corresponding transfer plasmid, 16.25 µg of the 
second generation pCMVdRd8.74 helper plasmid and 7 µg of the pMD2-VSV-G envelope plasmid. These 
mixtures were prepared in a final volume of 1125 µl of 0.1x Tris-EDTA buffer/dH2O (2:1) per plate and 
then 125 µl of 2.5 M CaCl2 were added. After 5 min incubation at RT, 1250 µl of 2x HBS buffer (100 mM 
HEPES, 281 mM NaCl, 1.5 mM Na2HPO4, pH 7.15) were added dropwise while vortexing at full speed, 
allowing the formation of Ca2+/DNA- precipitates. Immediately the total volume was added to the plates 
of 293T cells, which will subsequently phagocyte the precipitates. After 14 h, culture medium was 
replaced by fresh medium. Lentiviral supernatants were collected 24 and 48 h post-transfection, 
filtered through 0.1 µm pore-size filter (Milipore/Merck KGaA, Darmstadt, Germany) and concentrated 
by ultracentrifugation (25000 rpm, 2 h, 4 ºC). Viral pellets were then resuspended in StemSpam 
medium, quickly spun to eliminate insoluble junk, aliquoted and stored at -80 ºC. 
4.3. Titration of lentiviral vectors 
Viral titers were determined by infection of HT1080 cells with serial dilutions of the 
supernatants. 5x104 cells/well were seeded in 24-well tissue culture plates the day before. The same 
day of the titration, cell number in each well was determined. Serial dilutions of the lentiviral 
supernatants were prepared in DMEM-based complete medium from 1:100 to 1:100000 and then used 
to infect the HT1080 cells. After 3 days, cells were collected. 
4.3.1. Titration of GFP-containing lentiviral vectors 
Those vectors containing a GFP-expressing cassette were titered in the base of their ability to 
express this reporter protein in HT1080 cells. Thus, collected cells were analysed by flow cytoemtry for 
the percentage of GFP+ cells. Taking into account that the percentage of GFP+ cells can only take values 
from 0 to 100, so with a high amount of lentiviral particles the system reaches saturation, only those 
dilutions giving rise to values with a linear distribution were used for the calculation. An average of two-
three values was used as the final titer. The formula used for titer calculation is the following:  
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4.3.2. Titration of GFP-non containing lentiviral vectors 
Those vectors not containing a GFP-expressing cassette were titered by Q-PCR. DNA was 
obtained from the infected HT1080 cells and then analysed for the VCN (see section 5). The titer was 
calculated for each dilution and then an average of them was used as the final titer. The formula used 
for titer calculation is the following:  
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5. Quantitative PCR 
Quantitative PCR (Q-PCR) was used in order to determine VCN in transduced murine and human 
cells (using gDNA as template) or to measure mRNA levels of hCD18 and hCD11a (using cDNA as 
template). 
gDNA was extracted from a minimum of 5x105 cells using NucleoSpin® Tissue (Macherey-Nagel, 
Duren, Germany). Total RNA was isolated using Trizol reagent (Ambion/Life Technologies/Thermo 
Fisher Scientific, Waltham, USA). 1 µg of total RNA was reverse transcribed into cDNA by the use of the 
RetroScript RT kit (Ambion/Life Technologies/Thermo Fisher Scientific, Waltham, USA).  
gDNA/cDNA was further amplified by Q-PCR using specific primers (Table 11). Q-PCR 
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amplification was performed in a 7500 fast real-time PCR system (Applied Biosystems/Life 
Technologies/Thermo Fisher Scientific, Waltham, USA) using fast SYBR green PCR master mix or 
TaqMan. In the last case, the use of fluorescent probes was required (Table 12). After 95 ºC (20 s) 
incubation, amplification was performed as 40 consecutive cycles of 95 ºC (3 s) and 60 ºC (30 s). Primers 
were acquired from Grupo Taper (Alcobendas, Spain) and fluorescent probes were acquired from 
Sigma-Aldrich (St Louis, USA). 
 Primer Sequence (5’ to 3’) Tm (ºC) 
TaqMAN 
PsiF CAGGACTCGGCTTGCTGAAG 63 
PsiR TCCCCCGCTTAATACTGACG 59 
AlbF GCTGTCATCTCTTGTGGGCTG 64 
AlbR ACTCATGGGAGCTGCTGGTTC 63 
TtnF AAAACGAGCAGTGACGTGAGC 61 
TtnR TTCAGTCATGCTGCTAGCGC 60 
SyBR Green 
hCD18F CAGCAATGTGGTCCAACT 58 
hCD18R GAGGGCGTTGTGATCCAG 58 
hCD11aF GGGAATGAACCATTGACA 58 
hCD11aR GCCAGCAACGAAGTCTTT 58 
GAPDHF GGCATGGACTGTGGTCATGA 60 
GAPDHR TGCACCACCAACTGCTTAGC 60 
Table 11. List of Primers used for the different Q-PCR amplifications performed. 
 
Probe Sequence (5’ to 3’) Tm (ºC) 
PsiP [6FAM]-CGCACGGCAAGAGGCGAGG-[BHQ1] 75.7 
AlbP [TxRd]-CCTGTCATGCCCACACAAATCTCTCC-[BHQ2] 73.9 
TtnP [TxRd]-TGCACGGAAGCGTCTCGTCTCAGTC-[BHQ2] 75.7 
Table 12. List of fluorescent probes used in the TaqMan-based Q-PCR amplifications performed. 
5.1. Vector copy number determination 
The VCN is the parameter that indicates the number of integrated proviral copies per 
transduced cell. Proviral genome and host cell genome were amplified and quantified by TaqMAN-
based multiplex Q-PCR. Psi packaging sequence was used to quantify viral genome while albumin gene 
(Alb) or titin (Ttn) gene were used to quantify human or murine genome respectively. 
Quantification of viral and cell genomes was performed by interpolating the cycle threshold 
values (Ct) from the gDNA samples into a standard curve with ten-fold dilutions of plasmids containing 
known copies of both relevant sequences: Psi/Alb (contained in the pRRL.PGK.eGFP/Alb plasmid) and 
Psi/Ttn (pRRL.PGK.eGFP/Ttn). Both plasmids were kindly provided by Dr. Sabine Charrier (Genethon, 
Evry, France). Cell number corresponding to the calculated number of Alb or Ttn copies was determined 
assuming that each cell contains two copies of them. VCN was finally calculated as: 
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5.2. Relative expression of hCD18 and hCD11a 
Gene expression was calculated in based on ∆∆Ct calculation, which yields a normalized and 
relative gene expression value. This is accomplished by normalization of the gene of interest to an 
endogenous reference gene whose expression is considered to be invariable among samples. 
Afterwards, this value is normalized to the gene expression detected in a separate control sample.  
hCD18 and hCD11a expression in transduced lymphoblastoid cells and CD34+ cells was 
normalized to GAPDH reference gene expression levels within the same sample to determine ∆Ct. This 
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step serves to correct for non-treatment-related variation among wells such as potential differences in 
cell number.  
∆Ct  	)* K 	L 
This value was exponentially transformed and normalized to the expression of hCD18 and 
hCD11a respectively in untransduced cells. 
Relative	expression	$∆∆Ct&  2
$∆PQRSTUVWXYZW	YZ[[V&
2$∆PQXURSTUVWXYZW	YZ[[V& 
6. Statistical analysis 
The statistical analysis was performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego, USA, www.graphpad.com). For the analyses we performed a non-
parametric Mann-Whitney test or Kruskal-Wallis test. The significances are expressed as 
P<0.0001(****), P<0.001(***), P<0.01(**) or P<0.05(*). 
  
  
Results 
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1. Haematopoietic characterization of CD18HYP mice 
1.1. Study of the LAD-1 phenotype 
1.1.1. Haematological counts 
LAD-I human patients and different LAD-I animal models have a characteristic increment of 
circulating leukocytes in PB. We studied absolute numbers of total leukocytes, lymphocytes and 
granulocytes in PB samples from CD18WT and CD18HYP mice. As shown in Figure 22, all the parameters 
were statistically increased in CD18HYP PB samples in comparison with CD18WT PB samples 
 
Figure 22. Haematological counts for total leukocytes, lymphocytes and granulocytes in CD18WT and CD18HYP mice PB samples. 
The significance of differences between groups are expressed as P<0.0001 (****). 
1.1.2. β2-integrins expression in peripheral blood leukocytes and total bone marrow 
cells 
Peripheral blood leukocytes (PBLs) from CD18WT and CD18HYP mice were analysed by flow 
cytometry for the expression of the β2 common subunit (CD18) and the three different α subunits that 
are associated with it (CD11a, CD11b and CD11c). 
  
Figure 23. Expression of β2-integrins subunits in CD18
HYP
 mice PBLs relative to the expression found in CD18
WT
 mice PBLs. A) 
Relative CD18 surface expression in granulocytes (Gr-1), T cells (CD3) and B cells (B220) from CD18
HYP
 mice. B) Relative CD11a, 
CD11b and CD11c surface expression in PBLs from CD18
HYP
 mice. The significance of differences between CD18
HYP
 and CD18
WT
 
expression is expressed as P<0.05 (*) and P<0.01 (**). 
CD18 expression was analysed in three different subpopulations of PBLs (T cells, B cells and 
granulocytes), that were identified on the basis of their characteristic expression of surface markers 
CD3, B220 and Gr-1 respectively (Figure 23). An 80% reduction in CD18 surface expression levels was 
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found in B cells from CD18HYP mice in comparison with CD18WT mice while 70% and 63% reductions in 
CD18 expression levels were found in granulocytes and T cells respectively compared with CD18WT mice 
(Figure 25A). In line with these results, expression levels obtained for the three analysed α subunits 
(CD11a, CD11b and CD11c) were approximately 40% of the expression levels found in CD18WT PBLs 
(Figure 25B). Not only expression levels but also proportion of β2-integrins expressing cells was reduced 
in CD18HYP mice in comparison with CD18WT mice, apart from Mac-1+ cells (CD18+/CD11b+) that were 
slightly increased (Figure 24). 
  
Figure 24. Flow cytometry analysis of the expression of β2-integrins in PBLs. A) Dot Plots from representative CD18
WT
 and 
CD18
HYP
 mice PB samples. B) Percentage of β2-integrins
+
 cells in the studied mice groups. The significance of differences 
between groups is expressed as P<0.05 (*) and P<0.01 (**). 
The same analysis was performed in bone marrow cells (BMCs) from CD18WT and CD18HYP mice 
(Figure 25). A similar reduction of that observed in PBLs was noticed in BMCs for the four β2-integrins 
subunits from CD18HYP mice in comparison to CD18WT mice. 
1.1.3. LFA-1 and VLA-4 expression in mouse haematopoietic progenitors 
 After confirming a deep reduction of β2-integrins expression in mature PBLs and in total BMCs, 
mouse haematopoietic progenitors (LSK cells) from CD18WT and CD18HYP mice were interrogated for the 
expression of LFA-1 (CD18/CD11a) and the expression of the β1-integrin VLA-4 (CD24/CD49d) (Figure 
26A). Almost all LSK cells from CD18WT and CD18HYP mice expressed both VLA-4 subunits. In the case of 
LFA-1 integrin, only a tiny population of LSK cells from CD18HYP mice expressed CD18 and CD11a 
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subunits while 80% of LSK cells from the CD18WT mice expressed both subunits.  
  
Figure 25. Relative surface expression of β2-integrin subunits (CD18, CD11a, CD11b and CD11c) in BMCs from CD18
HYP
 mice 
normalized to that of BMCs from CD18
WT
 mice. The significance of differences between CD18
HYP
 and CD18
WT
 expression is 
expressed as P<0.01 (**) and P<0.001 (***). 
The small LFA-1-expressing population of LSK cells in CD18HYP mice displayed a marked 
reduction in expression levels of CD18 and CD11a in comparison with CD18WT mice while no differences 
in CD29 and CD49a expression levels were observed between groups (Figure 26B). 
  
Figure 26. Flow cytometry analysis of LFA-1 and VLA-4 expression in LSK cells from CD18WT and CD18HYP mice. A) VLA-4+ and 
LFA-1
+
 LSK cells found within BM of CD18
WT
 and CD18
HYP
 mice. B) Relative surface expression of VLA-4 subunits (CD29 and 
CD49d) and LFA-1 subunits (CD18 and CD11a) in LSK cells from CD18
HYP
 mice normalized to that of LSK cells from CD18
WT
 mice. 
The significance of differences between groups is expressed as P<0.05 (*). 
1.1.4. Study of neutrophil migration capacity in a LPS-induced asthma model 
As a consequence of ITGB2 mutations, leukocytes (mainly neutrophils) from LAD-I patients are 
unable to extravasate from PB to the infection sites. In order to confirm if the partial reduction of β2-
integrins expression in CD18HYP mice give rise to an impaired neutrophil migration capacity, CD18WT and 
CD18HYP mice were subjected to a LPS-induced asthma model. In this assay, mice were intranasally 
treated with LPS or PBS (as an untreated control). 24 hours later BAL was performed to collect the 
content of the epithelial lining fluid and determine the cellular composition of the pulmonary airways. 
In this context, the BAL fluid is mainly composed by alveolar macrophages (Ly6GLOW/CD11c+) and 
neutrophils (Ly6GHIGH/CD11c-) (Figure 27A). Cell count was determined and the percentage of 
neutrophils was analysed by flow cytometry in order to calculate the absolute number of neutrophils 
that had migrated to the lungs in response to the LPS stimulus (Figure 27B). A 55% reduction in the 
neutrophil migration capacity was observed in CD18HYP mice in comparison with CD18WT mice, 
indicating that the observed partial reduction of β2-integrins expression is sufficient to generate a LAD-I 
phenotype in CD18HYP mice. 
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Figure 27. LPS-induced asthma model. A) Representative flow cytometry analysis of the hematopoietic population that can be 
found in a BAL from CD18
WT
 mice treated intranasaly with PBS and LPS respectively. B) Relative numbers of neutrophils 
collected by BAL. Total collected cells were counted with the haemocytometer and the proportion of neutrophils was 
determined by flow cytometry to determine absolute number of neutrophils. Relative number of neutrophils in CD18
HYP
 vs. 
CD18
WT
 is shown. The significance of differences between groups is expressed as P<0.01 (**). 
1.1.5. Study of neutrophil migration in the air pouch model 
Ding et al174 described defects in neutrophil migration to a subcutaneous air pouch (AP) in 
response to TNF-α in CD11a-/- and CD18KO in comparison to WT animals. We performed a similar 
comparison with CD18HYP and CD18WT mice. Four hours after TNF-α injection, the content of the AP was 
collected and analysed. CD18WT animals were able to mount a proper inflammatory response after TNF-
α stimulus as observed by the increment of the leukocyte emigration ratio (Figure 28). On the contrary, 
no significant difference in the emigration ratio was observed between TNF-α and vehicle group in 
CD18HYP mice. These results indicated that CD18HYP leukocytes are not able to migrate to a 
subcutaneous air pouch in response to TNFα stimulus. This migration defect was more pronounced 
when the emigration ratio was studied in the neutrophil population. Interestingly, the neutrophil 
emigration ratio was also decreased in basal conditions in CD18HYP mice in comparison with CD18WT 
mice. 
  
Figure 28. TNFα-induced inflammation model in a subcutaneous AP. The emigration ratios for total leukocytes and neutrophils 
are shown. The significance of differences between groups is expressed as P<0.01 (**). 
1.2. Study of the role of β2-integrins in the regulation of haematopoietic 
stem cells 
1.2.1. In vitro analyses of the haematopoietic stem cell content in CD18HYP 
Adhesion molecules can play roles other than their canonical functions during the LAC. Mice 
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with mutations in different selectin genes have been recently described to present a higher content of 
haematopoietic progenitors18. To study the impact of Itgb2 mutations in the BM HSC content, BM 
samples from CD18WT and CD18HYP mice were interrogated by flow cytometry for the percentage of LSK 
cells (Figure 29). A 2.1-fold increase in the percentage of LSK cells was in CD18HYP mice in comparison 
with CD18WT mice, while no changes in cellularity were observed between these mice. A similar 
enrichment in BM LSK cells was observed in another adhesion molecule-deficient mouse model, PEdKO, 
which is a knock-out model for P- and E-Selectins. Although the role of adhesion molecules such as 
integrins or selectins in mature leukocytes have been extensively studied and described, little is known 
regarding its possible function in HSCs.  
  
Figure 29. Proportion of HSCs with LSK phenotype in BM samples from CD18WT and CD18HYP mice. The significance of 
differences between groups is expressed as P<0.05 (*). 
A more detailed study of the HSCs content was performed by flow cytometry using a complex 
panel of surface markers that allowed us to distinguish three subpopulations inside the LSK population: 
LT-HSCs, ST-HSCs and MPPs (Figure 30). A significant increment in the proportion of LT-HSCs and ST-
HSCs and a non-significant increment in the MPP were observed in BM samples from CD18HYP mice in 
comparison with CD18WT mice. 
  
Figure 30. Flow cytometry characterization of different subpopulations of LSK cells from CD18HYP and CD18WT mice: long-term 
haematopoietic stem cells (LT-HSC), short-term haematopoietic stem cells (ST-HSC) and multipotent progenitors (MPP). 
Specific markers are shown in Materials and Methods Section. The significance of differences between groups are expressed as 
P<0.01 (**) and P<0.0001 (****). 
Clonogenic studies in methylcellulose were performed with BMCs and MACS-sorted Lin- cells 
from CD18WT and CD18HYP mice. In both cases, CD18HYP samples gave rise to a higher number of CFUs in 
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comparison with CD18WT samples (Figure 31).  
  
Figure 31. Analysis of the haematopoietic progenitor content in 6 week-old CD18WT and CD18HYP mice. The number of CFUs 
present in purified lin
-
 (Panel A) and total BMCs (Panel B) from CD18
WT
 and CD18
HYP
 mice is shown. The significance of 
differences between groups is expressed as P<0.0001(****) and P<0.001(***). 
1.2.2. In vivo quantification of haematopoietic stem cells by limiting dilution assay 
The LDA, which is considered the gold standard method to assess the HSC content, is based on 
the fact that it is possible to estimate the number of HSCs by injection of distinguishable cell mixtures of 
a control and the population of study into irradiated recipients. In these mixtures, the proportion of the 
population of the study is progressively reduced. After transplantation, the percentage of differentiated 
cells produced by the population of the study is used to estimate the number of HSCs. 
 
CD18WT CD18HYP 
Transplanted Cell number Tested Positive Tested Positive 
500,000 4 4 4 4 
150,000 4 4 7 7 
50,000 5 5 5 5 
25,000 7 3 5 3 
15,000 4 2 7 4 
HSC Frequency 1/26,054 1/18,769 
P value 0.483 
Table 13. LDA with CD18HYP and CD18WT BMCs. The table summarizes the number of tested and positive animals for each of 
the transplantation groups, the estimated frequency of HSCs and the statistical analysis. 
Five doses of BMCs from CD18HYP and CD18WT were transplanted (together with a 
radioprotective dose of BMCs) into lethally irradiated P3B mice. At 3 mpt, levels of CD45.2 
(corresponding to the population of study) were determined within myeloid and lymphoid populations 
(see Materials and Methods section 1.3.2.). Based on these results, positive engrafted animals (>1% of 
both myeloid and lymphoid donor cells) were identified (Table 13). ELDA analysis performed on these 
results allowed us to estimate the frequency of HSCs within the initial dose of transplanted BMCs. There 
was a trend for HSCs to be more frequent within CD18-defficient BMCs (1/18,769) than in CD18-
proficient BMCs (1/26,054), although these results were not statistically significant. 
1.2.3. Characterization of CD18HYP LSK cells: Cell cycle, apoptosis and homing capacity 
LSK cells were evaluated for their cell cycle and apoptosis status by co-staining with Hoechst 
33342 and Pyronin Y. Hoechst 33342 is an exclusive DNA dye while Pyronin Y reacts with both DNA and 
RNA, but in the presence of Hoechst 33342, Pyronin Y reaction with DNA is blocked, so Pyronin Y stains 
only RNA. This staining allowed us to distinguish among cells in G0, G1, and S+G2+M cell cycle phases. A 
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significant increase in the proportion of LSK cells in G0 phase was found in CD18
HYP mice BM samples 
(Figure 32A), while no significant differences were found in the proportion of LSK cells in the rest of the 
cell cycle phases. This result indicated that CD18 deficiency leads to an enrichment in quiescent HSCs.  
The role of CD18 in the regulation of apoptosis in neutrophils has been extensively studied. The 
engagement of β2-integrin Mac-1 on neutrophils can either inhibit or enhance apoptosis depending on 
the activation state of the integrin and the presence of proapoptotic stimuli. Gr1+ BMCs were stained 
with a fluorescent AV conjugate, with a high affinity for phosphatidylserine, which is translocated from 
the inner to the outer leaflet of the plasma membrane in apoptotic cells. Gr1+ BMCs from CD18HYP mice 
have reduced levels of apoptosis compared to WT cells, as previously described for mature circulating 
neutrophils (Figure 32B). Apoptotic cells are characterized by a reduced DNA content due to that 
fragmented DNA leak out of the cells. Thus, apoptotic LSK cells were identified as the subG0 population. 
We did not detect any difference in the proportion of SubG0 cells in BM LSKs, suggesting that CD18 does 
not play a role in the regulation of apoptosis in HSCs (Figure 32A). 
  
Figure 32. Apoptosis and cell cycle status in BMCs from CD18WT and CD18HYP mice. A) Cell cycle study of LSK cells by co-staining 
with Hoechst 33342 and Pyronin Y. B) Apoptosis study of Gr-1
+
 BMCs by AV staining. The significance of differences between 
groups are expressed as P<0.05 (*) and P<0.01 (**).  
 
Figure 33. Seeding efficiency of FACS-sorted and DiD-stained BM LSK cells from CD18HYP or CD18WT mice intravenously 
transplanted into lethally irradiated WT recipients. 
Although current data indicate that β2-integrins do not play a direct role in HSC homing, it has 
been described that if the function of β1-integrins is compromised, defects in β2-integrin expression 
lead to a synergistic impairment in HSC homing78,175. To determine whether the seeding efficiency was 
affected in CD18HYP HSCs, BM samples were obtained from CD18HYP or CD18WT mice and LSK cells were 
FACS-sorted. These cells were stained with DiD and subsequently intravenously administered into 
lethally irradiated WT recipients. These animals were culled after 16 h and their BMCs were collected to 
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detect homed DiD+ LSK cells. We found that defective CD18 expression in HSCs has no effect on their 
homing capacity in irradiated CD18WT recipients (Figure 33). 
1.2.4. Regulation of the haematopoietic stem cell compartment by aged neutrophils 
clearance 
Clearance of PB aged neutrophils to the BM has recently been described to play an important 
role in mouse HSC regulation18. P- and E-selectin deficiency affects neutrophil migration back to the BM 
leading to enrichment in HSCs as observed in PEdKO mice. Aged neutrophils are defined in PB by high 
expression levels of CXCR4 and low levels of CD62L (Ly6G+ CXCR4high CD62Llow). 
  
Figure 34. FACS analysis of aged neutrophils (Ly6G+ CXCR4high CD62Llow) in representative PB samples from PEdKO, CD18HYP and 
CD18
WT
 mice. 
PB samples from PEdKO, CD18HYP and CD18WT mice were analysed for the presence of aged 
neutrophils (Figure 34). While a small proportion of aged neutrophils could be detected in CD18WT mice 
(7%), PEdKO mice presented a huge accumulation of these cells (95%). In the case of CD18HYP mice, we 
could observe an intermediate situation between PEdKO and CD18WT (57%), likely due to the reduced 
but detectable presence of β2-integrins expression. This result suggested that clearance of CD18-
defective neutrophils to the BM was partially impaired in comparison with CD18WT mice.  
To clarify if the partial accumulation of aged neutrophils in the PB of CD18HYP is responsible for 
the observed HSC enrichment in the BM, we carried out an experiment where ex vivo senesced WT 
neutrophils were daily transferred during 5 days into CD18HYP mice. If the observed HSCs enrichment in 
CD18HYP BM occurs as a consequence of the lack of the signalling pathway initiated by the clearance of 
aged neutrophils to the BM, the transfer of WT neutrophils, which are able to properly migrate back to 
the BM, should restore a normal proportion of LSK cells. At day 6, BMCs were collected and the 
percentage of LSK cells was determined. As shown in Figure 35A, no significant differences were 
detected in the proportion of LSK cells among non-treated, PBS-treated or neutrophil-transferred 
CD18HYP mice.  
Donor neutrophils were purified from the BM of P3B mice (CD45.1) with a purity of 85.5±2.7 of 
Ly6G+ cells (Figure 17). To discard the possibility that donor neutrophils samples could have some 
contaminating LSK cells that could have homed in the recipient BM, thus masking a possible reduction 
in the proportion of LSK cells after WT neutrophil transference, we analysed the presence of donor cells 
in the recipient BM. Although it was possible to detect donor cells within recipient BM by the analyses 
of CD45.1+ cells, no CD45.1+ donor LSK cells were detected (Figure 35B). All together, these results 
indicate that the HSC enrichment observed in CD18HYP mice BM is not caused by defects in neutrophil 
extravasation and that, in this particular mouse strain, other factors should play a role in the observed 
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HSC phenotype.  
  
Figure 35. A) Determination of LSK cell proportion in non-treated (-) CD18WT mice and non-treated (-), PBS-treated (PBS) and 
neutrophils-transferred (NF) CD18
HYP
 mice. B) Analysis of donor cells in the BM of neutrophil-transferred CD18
HYP
 mice.  The 
significance of differences between groups are expressed as P<0.05 (*) and p<0.01 (**). 
1.2.5. Competitive repopulation assays 
As clearance of aged neutrophils seemed not to be the mechanism responsible for the HSC 
enrichment observed in the BM of the CD18HYP mice, we decided to study whether this HSC enrichment 
could be due to other factors. CD18 deficient expression in HSCs could affect their interaction with 
other BMCs in the niche or could mediate an autonomous effect on HSCs self-renewal. In order to study 
the different possible mechanisms involved in the observed phenotype we conducted in vivo CRAs. In 
this kind of experiments, two different competitor populations of haematopoietic repopulating cells 
(total BMCs, lin- cells, purified HSCs…) are mixed and transplanted together in conditioned recipients, 
thus making possible to study which is the contribution of each competitor population to the recipient 
haematopoiesis. To this aim, we mixed together different populations of haematopoietic cells from 
CD18HYP and CD18WT mice to evaluate the repopulation properties of CD18-defficient HSCs. In our case 
P3B-ΔhCD4 mice, which were previously generated in the laboratory149, were used as a CD18WT BM 
competitor population and P3B mice as WT recipients. These mice express a truncated hCD4 protein 
(ΔhCD4) as a panleukocytic marker. In combination with the classical CD45.1 and CD45.2 markers, 
ΔhCD4 detection allowed us to distinguish both competitor populations and the possible remaining 
endogenous haematopoiesis (see Materials and methods for the identification of the different 
populations on the basis of these surface markers). 
We performed two different CRAs where total BMCs or purified lin- cells from CD18HYP and 
CD18WT mice were mixed at the same proportion and transplanted into lethally irradiated WT recipients 
(Table 14). Donor chimerism levels were evaluated both in PB and BM.  
 Cell type Proportion CD18WT/CD18HYP Administered cell dose 
Experiment 1 Total BMCs 50:50 3x106 
Experiment 2 Lin- cells 50:50 3x105 
Experiment 3 Total BMCs 70:30 3x106 
Table 14. Competitive repopulation assays performed with haematopoietic repopulating cells from CD18WT and CD18HYP mice. 
In the first experiment, a mixture of total BMCs from CD18HYP and CD18WT at the same 
proportion was used to transplant lethally irradiated WT recipients. Four months after transplantation, 
primary recipients were culled and their BMCs were collected and transplanted into secondary 
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recipients. The study of donor chimerism levels in PB revealed a higher contribution of CD18HYP cells to 
the haematopoietic reconstitution of recipient mice (Figure 36A). CD18-deficient derived 
haematopoiesis increased over time in PB and increased from primary to secondary recipients. Donor 
chimerism was also evaluated in total BMCs and in BM-derived CFUs, showing that CD18-deficient cells 
represented more than 80% of the cellularity in these populations (Figure 36B). 
  
Figure 36. Donor chimerism levels in lethally irradiated WT (P3B) animals transplanted with a mixture of BMCs from CD18HYP 
and CD18
WT
 (P3B-ΔhCD4) mice at the same proportion. A) PB donor chimerism levels in primary and secondary recipients. B) 
Donor chimerism levels in total BMCs and BM-derived CFUs in primary recipients 4 months after transplantation. The 
significance of differences between groups is expressed as P<0.0001 (****). 
In a second experiment, BM-derived purified lin- cells from CD18HYP and CD18WT mice were 
mixed at the same proportion and then transplanted into lethally irradiated WT recipients. The use of 
lin- cells, which represent a BM population enriched in haematopoietic progenitors, resulted in a much 
higher contribution of CD18-deficient cells to the haematopoietic reconstitution of recipient mice, both 
in PB (Figure 37A) and BM (Figure 37B)  
  
Figure 37. Donor chimerism levels in lethally irradiated WT animals (P3B) transplanted with a mixture of BM-derived lin- cells 
from CD18
HYP
 and CD18
WT
 (P3B-ΔhCD4) mice at the same proportion. A) PB donor chimerism levels during 4-month’s follow up. 
B) Donor chimerism levels in total BMCs and BM-derived CFUs 4 months after transplantation. The significance of differences 
between groups is expressed as P<0.01 (**). 
 Finally, we conducted a third CRA in which non-purified BMCs from CD18HYP and CD18WT mice 
were mixed at a 30:70 proportion and transplanted into lethally irradiated WT recipients (Table 14). 
Taking into account the different LSK cell content of each BM population, similar numbers of LSK cells 
would have been infused at this ratio. In spite of the low proportion of total CD18HYP BMCs transplanted 
in these animals, a progressive increase of CD18HYP-derived haematopoiesis could be observed in PB 
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analyses from primary recipients. In secondary recipients, a 50% of CD18HYP PB chimerism was observed 
up to 120 days post-transplantation, consistent with the initial proportion of CD18HYP transplanted LSK 
cells. (Figure 38A). Analyses of BM chimerism revealed similar contribution of both populations to BM 
cellularity. This was also observed when donor chimerism was analysed within LSK population and BM-
derived CFUs (Figure 38B, upper panel). Remarkably, when BM-chimerism from secondary recipients 
was analysed, a tendency for the CD18-defficient haematopoiesis to be predominant was observed, 
reaching statistical significance within the LSK cell population. (Figure 38B, lower panel).  
  
Figure 38. Donor chimerism levels in lethally irradiated WT animals (P3B) transplanted with a mixture of total BMCs from 
CD18
HYP
 and CD18
WT
 mice (P3B-ΔhCD4) at 30:70 proportion. A) PB donor chimerism levels in primary and secondary recipients. 
B) Donor chimerism levels in total BMCs, LSK population and BM-derived CFUs in primary and secondary recipients at 5 and 4 
months after transplantation respectively. The significance of differences between groups is expressed as P<0.05 (*). 
2. LAD-I gene therapy in human models 
2.1. Phenotypic correction of LAD-I lymphoblastoid cells 
The ZJ cell line is a LAD-I patient derived LCL with no detectable expression of β2-integrins. As a 
proof of concept for the in vitro GT of LAD-I, ZJ cells were transduced with a LV where the human CD18 
cDNA is expressed under the control of the Chimera promoter (LV:Chim.hCD18) at increasing MOI 
values (from 1 to 100 vp/cell).  
hCD18 and hCD11a surface expression levels were first analysed by flow cytometry (Figure 39). 
Transduction of ZJ cells with LV:Chim.hCD18 at all the tested MOIs resulted in the recovery of both 
hCD18 and hCD11a membrane expression. The use of a MOI of 10 vp/cell was sufficient to recover the 
expression of both hCD18 and hCD11a in most of the cells (Figure 39A). Surface expression levels of 
both subunits were rapidly saturated from MOI 10 onward (Figure 39B). hCD18 and hCD11a surface 
expression levels showed a high degree of linear dependence with a Pearson's correlation coefficient of 
0.9888 (p-value 0.0002) (Figure 39C). On the other hand, there was no correlation between hCD18 
surface expression levels and the used MOI (data not shown). 
On the contrary, hCD18 mRNA levels in transduced ZJ cells increased proportionally to the MOI 
used (Figure 39D). This increment in hCD18 mRNA levels did not translate into any modification on 
hCD11a mRNA levels, which remained stable despite of the transduction conditions (Figure 39D). 
VCN determination, which was performed by Q-PCR using primers against LTR and hAlb, 
confirmed that increasing doses of LVs resulted in increasing levels of integrated proviral copies (Figure 
39E). 
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Figure 39. Transduction of ZJ cells with increasing MOIs of LV:Chim.hCD18: Flow citometry and Q-PCR Analysis. A) Percentage 
of hCD18/hCD11a expressing cells. B) hCD18 and hCD11a surface expression levels C) Correlation between hCD18 and hCD11a 
surface expression levels. D) mRNA CD18 and CD11a expression levels relative to untransduced ZJ cells. E) VCN determination. 
Based on the previous results we decided to perform the next experiments with a MOI of 10. As 
control for these experiments we used two WT LCLs, MARK and GUS-1, derived from two different 
healthy donors. Thus, ZJ cells were transduced with the four hCD18-LVs that we have designed. In two 
of them, CD18 is expressed under the control of ubiquitous promoters (LV:PGK.hCD18 and 
LV:UCOE.hCD18) and in the other two, hCD18 expression is driven by myeloid promoters 
(LV:Chim.hCD18 and LV:MIM.hCD18). These transduction conditions resulted in ZJ cells recovering WT 
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levels of hCD18 and hCD11a membrane expression with all LVs tested (Figure 40A). Transduced ZJ cells 
showed between 4 and 5.5 proviral copies per cell (Figure 40B). hCD18 surface expression levels were 
determined by flow cytometry and expressed as MFI per integrated proviral copy (MFI/VCN). The UCOE 
promoter drove the highest expression levels while the other 3 promoters provided very similar 
expression levels. The hCD18 expression levels drove by these promoters were very similar to  the basal 
level of hCD18 expression in the GUS-1 WT cell line and a little bit higher than that of MARK WT cell 
line, indicating that the 4 designed hCD18-LVs are able to drive physiological levels of the transgene 
when one proviral copy is integrated (Figure 40C). 
  
Figure 40. Transduction of ZJ, GUS-1 and MARK cells with hCD18-LVs and control eGFP-LV. A) Percentage of hCD18+ and 
hCD11a
+
 cells 5 days after transduction. B) VCN determination in gDNA from CD18-LVs-transduced ZJ cells 10 days after 
transduction. C) Relative hCD18 surface expression. In the case of hCD18-LVs-transduced cells, surface expression is corrected 
with the VCN. 
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phenotypic correction of these cells, we conducted two functional assays: A PMA-induced aggregation 
assay and a sICAM-1 binding assay. As controls for these experiments we used two WT LCLs (MARK and 
GUS-1) and ZJ LAD-I cells transduced at an MOI of 10 vp/cell with a LV expressing eGFP (LV:EF1α.eGFP). 
The aggregation assay is based on the ability of LCLs to aggregate when they are stimulated with 
PMA, which is a potent and sustained activator of PKC. As it could be observed in Figure 41, eGFP-
transduced MARK and GUS-1 cells were able to aggregate after PMA stimulus while eGFP-transduced ZJ 
cells presented no aggregation, either in the presence or in the absence of PMA. ZJ cells that had been 
transduced with each of the hCD18-LVs recovered the ability to aggregate after PMA stimulus, 
indicating that the ectopic provided hCD18 is functionally active. The aggregation observed in MARK 
and GUS-1 control cells and in corrected ZJ cells was abrogated in the presence of an anti-hCD18 
blocking antibody, indicating that the observed aggregation was actually dependent on hCD18 
expression. 
  
Figure 41. PMA-induced aggregation assay. Cells were incubated either with PBS (first column) or PMA (second column) and 
let to aggregate for 1 h. Anti-CD18 blocking antibody (third column) was also added to demonstrate that the observed 
aggregation was dependent on hCD18. Two types of ZJ cells transduced with LV:Chim.hCD18 were used: LM, transduced at low 
MOI (10 vp/cell) and HM, transduced at high MOI (100 vp/cell). 
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In the second functional assay we measured the ability of corrected cells to bind to a soluble 
form of the typical β2-integrins ligand ICAM-1. sICAM-1 has been found in different body fluids including 
serum, cerebrospinal liquid, urine and synovial fluid. It is normally released by endothelial cells by 
proteolytic cleavage of pre-existing ICAM-1 proteins or directly synthetized from specific mRNA after an 
inflammation stimulus176. In this assay, integrin activation of LFA-1 molecules was induced (directly 
from outside the cells) by altering the extracellular divalent cation conditions, in particular by the 
addition of millimolar levels of Mg2+ when Ca2+ is removed with a chelating agent such as EGTA. The two 
different WT LCLs showed a similar basal sICAM-1 binding capacity. However, after stimulation with 
Mg2+/EGTA, GUS-1 cells bound to ICAM-1 at a higher level than MARK cells. ZJ cells did not present any 
sICAM-1 ability either in the absence or in the presence of activating agents. On the contrary, hCD18-
LV-transduced ZJ cells bound to sICAM-1 at a similar degree than GUS-1 cells (Figure 42).  
Both functional assays were also carried out with ZJ cells that had been transduced with 
LV:Chim.hCD18 vector at a high MOI (100 vp/cell, HM). Similar outcomes were obtained in both tests 
with those cells in comparison with ZJ cells transduced at a lower MOI (10 vp/cell, LM) (Figures 43 and 
44). 
 
Figure 42. Soluble ICAM-1 binding assay. Fc-ICAM-1 chimeric protein was incubated with a PE-conjugated Anti-Fc antibody so 
ICAM-1 binding cells could be identified by flow cytometry. Cells were let to bind ICAM-1 in the presence or in the absence of 
Mg
2+
 and EGTA. Two types of ZJ cells transduced with LV:Chim.hCD18 were used: ones transduced at low MOI (10, LM) and 
others transduced at high MOI (100, HM). The significance of differences between groups is expressed as P<0.05 (*) and 
P<0.01 (**). 
2.2. CD18-interferred human CD34+ cells as a new model for LAD-I gene 
therapy  
2.2.1. Screening of different shRNA-LVs against hCD18 mRNA 
Six different shRNA sequences were cloned in a LV backbone to target different regions of the 
hCD18 mRNA. These shRNA-LVs also contained an eGFP-expression cassette, which enabled us to 
identify the interfered cells. As a proof of concept, 50 µL of the shRNA-LV supernatants were used to 
transduce both MARK and cord blood CD34+ cells from a healthy donor in order to evaluate the level of 
hCD18 downregulation driven by each shRNA-LV after 5 days in culture. Transductions were performed 
on RN and, in the case of CD34+ cells, after 2 days of cytokine prestimulation. LV:sh10 was the most 
efficient for downregulating hCD18 expression in both cell types (Figure 43A and 43B), taking into 
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account that similar levels of transduction (% eGFP+ cells) were observed in the different conditions 
(Figure 43C). LV:sh10 was therefore selected to perform the rest of the experiments. 
  
Figure 43. Transduction of MARK cells and cord blood CD34+ cells from a healthy donor with anti-hCD18 shRNA LVs. Relative 
hCD18 surface expression normalized to expression levels found in untransduced cells (A) and percentage of hCD18 expressing 
cells (B) after shRNA-LV transduction. C) Percentage of GFP
+
 CD34
+
 cells after shRNA-LV transduction. 
2.2.2. Generation of LAD-I like haematopoietic stem cells 
Cord blood CD34+ cells from different healthy donors were purified, prestimulated and 
transduced with LV:sh10 and LV:shSCR at a MOI of 100 vp/cell. After 6 days in culture, hCD18 and 
hCD11a expression was evaluated by flow cytometry (to detect cell surface expression levels) and by Q-
PCR (to determine total mRNA expression levels) (Figure 44). Consistent with data in Figure 43, levels of 
hCD18 determined by flow citometry were dramatically and significantly reduced in LV:sh10-transduced 
cells in comparison with LV:shSCR-transduced cells (Figure 44A and 44B). This effect resulted in a 
concomitant reduction of hCD11a surface expression levels (Figure 44B) in concordance with the 
requirement of this subunit to be co-expressed with hCD18. In order to evaluate if there was a direct 
relationship between higher levels of eGFP reporter gene and hCD18/hCD11a downregulation, hCD18 
and hCD11a expression were evaluated in a population of high eGFP expression. Expression of both β2-
integrin subunits was reduced in this population in comparison with the total eGFP-expressing 
population, being this difference significant in the case of hCD18 expression (Figure 44B). When the 
expression of β2-integrin subunits was analysed by Q-PCR, also a marked reduction in the hCD18 
expression was observed. However, CD11a expression levels remained unchanged after LV:sh10 
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transduction (Figure 44C), consistent with the specificity of the sh10 against hCD18 mRNA. 
 
Figure 44. Expression of β2-integrin subunits in LV:shSCR and LV:sh10-transduced healthy cord blood CD34
+
 after 5 days of 
culture. A) Representative histogram of CD18 surface expression. B) hCD18 and hCD11a surface expression levels. MFI values 
were normalized to MFI values of untransduced cells. C) hCD18 and hCD11a relative gene expression assessed by Q-PCR data 
using a ∆∆Ct method with GAPDH as an endogenous reference gene and normalized to untransduced cells. The significance of 
differences between groups is expressed as P<0.05(*) and P<0.001 (***). 
2.2.3. Neutrophil differentiation and functional evaluation  
In order to generate CD18-interferred neutrophils in vitro, healthy cord blood CD34+ cells were 
transduced with LV:shSCR and LV:sh10 and expanded for 2 days. Then, transduced eGFP+ cells were 
sorted out and cultured for 1 day in expansion medium. On the next day an aliquot of LV:sh10-
transduced cells was transduced with the therapeutic LV:Chim.hCD18 at a MOI of 100 vp/cell. 
Transduced and untransduced cells were then cultured for 12 additional days in differentiation media 
containing G-CSF, IL3 and SCF. Thus, four types of neutrophils were generated: untransduced, control 
(LV:shSCR), LAD-I like (LV:sh10) and corrected LAD-I like (LV:sh10 + LV:Chim.hCD18) (Figure 45). 
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Figure 45. Different types of in vitro differentiated neutrophils generated from cord blood healthy human CD34+ cells and their 
characteristics. 
The expression of β2-integrin subunits (hCD18, hCD11a and hCD11b) was evaluated at day 12 of 
differentiation (Figure 46). As expected, no significant differences were observed in hCD18 expression 
between untransduced (Type 1) and control (Type 2) neutrophils. Consistent with previous 
observations in undifferentiated CD34+ cells, LAD-I like (Type 3) neutrophils showed a drastic and 
significant reduction of hCD18 expression. Additionally, the expression of its counterpart subunits, 
hCD11a and hCD11b, was also significantly reduced. Transduction with the LV:Chim.hCD18 (Type 4) 
resulted in 43% recovery of untransduced neutrophil hCD18 levels. As expected, similar increments for 
hCD11a and hCD11b β2-integrins subunits expression were observed in corrected LAD-I like neutrophils 
(Figure 46). 
  
Figure 46. β2-integrins expression in control, LAD-I like and corrected neutrophils obtained by in vitro differentiation of cord 
blood CD34
+
 cells. Differentiation was carried out in the presence of SCF, IL3 and GCSF for up to 12 days. Expression levels 
were determined by flow cytometry as MFI and then normalized to the MFI of untransduced cells. The significance of 
differences between groups are expressed as P<0.05(*) and P<0.01 (**). 
VCN was also determined in 12-day differentiated neutrophils (Figure 47). Between 1.5 and 1.3 
copies per cell of the LV:sh10 and LV:shSCR were detected. VCN from LAD-I like neutrophils (Type 3) 
was subtracted from VCN detected on corrected LAD-I like neutrophils (Type 4) in order to determine 
the VCN for LV:Chim.hCD18. Thus, around 2 copies of the therapeutic LV:Chim.hCD18 were deduced to 
be integrated in corrected LAD-I like neutrophils (Type 4). 
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Figure 47. VCN determination in 12-day differentiated control (Type 2), LAD-I like (Type 3) and corrected LAD-I like (Type 4) 
neutrophils. VCN from LAD-I like neutrophils was subtracted from VCN detected on corrected LAD-I like neutrophils in order to 
determine the VCN for LV:Chim.hCD18. 
Three different functional assays were carried out to evaluate if the moderate hCD18 recovery 
obtained after LV:Chim.hCD18 had an impact on the functionality of the corrected LAD-I like 
neutrophils. In the first set of experiments, we evaluated the ability of neutrophils to bind to sICAM-1. 
As shown in Figure 48, untransduced and control neutrophils showed very similar levels of sICAM-1 
binding, both before and after stimulation. On the contrary, LAD-I like neutrophils presented a marked 
reduction in their capacity to bind sICAM-1, which was partially restored after LV.Chim.hCD18 
transduction.  
  
Figure 48. sICAM-1 binding assay on In vitro differentiated neutrophils. Cells were incubated with a chimeric sICAM-1-Fc 
protein that can be detected easily by flow cytometry. Percentage of sICAM-1 was determined before and after stimulation 
with Mg
2+
/EGTA.  
In the second set of experiments, we evaluated the adhesion capacity in a dynamic setting 
(Figure 49). For this purpose we performed a flow chamber assay in which differentiated cells were 
allowed to attach to fibrinogen, a Mac-1 ligand. Afterwards, flow rates were increased at 10–20 
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dyn/cm2 increments in 1-min intervals to a maximum sheer stress of 80 dyn/cm2. The percentage of 
adherent cells was evaluated after each increment of fluid shear stress. As expected, no differences 
were found between untransduced and control cells. However, LV:sh10 transduction resulted in a 
decreased ability to resist shear stress when cells were bound to fibrinogen. LV:Chim.hCD18 
transduction of hCD18-interferred cells resulted in a higher resistance to shear stress indicating that LV-
mediated hCD18 actopic expression was able to improve the adhesion properties of LAD-I like 
neutrophils, thus partially restoring the WT phenotype. 
  
Figure 49. Flow chamber experiments with control, LAD-I like neutrophils and corrected LAD-I like neutrophils. Cells were 
allowed to attach to fibrinogen and then non-adherent cells were removed at low flow.  Subsequently, flow rates were 
increased in 10–20 dyn/cm
2
 increments in 1-min intervals to a maximum sheer stress of 80 dyn/cm
2
. The number of attached 
cells after each increment of shear stress was calculated and expressed as a percentage of the total number of adherent cells 
in the same field after the low flow wash. The significance of differences between groups is expressed as P<0.001(***). 
Finally, we evaluated the ability of in vitro differentiated neutrophils to undergo a respiratory 
burst response (Figure 50). The respiratory burst in neutrophils plays an important role in host defence 
against pathogens and has been shown to be a CD11b/CD18-mediated function when C3bi-opsonized 
Zymosan is used as the stimulus. It is based on a rapid release of reactive oxygen species that can be 
detected by different techniques including the use of luminol, a chemical compound that exhibits 
chemiluminescence, in the presence of oxidizing agents. 
 
Figure 50. Respiratory Burst on in vitro CD34+ cells-derived neutrophils.  Respiratory burst response was induced by C3bi-
opsonized Zymosan (specifically recognized in a CD11/CD18-dependent manner) and detected by luminol-enhanced 
chemoluminescence. Luminescence detected for each sample was extrapolated for 10
6
 cells with the following equation: 10
6
 
cell luminescence = sample luminescence * 10
6
 cells / cell number. The significance of differences between groups are 
expressed as P<0.01 (**) and P<0.001(***). 
Shear stress (Dyn/cm2)
R
e
la
ti
ve
 A
tt
ac
h
e
d
 C
e
ll
 N
u
m
b
e
r
0
20
40
60
80
100
Untransduced
Control
LAD-I like
Corrected LAD-I like
1 10 20 40 60 80
***
***
***
ns
Time (minutes)
Lu
m
in
is
ce
n
se
(R
LU
 /
 1
06
 c
el
ls
 /
 1
0s
)
0
500
1000
1500
2000
2500 Untransduced
Control
LAD-I like
Corrected LAD-I like
5 15 30 45 60
***
ns
**
RESULTS │ 73 
As shown in Figure 50 control untransduced and LV:shSCR-transduced neutrophils were able to 
mount a rapid respiratory burst in the presence of opsonized zymosan that was maintained at least 
during an hour. Respiratory burst of LAD-I like neutrophils was clearly diminished in comparison to 
control neutrophils. Major differences were observed for the first two time points also showing 
statistical significance. Surprisingly, despite of the low recovery of hCD11b surface expression after 
LV:Chim.hCD18 transduction (Figure  46), corrected LAD-I like neutrophils mounted a respiratory burst 
very similar to that of the control cells. These results show that very low levels of correction are 
sufficient to restore phagocytic ability of CD18-defficient cells.  
3. Ex vivo gene therapy in CD18HYP mice 
3.1. In vitro transduction of mouse haematopoietic progenitors 
BM lin- cells, which is a population enriched in mouse haematopoietic progenitors, are often 
used as target cells in ex vivo GT experiments conducted in mice. 
Lin- cells were purified from CD18HYP BMCs by FACS. Purities from 82.3 to 97.3 % were usually 
obtained (Figure 12). Once purified, lin- cells were transduced with the different hCD18-LVs in the 
presence of haematopoietic growth factors (hIL-11 and mSCF) capable to preserve the long-term 
repopulating ability of the HSCs177. On next day cells were washed and maintained both in expansion 
medium and in myeloid differentiation medium (containing G-CSF and IL-3). Cells were differentiated 
towards the myeloid lineage since neutrophils are the mainly affected cells as a consequence of CD18 
deficiency.  
  
Figure 51. hCD18 expression in LV-transduced myeloid-differentiated CD18HYP lin- cells. A) Percentage of hCD18+ cells. B) Levels 
of hCD18 expression expressed as MFI.  
hCD18 and mCD11a surface expression levels were evaluated after 7 days of myeloid 
differentiation (Figures 51 and 52). hCD18+ cells were detected in a range between 30 and 40%, with no 
statistically significant differences among the different hCD18-LVs. In addition, hCD18 was expressed at 
very similar levels among the different hCD18-LVs (Figure 51). After 7 days of myeloid differentiation, 
untransduced and eGFP-transduced CD18HYP cells expressed about 50% of mCD11a levels observed in 
untransduced CD18WT cells. In the case of the hCD18-transduced cells, lentiviral-mediated enforced 
hCD18 expression resulted in mCD11a levels between 70 and 80% of WT levels, indicating that 
exogenous hCD18 is able to bind to mCD11a subunits and form new β2 chimeric integrins composed by 
murine and human subunits (Figure 52).  
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Figure 52. Surface expression of mCD11a in transduced, untransduced and myeloid-differentiated CD18HYPand CD18WT lin- 
cells. mCD11a surface expression levels were determined by flow cytometry and then normalized to those found in 
untransduced CD18
WT
 cells. 
hCD18 expression was also evaluated after PMA stimulation and compared to non-PMA treated 
cells. PMA stimulus resulted in a slight increment in the percentage of hCD18+ cells as can be observed 
in Figure 53. These results indicate that ectopic hCD18 is able to be up-regulated in a physiological way 
under an activating stimulus. 
  
Figure 53. Post-transductional hCD18 regulation in response to PMA in neutrophils generated in vitro form transduced CD18HYP 
lin
-
 cells. hCD18
+
 cells were determined by flow cytometry before and after PMA stimulation. 
Haematological toxicity of lentiviral transduction was evaluated by 7-day culture in 
methylcellulose (Figure 54). No differences in CFUs were observed among untransduced, eGFP-
transduced and hCD18-transduced CD18HYP lin- cells suggesting that neither lentiviral transduction nor 
hCD18 exogenous expression affects clonogenic capacity of CD18HYP murine haematopoietic 
progenitors. 
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Figure 54. Clonogenic assays in methylcellulose with transduced and untransduced CD18HYP lin- cells. 
3.2. Ex vivo gene therapy in CD18HYP mice 
Lin- cells from CD18HYP mice were isolated and transduced with the four hCD18-LVs as described 
in section 3.2 of Results. One day after transduction cells were washed and resuspended in PBS and 
transplanted into lethally irradiated CD18HYP mice. As control groups, CD18HYP mice were transplanted 
with LV:SFFV.eGFP-transduced CD18HYP and CD18WT lin- cells.  Six independent GT experiments were 
carried out (Table 15). In experiments 1 and 2, secondary transplants were also performed. As similar 
outcomes were observed in the different experiments, results were treated together. 
Experiment MOI Donor Cells Vector Number of Recipients 
1* 20 CD18HYP 
LV:Chim.hCD18 3 
LV:UCOE.hCD18 4 
2* 20 
CD18
HYP
 
LV:Chim.hCD18 3 
LV:MIM.hCD18 3 
LV:PGK.hCD18 5 
LV:SFFV.eGFP 5 
CD18
WT
 LV:SFFV.eGFP 3 
3 20 
CD18
HYP
 
LV:Chim.hCD18 5 
LV:MIM.hCD18 2 
LV:PGK.hCD18 6 
LV:UCOE.hCD18 4 
LV:SFFV.eGFP 4 
CD18
WT
 LV:SFFV.eGFP 4 
4 50 
CD18
HYP
 
LV:Chim.hCD18 3 
LV:PGK.hCD18 4 
LV:UCOE.hCD18 4 
LV:SFFV.eGFP 3 
CD18
WT
 LV:SFFV.eGFP 2 
5 50 
CD18
HYP
 
LV:Chim.hCD18 7 
LV:PGK.hCD18 5 
LV:SFFV.eGFP 4 
CD18
WT
 LV:SFFV.eGFP 6 
6 50 
CD18
HYP
 
LV:Chim.hCD18 8 
LV:PGK.hCD18 2 
LV:SFFV.eGFP 4 
CD18
WT
 LV:SFFV.eGFP 3 
Table 15. Ex vivo GT experiments carried out in CD18HYP lethally irradiated animals. Total numbers of treated animals were: 
LV:Chim.hCD18 n=29;  LV:UCOE.hCD18 n= 12; LV:MIM.hCD18 n= 5; LV:PGK.hCD18 n= 22. *In experiments 1 and 2, secondary 
transplants were also performed (See Table 15).  
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3.2.1. β2 integrins’ expression in gene therapy-treated CD18HYP primary recipients 
From the first month, hCD18+ PBLs could be detected in all recipients that had been 
transplanted with LV:hCD18-transduced cells. Interestingly, hCD18 was co-expressed with the three 
CD11 murine subunits (Figure 55).  
 
Figure 55. β2 integrins’ expression of representative GT-treated CD18
HYP
 primary recipients. 
Similar proportion of hCD18+/mCD11a+ cells was observed in PB of transplanted mice at 1 and 3 
mpt (Figure 56A). In hCD18+ cells, levels of mCD11a were higher than the ones of CD18HYP untransduced 
cells (Figure 57) indicating that hCD18 is able to heterodimerize with mCD11a increasing the expression 
of murine β2 integrins. hCD18
+ cells recovered approximately a 50% of the CD18WT mCD11a expression 
levels in all treated groups. 
RESULTS │ 77 
 
Figure 56. Percentage of hCD18+/mCD11a+ PBLs at 1 and 3 mpt in ex vivo primary (A) and secondary (B) GT-treated CD18HYP 
mice. Presented results correspond to 6 independent experiments. 
 
Figure 57. Mean of mCD11a surface expression levels (MFI) in PBLs at the different time points after transplant of transduced 
cells in primary (orange) and secondary (scratched orange) CD18
HYP
 recipient mice and eGFP control animals (dark blue and 
brown). Presented results correspond to 6 independent experiments (primary recipients) and secondary recipients from 
experiments 1 and 2. The significance of differences between groups is expressed as P<0.0001(****) and is always referred to 
the CD18
HYP
 + LV:SFFV.eGFP group. 
Three months after transplantation, hCD18 expression was evaluated in different 
subpopulations of PBLs (T cells, B cells and neutrophils). These subpopulations were identified on the 
basis of the expression of specific markers (CD3+ for T cells, B220+ for B cells and Gr1HIGH for 
neutrophils). It was possible to detect hCD18+ neutrophils, B and T cells in all the transplanted groups 
(Figure 58A). Surface hCD18+ expression levels (MFI) in myeloid cells were always higher than the ones 
observed in lymphoid cells, regardless of the nature of the promoter (ubiquitous or myeloid promoters) 
that was driving hCD18 expression (Figure 58B). However, the ratio between hCD18 expression levels in 
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myeloid and lymphoid cells in LV:Chim.hCD18 and LV:MIM.hCD18-transduced cells was higher than in 
the other groups, being statistically significant and the most similar to the CD18WT mice in the case of 
LV:Chim.hCD18 (Figure 58C). 
 
Figure 58. Lineage hCD18 surface expression after transplant of transduced cells in CD18HYP recipient mice. 
Presented results correspond to independent experiments 1 and 2. A) Percentage of neutrophils, B cells and T 
cells expressing hCD18. B) Surface hCD18 expression levels (MFI) in different haematopoeitic lineages. C) Ratio of 
myeloid and lymphoid hCD18 expression. This ratio was calculated as following: hCD18 MFI in Gr
HIGH
 cells / (hCD18 
MFI in CD3
+
 cells + hCD18 MFI in in B220
+
 cells). The significance of differences between groups is expressed as 
P<0.05(*) and P<0.01 (**).   
Four months after transplantation, primary recipients were culled and BMCs were also analysed 
for hCD18 and mCD11a expression (Figure 59). Percentages of hCD18+/mCD11a+ cells ranged from 11 % 
(in the case of LV:PGK.hCD18-treated mice) to 38 % (in the case of LV:MIM.hCD18-treated mice) in a 
very similar way to that noted in PB (Figure 59A). Furthermore, similar levels of mCD11a upregulation 
were observed in BMCs (Figure 59B). hCD18+ BMCs expressed from 51 to 62 % of the mCD11a 
expression levels observed in LV.SFFV.eGFP-treated CD18WT. 
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Figure 59. CD11a expression in BMCs of GT-treated CD18HYP mice. Presented results correspond to experiments 1 and 2. A) 
Percentage of hCD18
+
/mCD11a
+
 cells in the total BMC population at 4 months post transplantation B) mCD11a surface 
expression levels observed in the transplanted mice. The significance of differences between groups is expressed as P<0.01 
(**) and P<0.05 (*). 
3.2.2. Long term β2 integrins’ expression in gene therapy-treated CD18HYP mice 
In order to evaluate if hCD18-LVs were able to transduce true LT-HSCs, when primary recipients 
from experiments 1 and 2 were culled at 4 mpt, total BMCs from these recipients were harvested and 
transplanted into lethally irradiated CD18HYP secondary recipients (Table 16).  
Experiment Donor Cells Vector 
Number of recipients 
Pool Mouse to mouse 
1 CD18HYP 
LV:Chim.hCD18 1 3 
LV:UCOE.hCD18 1 4 
2 CD18HYP 
LV:Chim.hCD18  3 
LV:MIM.hCD18  3 
LV:PGK.hCD18  3 
Table 16. Secondary recipients from GT-treated primary CD18HYP recipients. 
Similar proportion of hCD18+/mCD11a+ cells was observed in PB of secondary recipients at 1 and 
3 mpt. In any case, these levels were reduced in comparison with primary recipients with the exception 
of LV:MIM.hCD18 group, which maintained very similar levels to that of the primary recipients. This 
reduction in the percentage of hCD18+ mCD11a+ cells is likely more related to the loss of engraftment 
ability of transduced cells after secondary transplantation rather than to epigenetic silencing of the 
promoters. Despite of the diminished proportion of hCD18+ cells, this population showed similar 
mCD11a upregulation to that of the primary recipients (Figure 57B), confirming the hypothesis that no 
epigenetic silencing was taking place. 
9 months after transplantation, secondary recipients were sacrificed and BM was collected and 
analysed for hCD18 expression. As can be observed in Figure 60, both in TBM cells and in the LSK 
population, low but still detectable levels of hCD18+ cells were observed, with the exception of 
LV:MIM.hCD18 group, which maintained a high proportion of hCD18+ cells despite of the long-time of 
analysis. 
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Figure 60. Long-term analysis of BM in secondary CD18HYP recipients. Analysis of hCD18+ cells at 9 mpt in total BMCs and in the 
LSK subpopulation.  
All these results indicate that hCD18-LVs were able to transduce true and primitive LT-HSCs, 
which can generate hCD18+ haematopoiesis in secondary recipients, and thus it is possible to detect 
hCD18+ BM cells even at 9 months after secondary transplantation.     
3.2.3. Assessment of the lentiviral vector-associated risk 
Secondary transplantation is a powerful tool to detect possible leukaemogenic events induced 
by insertional oncogenesis. However, none of the secondary recipients from hCD18-LV-treated mice 
showed symptoms of leukaemia, and all of them presented normal levels of WBCs (Figure 62) and 
normal multilineage distribution (Figure 61). 
 
Figure 61. Multilineage distribution in PB at 4 months post-transplantation of secondary recipients and age-matched 
untransplanted CD18
WT
 and CD18
HYP
 mice. 
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Although LVs have been shown to be safer in terms of insertional oncogenesis than classical 
γRVs114,178, this phenomenon is still a potential risk when using integrative viral vectors, particularly if 
multicopy insertion takes place. Therefore, in GT protocols, the number of vector copies per cell (VCN) 
is generally limited because of safety purposes. VCN was determined by Q-PCR in gDNA extracted from 
PBLs from both primary and secondary recipients. Between 1 and 0.5 proviral copies per cell were 
detected in PBLs from primary recipients and between 0.3 and 0.6 in secondary recipients. (Table 17). 
 LV:Chim.hCD18 LV:MIM.hCD18 LV:PGK.hCD18 LV:UCOE.hCD18 
Primary recipients 0.897±0.430 0.703±0.130 0.738±0.162 0.438±0.005 
Secondary recipients 0.457±0.145 0.613±0.090 0.358±0.112 0.350±0.087 
Table 17. VCN determination in gDNA extracted from PBLs from primary and secondary recipients at 3 mpt. 
3.2.4. Correction of LAD-1 phenotype in gene therapy-treated CD18HYP mice  
As mentioned in section 1.1.1., CD18HYP mice displayed leukocytosis as a typical symptom of 
CD18 deficiency. Levels of leukocytes were evaluated in ex vivo GT-treated primary and secondary 
CD18HYP mice recipients (Figure 62). Primary recipients maintained the characteristic leukocytosis along 
the analysis time. This behaviour was very similar to that observed in the control eGFP CD18HYP group. 
However, normalization in white blood cell counts could be observed in secondary recipients despite of 
having a considerable lower proportion of hCD18+ cells in PB. 
 
Figure 62. White blood cell counts in ex vivo GT-treated primary and secondary CD18HYP mice recipients.  Control mice were 
transplanted with eGFP transduced CD18
WT
 and CD18
HYP
 mice. 
CD18 deficiency leads mainly to defects in neutrophil extravasation from PB to inflamed tissues. 
As shown before in section 1.1.5., neutrophils from CD18HYP mice showed reduced capacity of 
extravasation in an air-pouch-based inflammation model. Therefore, we performed the same 
experiment with ex vivo GT-treated primary CD18HYP mice and control animals. As can be observed in 
Figure 63, hCD18+ CD18HYP neutrophils migrated to the air-pouch significantly better than eGFP+ CD18HYP 
control neutrophils and in a similar way to eGFP+ and untransduced CD18WT indicating that ectopic 
hCD18 expression was able to correct neutrophil migration defects in CD18HYP mice. 
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Figure 63. Air pouch-based inflammation model in ex vivo GT-treated primary CD18HYP recipients and control mice treated 
either with TNFα (proinflammatory stimulus) or CMC (vehicle). Neutrophils emigration ratio is calculated as described in 
material and methods from the total cell number found within the pouch and the percentage of Gr1
+
 cells determined by flow 
cytometry. The significance of differences between groups is expressed P<0.05 (*). 
Furthermore, in the group of LV:Chim.hCD18-treated CD18HYP mice we could performed a 
second functional assay to evaluate neutrophil migration capacity based on the intranasal 
administration of LPS. Although differences were not significant, we could observe a clear trend for GT-
treated neutrophils to migrate similarly or even higher than those from CD18WT animals (Figure 64).  
These two functional experiments demonstrated that hCD18+ CD18HYP neutrophils recovered the 
capability to extravasate from PB to inflamed tissues. 
 
Figure 64. Neutrophil migration to a lung inflammation model based on LPS intranasal administration. The relative neutrophil 
number is calculated as described in material and methods from the absolute cell number found in the BAL and the percentage 
of Ly6G
+
 CD11c
-
 cells determined by flow cytometry. The significance of differences between groups is expressed P<0.05 (*). 
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In the present thesis we have characterised a mouse model of LAD-1 immunodeficiency 
(CD18HYP mice), which allowed us to uncover new roles of β2 integrins in HSC regulation. Moreover, we 
have developed new LVs for the GT of LAD-I, testing them in three different models: human LCLs, 
human CD18-interferred CD34-derived neutrophils and CD18HYP mice. In any case, hCD18-LVs have 
appeared as a powerful tool for LAD-I GT. 
 
1.  Characterization of the CD18HYP mouse model: New role of 
β2 integrins in HSC regulation 
 
CD18HYP mice (B6.129S7-Itgb2tm1Bay/J) were generated by homologous recombination of a 
targeting vector containing the neomycin resistance gene75. The presence of a cryptic promoter in the 
plasmid backbone resulted in a hypomorphic mutation, leading to a decreased but not absent 
expression of CD18, resembling the characteristics of the moderate LAD-I phenotype. These mice were 
originally generated and described in a mixed background C57BL6/J and 129/Sv. They have been 
backcrossed for more than 10 generations to the C57BL/6J inbred strain but no description has been 
performed after backcrossing. Our first aim was then to characterize the CD18HYP haematopoietic 
phenotype in the C57BL6/J background. 
 
LAD-I human patients and different LAD-I animal models have a characteristic increment of 
circulating leukocytes in PB41. CD18HYP mice recapitulate this symptom, with high numbers of 
lymphocytes and granulocytes in PB in comparison to CD18WT mice (Figure 22). This neutrophilia has 
been extensively studied and several hypotheses have been proposed to explain this phenotype. The 
first one is that the defective antimicrobial function of CD18-deficient neutrophils leads to the 
occurrence of infections  and thus to a continuous BM stimulation and granulocyte production79. The 
second one is an increased production of hematopoietic cytokines, including IL-17, by unidentified cells 
in tissues due to the incapacity of CD18-deficient neutrophils to extravasate from PB. IL17 contributes 
to increase G-CSF levels thus enhancing granulopoiesis179. A third hypothesis propose that CD18-
defficiency leads to an apoptosis delay in neutrophils, leading to an alteration in their homeostasis and 
their accumulation in PB180. Related to this last mechanism, Casanova-Acebes et al18 demonstrated the 
importance of the granulocyte homeostasis maintenance in the regulation of haematopoiesis and 
showed that defects on adhesion molecules expression can alter the hematopoietic stem cell niche. All 
of these studies demonstrated that β2 integrins’ expression may be implicated in complex HSC 
regulation, that need to be further explored. 
 
First, total PBLs and BMCs were interrogated for β2 integrins’ expression and, as expected, they 
showed a marked decrease in CD18 and CD11 subunits membrane expression (Figures 23 and 25). CD18 
expression was equally reduced in T cells, B cells and neutrophils. The reduction of β2 integrins’ 
expression found in CD18HYP mice was very similar to that observed in LAD-I patients with a moderate 
phenotype. Not only the expression levels but also proportion of β2 integrin expressing cells was 
reduced in CD18HYP mice in comparison with CD18WT mice, apart from Mac-1+ (CD18-CD11b) cells that 
were slightly increased (Figure 24). Mac-1 is mainly expressed by neutrophils so this increment in Mac-
1+ cells could be related to the expansion of neutrophil population. Similar analysis was performed in 
mouse HSCs (defined as LSK cells) from CD18HYP mice. They barely expressed LFA-1 β2 integrin (CD18 
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and CD11a) while no differences were found in VLA-4 β1-integrin, suggesting that β2 integrin deficiency 
is not compensated by an overexpression of other hematopoietic integrins (Figure 26). 
 
β2 integrins play an important role during leukocyte extravasation
24. As a consequence of CD18 
deficiency, this process is particularly impaired in neutrophils41. This extravasation defect was 
corroborated in CD18HYP mice in two different inflammation models: an LPS-induced pulmonary damage 
model181 and a TNFα-induced air-pouch model. In both cases, where two different stimuli and two 
different body locations (respiratory tract and subcutaneous space) were employed, migration to the 
inflamed tissue of CD18HYP neutrophils was highly reduced in comparison to CD18WT ones (Figures 27 
and 28). These results correlated with the impaired migration of CD18HYP neutrophils to the peritoneal 
cavity described by Wilson et al75 when a chemical peritonitis was induced by intraperitoneal injection 
of thioglycollate medium. In addition, Ridger et at182 had already described that intravenous 
administration of anti-CD18 antibodies inhibited neutrophil migration after LPS instillation. Impaired 
leukocyte influx in a subcutaneous air pouch in response to TNFα was already described by Ding et al 
for both CD18KO and CD11a-/- mice while in CD11b-/- mice was markedly increased 174. According to 
these results, migration is response to TNFα can be definied as a LFA-1-dependent process. 
 
Adhesion molecules, specially integrins, do not only mediate cell-cell and cell-ECM adhesion, but 
can also play roles other than their canonical functions and affect the multitude transduction cascades 
that control cell survival, proliferation, differentiation and organ development21. In addition, some 
authors have described implications of adhesion molecules in the regulation of HSCs18,183. Thus, we 
further investigated a possible implication of β2 integrins in HSC regulation. 
 
When the LSK cell content was investigated in CD18HYP mice, a significant increment was found 
in comparison to CD18WT mice (Figure 29) and was consistent with that observed in a transgenic mouse 
model deficient in other adhesion molecules: E- and P-selectins (PEdKO mice)18. A more detailed FACS 
analysis revealed a significant increment of ST and LT-HSCs within CD18HYP BM in comparison to CD18WT 
mice (Figure 30). This enrichment was confirmed as an increased clonogenic capacity in methylcellulose 
cultures (Figure 31). These results pointed out an important role of different adhesion molecules in the 
regulation of the HSC content in BM. 
 
The gold standard test to estimate the number of HSC is the LDA184, in which graded decreasing 
donor BM cell numbers of a particular genotype are mixed with a radio-protective and constant dose of 
BMCs from a distinguishable donor. The engraftment of test donor cells is evaluated then at 3 months 
post-transplantation, both in the lymphoid and in the myeloid lineages. The number of engrafted 
animals on each transplantation group could be used to estimate the frequency of HSCs using different 
mathematical models. When using the ELDA software to analyse our results of LDAs151,185 assays with 
CD18WT and CD18HYP mice, we observed a trend showing increased number of HSCs within CD18HYP BM 
in comparison with CD18WT BM, although this difference was not statistically significant (Table 13).   
 
As previously mentioned, CD18 deficiency might be related with altered apoptosis in deficient 
cells. Gomez et al77 described reduced apoptotic levels in Gr-1+ cells in the BM of mice transplanted 
with different proportions of CD18-deficient and WT cells. We obtained similar results in Gr1+ PB cells 
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of CD18HYP mice (Figure 32B). There are many other papers in which the role of CD18 in the regulation 
of apoptosis in mature circulating neutrophils has been studied. Engagement of β2 integrin on these 
cells can either inhibit or enhance apoptosis depending on the activation state of the integrin and the 
presence of pro-apoptotic stimuli such as TNFα or FAS186,187. In our studies, a significant increment in 
the proportion of LSK cells in G0 phase within CD18
HYP BM in comparison with CD18WT was found (Figure 
32A). When apoptosis in LSK cells was analysed, no differences were found between CD18WT and 
CD18HYP mice. Thus, our results suggested that CD18 is not playing a relevant role in the regulation of 
apoptosis on early hematopoietic progenitors. 
 
Previous reports showed that deficiencies in β2 integrins by themselves do not affect the ability 
of BM cells to home to the hematopoietic niche once intravenously administered175,188. However, 
inhibition of VLA-4 in CD18 deficient HSCs resulted in a dramatic reduction in BM homing in comparison 
to the inhibition of VLA-4 in WT mice. This suggests that CD18 can contribute to BM homing when the 
function of VLA-4 is compromised175,189. Our studies on the homing ability of CD18WT and CD18HYP LSK 
cells revealed that LSK cells migrate equally to the BM regardless of the level of CD18 expression (Figure 
33). β1 integrins have shown to be essential for the retention of HSCs within the hematopoietic 
niche78,189. Thus, disrupting VCAM-1/VLA-4 axis (with antibodies or small molecules) provides modest 
mobilization in mice, macaques and humans190,191. Mobilization induced by the combination of CXCR4 
and VLA-4 blockage has been described to have an additive effect and could provide an alternative to 
G-CSF treatment190. A possible role of β2 integrins in HSC mobilization remains to be defined and 
CD18HYP mice could provide a useful model in this respect. 
 
Casanova-Acebes et al 18 described a new role of an specific population of aged neutrophils in 
HSCs regulation. These PB aged neutrophils are able to migrate back to the BM as a clearance 
mechanism. in BM, these cells are phagocytized by BM-resident macrophages, thus initiating a 
signalling cascade that leads to a reduction in the number of CAR cells and in the levels of CXCL12 that 
eventually produces the mobilization of HSCs from the BM to PB. However, the physiological 
significance of this link between hematopoietic and immune system remains to be defined. In PEdKO 
mice, deficient for the adhesion molecules P- and E-selectins, aged neutrophils are not able to migrate 
back to the BM, leading to their accumulation in PB and to the enrichment in primitive HSCs within BM. 
A more moderate accumulation of aged neutrophils was observed in CD18HYP mice (Figure 34). To clarify 
if this partial accumulation of aged neutrophils could explain the observed enrichment in HSCs in 
CD18HYP mice, we daily injected I.V. ex vivo-senesced WT neutrophils into CD18HYP mice. This procedure 
did not result in a recovery of normal levels of LSK cells in the BM of recipient mice (Figure 35). Thus, a 
possible defect in CD18-defficient neutrophil BM clearance may not be sufficient to produce the 
enrichment in BM HSCs observed in CD18HYP mice. 
 
In order to investigate if the higher content of HSCs could lead to a higher hematopoietic 
repopulation capacity of CD18HYP cells, we performed a CRA where equal proportion of CD18HYP and 
CD18WT  total BMCs were mixed together and transplanted into irradiated WT recipients. For the CRAs 
we took advantage of the P3B-ΔhCD4 mice previously generated in the laboratory149, which are 
characterized by the expression of a truncated form of the human CD4 protein (hCD4) in all the 
hematopoietic system. The use of three isogenic mouse strains (P3B-ΔhCD4 and CD18HYP as donors and 
P3B as recipients), each one expressing a different specific panleukocytic marker (hCD4+CD45.1+, 
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CD45.2+, CD45.1+ respectively) allowed us to obtain a detailed and accurate follow up of the HSC 
repopulating kinetics. After the transplantation of this mixture it was possible to observe that CD18HYP 
cells contribute greater than CD18WT cells to the hematopoietic reconstitution of recipients, both in PB 
and BM, confirming a higher repopulation capacity of CD18HYP BM cells. This repopulation capacity must 
be only due to higher capacity of the  CD18HYP HSCs to repopulate as the receptor microenvironment of 
the BM is WT. The BM of primary recipients was infused into lethally irradiated WT secondary 
recipients, where the contribution of CD18HYP cells to the hematopoietic reconstitution was even higher 
than that observed in primary recipients (Figure 36). This increment in the hematopoietic reconstitution 
capacity of the CD18HYP cells could be attributed to cells in the BM, other than the primitive HSCs, that 
could be contributing to the engraftment or helping the deficient cells to engraft. When we enriched 
the BM in HSCs and haematopoietic progenitors by lineage depletion (so less accessory cells were 
infused) and performed the CRA as defined, an even higher repopulating capacity of CD18HYP cells was 
observed (Figure 37). 
 
To demonstrate that the increased engraftment was due to the CD18HYP true HSCs we would 
need to infuse the exact same number of this true HSC population in a CRA. To this aim, a third CRA was 
carried out mixing BMCs from CD18HYP and CD18WT in a 70:30 proportion. Taking into account the 
percentage of LSK cells on each type of competitor population, the actual proportion of LSK cells in this 
mixture would be the same. At 1 mpt, CD18HYP cells contributed less than WT cells to the 
haematopoietic reconstitution, something that would be expected as less cells were infused. 
Nevertheless, the CD18HYP engraftment increased along time and when BM was analysed at 5 mpt, 
similar donor chimerism was observed from both competitor populations although the initial 
proportion of CD18HYP was more than two times lower. BMCs from these animals were transplanted 
into secondary recipients and donor chimerism was analysed. While similar engraftment levels of 
CD18HYP and CD18WT cells were observed in PB, a higher engraftment of CD18HYP cells was observed in 
the BM, being possible to detect statistically significant differences in the proportion of LSK cells (Figure 
38) at the end of the experiment. Gomez et al77 described very similar observations for CD18KO mice. 
These mice showed increased proportion of LSK cells within the BM. CRAs were conducted mixing 
different proportions of CD18KO and WT fetal liver cells and in every case the contribution of CD18KO to 
the recipient hematopoietic reconstitution was higher than the proportion in the initial mixture. 
 
On the basis of these results, we hypothesized that CD18 deficiency leads itself to a cell-
autonomous expansion of HSCs. CD18-defficiency may deprive HSCs from specific signalling leading to 
deregulation of the normal HSC pool. The fact that the deficiency of CD18 in HSC might be the 
mechanism underlying the enrichment in HSCs was confirmed by the observations in secondary 
recipients. CD18HYP HSCs transplanted in a WT environment are able to expand and contribute in a 
higher extent to the secondary recipient’s hematopoietic reconstitution. If the enrichment of CD18HYP 
HSCs was due to CD18-defficiency in other cells different from HSCs themselves, the presence of WT 
cells either by the ex vivo neutrophil transfer or by the cotransplantation with CD18WT HSCs would have 
reduced LSK cell content to normal levels and similar repopulation ability would have been observed in 
secondary recipients.  
 
CD18 deficiency may private BM cells from many signals coming from the extracellular matrix 
and the hematopoietic niche. On the one hand, β2 integrins can play a role as intracellular signal 
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transducers24. Ligand-induced clustering of the β2 integrins induces SFK activation, leading to the 
activation of important signalling molecules as PKC, ERK1/2 and Akt, which can regulate gene 
transcription. β2 integrin-induced SFK activation also regulates actin reorganization via Syk/Vav1/3 
pathway and many other molecules have been found to be directly associated with the β2 integrin 
intracellular region. On the other hand, the relationship between stem cells and their niches has been 
largely characterized. Stem cell niches regulate such important aspects as self-renewal, proliferation 
and survival189,192. Therefore, the lack of communication between CD18-defficent HSCs and the 
hematopoietic niche is sufficient to explain the deregulation in the HSC pool observed in the CD18HYP 
mice. HSC deregulation due to deficiencies in other adhesion molecules such as E-selectin183 or αII 
integrin193 have been previously reported, but our results constitute the first link between CD18 and 
HSCs.  
 
One of the bottlenecks for the ex vivo GT of some hematopoietic disorders is the availability of 
enough numbers of autologous HSCs. Patients with some genetic diseases, such as Fanconi anaemia, 
are characterised by a progressive loss of HSCs194 and current efforts have been focused on the early 
diagnosis of the disease aiming the collection of the HSCs before the patients develop the BM failure195. 
In the case of LAD, no relationship between β2 integrins and HSCs has been described in humans. For 
this reason, and on the basis of the results observed in CD18HYP mice, the study of HSC content in the 
BM of LAD-I patients would be highly relevant, as such a potential HSC enrichment in LAD-I patients 
would be very useful for the GT of these patients. 
 
In some PIDs such as X1-SCID or WAS, that have been successfully treated by ex vivo 
haematopoietic GT, corrected cells present a proliferative advantage over uncorrected ones. Thus, 
although a limited number of corrected cells engraft, these can overcome the non-corrected cells and 
residual defective haematopoiesis196,197.  The availability of a great number of autologous HSCs would 
be of special interest for the GT of LAD-I because a proliferative advantage of the corrected cells is not 
expected, except for corrected T cells (as described in HSCT and GT experiments in CLAD dogs64,141). 
 
2.  Gene Therapy for LAD-I 
 
LAD-I is a severe immunodeficiency disorder leading to the death of most of the patients within 
the first two years of their life, in the case of those patients with the severe phenotype. Despite the fact 
that allogeneic HSCT has resulted in survival rates from 71 to 91 %51,61-63, the access to HLA-matched 
donors is still a major limitation for this therapy. 
 
Haematopoietic ex vivo GT is a promising therapeutic approach for many genetic 
haematological and non-haematological disorders and a powerful alternative to the allogeneic HSCT. 
Indeed, in some diseases such as ADA-SCID, haematopoietic GT is currently considered an alternative to 
unrelated HSCT. Much research has been done in preclinical models in terms of efficacy and safety that 
has enabled GT to make a great leap forward and nowadays GT clinical trials have become a reality. 
Patients from different diseases such as X1-SCID, ADA-SCID, ALD, or WAS have actually benefited from 
this new approach84,99,197. The appearance of some cases of acute lymphoid leukaemia due to LTR-
mediated insertional oncogenesis has changed the vector of choice from γ-RVs to  LVs. The most 
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common form of insertional oncogenesis occurs when the vector is integrated close to a proto-
oncogene and the viral LTR is able to transactivate its expression. Some additional modifications have 
been made in the LV backbone to minimize its transactivation capacity. Among them, it is worth to 
point out the elimination of specific enhancer sequences in the LTR regions leading to the so-called SIN 
LVs. This modification requires the introduction of internal promoters with less transactivation capacity 
in the SIN LVs to drive the expression of the therapeutic transgene99. Moreover, LVs themselves have a 
safer integration profile than classical γ-RV. LVs do not integrate in regulatory regions but have a 
preference for integration into the body of genes, which lowers considerably the risk of genotoxicity as 
shown by different in vitro and in vivo studies114,198. Although there are other retroviral vectors derived 
from foamy viruses and α-retroviruses and even non-viral vectors such as transposons with a 
considered more random and safer integration profile123 that are being investigated for GT199-201, SIN 
LVs are nowadays the vector of choice for ex vivo hematopoietic GT. A great efficacy with a very good 
safety profile has been recently published for SIN LVs for the treatment of WAS90 and MLD98 and new 
LV-based GT clinical trials are currently on going for PIDs such as X-CGD, ADA-SCID and X1-SCID. 
Furthermore, LVs can be produced in large scale under GMP conditions, something that will be required 
for any hematopoietic GT clinical trial202. 
 
In the last few years, new approaches of GT have emerged based on gene editing, as an 
alternative to vector-mediated gene addition strategies. Gene editing is based on the modification of 
the cell genome taking advantage of the process of homologous recombination to correct a pathogenic 
mutation or to introduce a correct copy of the affected gene in a safe harbour. Many efforts have been 
made to improve the efficacy of gene editing but the use of engineered genetic scissors has allowed the 
huge boom that gene editing has experience over the last decade203,204. There is currently one clinical 
trial based on these technology which aims the disruption of the CCR5 gene in T cells as a new 
therapeutic approach for AIDS205 and the modification of human HSCs is still at a preclinical level206.  
 
For all these reasons, we have attempted to develop new GT approaches for LAD-I based on SIN 
LVs where hCD18 cDNA was expressed under the control of 4 different internal promoters. Two of 
them are ubiquitous promoters, the PGK and the UCOE promoter. As CD18 is expressed in all the 
leukocytes and in some populations of HCS and hematopoietic progenitors, the use of ubiquitous 
promoters will allow us to drive transgene expression in all the cells lacking CD18 expression as a 
consequence of ITGB2 mutations. Many data has been already published regarding the PGK promoter 
in preclinical GT studies95,207,208. In addition, a PGK LV has been recently used in the GT clinical trial for 
MLD98 and another is going to be used in a future clinical trial for Fanconi Anaemia95. SIN PGK γRV 
displayed a similar immortalization capacity than a full-length PGK γRV209 probably due to the presence 
of an enhancer sequence210. In addition, some authors described aberrant transcript arising from the 
antisense strand of the PGK-neomycin constructs intended for KO mice generation211,212. However, no 
transformation capacity was observed for the PGK promoter in the context of LVs by the in vitro 
immortalization assay114 and no clonal dominance has been observed in the MLD GT clinical trial, 
confirming the attractive safety profile of this promoter. The other ubiquitous promoter used to drive 
the expression of hCD18 was A2UCOE, which has several interesting features for GT. This promoter has 
been shown to be more resistant to epigenetic silencing than other frequently used promoters, such as 
SFFV, CMV or EF1α168; and to lack classic enhancer activity167, which in the context of GT vectors may be 
useful to reduce the risk of enhancer-mediated insertional oncogenesis. It has also been shown to 
provide relatively efficient therapeutic correction of different preclinical disease mouse models such as 
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X1-SCID167 and Recombination activating gene 2 (RAG2)-SCID213,   with no significant adverse effects. 
Furthermore, this promoter was also capable to confer resistance to epigenetic silencing to an adjacent 
promoter168,214. However, it has the potential to cause insertional mutagenesis through aberrant 
splicing, so a refined version has been designed recently215.  
 
The other two promoters used in this study are promoters preferentially active in myeloid cells. 
Although CD18 is expressed in all leukocytes, LAD-I is considered as a phagocytic disorder rather than a 
lymphocytic disorder. The use of myeloid promoters would thus induce a higher CD18 expression in the 
cell type that is most markedly affected in this disease. In the case of Chim promoter, it has been 
already used in the context of a SIN LV for the GT of a mouse model of X-CGD with very promising 
results115, based on which a new clinical trial will be carried out for the GT of X-CGD patients. Actually, 
two X-CGD patients have been already treated with this LV on a compassionate-use: The first one died 
early after the transplant because of complications not related to the gene therapy. In the second 
patient, neutrophil function recovery could be observed in vitro, although the patient died early after 
the transplant also due to a GT-unrelated complication (Personal communication, ESGCT 2014, The 
Hague).  
 
In these four hCD18-LVs, a WT sequence of the hCD18 cDNA has been included. Aditionally, we 
analysed hCD18 cDNA for coding optimization. Using OptimumGene codon optimization tool we 
obtained a codon adaptation index (CAI) of 0.84 for the WT sequence, which is very close to the optimal 
CAI (1). Although many authors have proposed the utilization of codon-optimised transgenes for 
GT207,216, other authors support the need of a deep safety analysis of codon optimised-constructs 
intended for clinical application217. 
 
We aimed to test these four hCD18-LVs in in vitro human LAD-I models. For this objective, we 
first took advantage of the ZJ cell line, which is a human lymphoblastoid cell line obtained by 
immortalization of B cells obtained from a LAD-I patient156. This cell line showed no detectable levels of 
β2 integrins in the cell membrane and has been previously used for CD18 transference studies 
132,134,135. 
Transduction of ZJ cells with increasing doses of LV:Chim.hCD18 resulted in the recovery of hCD18 and 
hCD11a membrane expression (Figure 39). Interestingly, surface expression levels of both subunits 
were rapidly saturated from the MOI of 10 vp/cell  onward. To investigate the effect of the transduction 
on the mRNA levels of both subunits, QPCR gene expression analysis were performed and thus it was 
possible to observe a progressive increment in the expression of hCD18 mRNA while no alteration of 
hCD11a mRNA levels was observed. All these results indicated that ectopic expression of hCD18 had no 
apparent impact on the endogenous regulation of CD11a expression. As CD18 has to be expressed in 
the membrane together with CD11 subunits, CD18 membrane expression got saturated by endogenous 
levels of CD11 proteins. 
 
Transduction of ZJ cells with each of the four hCD18-LVs (at a MOI of 10 vp/cell) resulted in full 
recovery not only of CD18 but also of CD11a subunit expression at a very similar VCN in all the cases 
(between 4 and 5.5; Figures 40A and 40B). When transduced ZJ cells were interrogated for CD18 
expression levels, no significant differences could be observed between these levels and the ones found 
in the GUS-1 cell line (a human WT LCL; Figure 40C). However, levels of CD18 membrane expression 
were significantly higher than those obtained for the MARK cell line, a WT LCL from a different donor. 
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This could be due to differences on CD18 expression between different individuals as it has been 
described that there are many factors that can alter the levels of expression of β2 integrins  such as life 
habits218, environmental factors219, traumatic processes220 and even diseases221,222. With each of the 
hCD18-LVs, transduced ZJ cells were able to aggregate in the presence of PMA and to bind to sICAM-1 
after Mg2+/EGTA activation (Figure 41 and 42). These results indicated that hCD18-LVs are able to 
restore β2 integrin expression and to correct LAD-I phenotype in a cell line derived from a patient. 
Similar recovery of PMA-dependent aggregation was shown for γ-RV-transduced ZJ cells by Wilson et 
al132,134 although the proportion of CD18+ cells was much lower in all the cases and FACS-sorted CD18+ 
cells were used for the functional assays. Moreover, this aggregation assay is not easily quantifiable so 
the utilization of the sICAM-1 binding assay provided a more objective and easy-to-measure 
information regarding the functionality of the β2 integrins. 
 
An ideal in vitro model for LAD-I GT would be the use of patient’s HSCs that could be transduced 
and then in vitro differentiated into neutrophils or even transplanted into immunodeficient mice. 
However, it is important to keep in mind that LAD-I is a very rare condition (around 350 patients have 
been diagnosed in Europe and, to our knowledge, there are no alive LAD-I patients in Spain up to date). 
In addition, BM aspirations are not routinely performed on these patients as this procedure is not 
required for the diagnosis or the follow-up of these patients. For these reasons, we aimed to generate 
LAD-I like human HSCs taking advantage of the RNA interference technology. This strategy has been 
previously used to generate human models to study the efficacy of GT for other diseases129,130. 
 
To this end, we used a previously reported LV construct171,172  to clone our shRNAs. After 
studying the efficacy of different constructs, a LV expressing a shRNA against the 3’ UTR region of the 
hCD18 mRNA (LV:sh10) was selected for the experiments because of its high efficiency. Transduction of 
healthy cord blood human CD34+ cells with this LV resulted in a 90% reduction of hCD18 expression 
levels determined by QPCR and by FACS, with a concomitant reduction in the hCD11a surface 
expression levels (Figure 44). β2 integrins are obligated heterodimers thus, although LV:sh10 
transduction did not alter hCD11a transcription, hCD11a cannot be expressed at the membrane without 
hCD18. The expression levels found on these LAD-I like HSCs (10 % of that found on control cells) 
allowed us to mimic HSCs obtained from LAD-I patients with the moderate phenotype.   
 
These LAD-I like HSCs were subsequently used to test the efficacy of the LV:Chim.hCD18 to 
correct the LAD-I like HSCS. Neutrophils were generated in vitro from these HSCs. LAD-I like neutrophils 
showed surface expression levels of CD18, CD11a and CD11b that were drastically reduced in 
comparison with control neutrophils (Figure 45). Moreover, LAD-I neutrophils showed defects in their 
functionality as seen in three different CD18-dependent assays: they were unable to properly bind to β2 
integrins’ ligands like ICAM-1 and fibrinogen and they could not mount a proper respiratory burst upon 
opsonised zymosan activation (Figures 48, 49 and 50).On the other hand, neutrophils derived from LAD-
I like HSCs that had been transduced with the therapeutical LV, showed partial recovery on CD18, 
CD11a and CD11b surface expression levels. As a consequence of this expression restoration, they 
showed improved capacity to bind to ICAM-1 and fibrinogen in comparison with uncorrected 
neutrophils and, moreover, full restoration of the ability to mount a respiratory burst in response to 
opsonized-zymosan (Figures 48, 49 and 50). These results pointed out that CD18-dependent adhesion 
and physical functions are more sensitive to CD18 expression levels while CD18-dependent signalling 
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functions (e.g. sensing the environment to mount a respiratory burst) only required a partial CD18 
expression to be run properly. In other GT clinical trials for diseases in which the affected protein is 
involved in signalling pathways (such as X1-SCID), very low transgene expression has been shown to be 
enough to correct the phenotype of the disease196. 
 
The fact that the therapeutic LV:chim.hCD18 was not able to restore more than 50% of the 
CD18 expression levels found in control cells could be explained by different reasons. Sh10 was 
designed to target the 3’ UTR of hCD18 mRNA, which is the mRNA sequence that immediately follows 
the translation termination codon and contains regulatory regions  involved in post-transcriptional gene 
expression. This strategy has the advantage that LV-mediated expression of hCD18 would not be 
recognised by the shRNA as the ectopic CD18 mRNA does not contain that region. However, regulatory 
motifs in UTRs are often conserved in genes belonging to the same family223. Actually, using the results 
received through BLAST analyses we can predict that the sh10 would potentially be able to recognise at 
least 6 human mRNAs. We hypothesize that  downregulation of some of these genes could be affecting 
the ability of hCD18 to be re-expressed in the membrane, limiting somehow the utility of this model. 
Although more recent and accurate tools like CRISPR-Cas9 genome editing could be used as an 
alternative to shRNAs to generate a LAD-I disease-model in primary mouse224 and human HSCs225, our 
results provide a human model to test our vectors in vitro.  
 
In vitro models are always very powerful tools for testing the efficacy of new therapeutic 
approaches and reduce the number of experimental animals. However, in vitro experiments cannot 
reproduce the complexity of a haematopoietic ex vivo GT protocol, so in vivo experiments are always 
required to finally assess its efficacy and safety. To test our hCD18-LVs we took advantage of the 
CD18HYP mouse model. Although CD18KO mice could appear as a good experimental model due to the 
absence of CD18 expression the fact that these animals are poor breeders make them problematic for 
these kind of experiments.  The CD18HYP mice behave as normal breeders and previous works75 and our 
own experiments demonstrated that CD18HYP mice had a sufficient phenotype to study the efficacy of 
the GT. 
 
BM-derived lin- cells, that is a population enriched in haematopoietic progenitors and HSCs, was 
selected as the target population for the gene transfer. These cells, once transduced and transplanted 
into irradiated animals, are able to repopulate the animals generating hematopoietic cells of all the 
lineages carrying the provirus integrated in their genomes. Although more primitive populations can be 
used as target cells, like lin-cKit+ cells226 or even LSK cells227, lin- cells are common target cells for 
haematopoietic ex vivo GT in mice95,149,196,207.  
 
First, we wanted to analyse the in vitro transduction process.  With this aim, freshly isolated lin- 
cells were transduced with the different hCD18-LVs and then differentiated towards the myeloid 
lineage for seven additional days. hCD18 was detected in every case, in a range between 30 and 40% 
(Figure 51). hCD18-LV transduction resulted in increased mCD11a surface expression levels which 
indicated that new β2 integrins were formed and transported to the membrane, consisting of hCD18 
and mCD11a subunits (Figure 52). These results indicated that hCD18 can be expressed in mouse 
haematopoietic cells, in concordance with previous works131,132, leading to the recovery of mCD11a 
expression in the cell membrane.  
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Leukocytes have been reported to develop an important posttranscriptional regulation of β2 
integrins both in vitro and in vivo, in response to a variety of stimuli such as cytokines, phorbol esters, 
and complement228. Neutrophils derived from transduced lin- cells did show upregulation of hCD18 
expression upon PMA stimulation (Figure 53), which pointed out that the ectopic hCD18 expression can 
be regulated in a physiological way in mouse hematopoietic cells.  
 
Finally, the toxicity of the transduction process was evaluated in a methylcellulose-based colony 
forming cell assays (Figure 54). No differences in the number of CFUs were observed among 
untransduced, GFP- or hCD18-transduced cells indicating that neither the LV-transduction or the 
ectopic hCD18 expression mediate a significant hematopoietic toxicity. Other therapeutic transgenes 
used in GT studies have been proposed to result in toxicity for transduced HSCs. This is the case of 
gp91phox (for the GT of X1-CGD), whose constitutive expression may lead to the inappropriate 
production of ROS, limiting their functionality or engraftment potential. However, there is no currently 
enough evidence supporting this hypothesis and expression of gp91phox and induction of intracellular 
ROS in HSCs has to be studied in more detail88. 
 
Once we had checked that hCD18-LVs were able to efficiently transduce CD18HYP lin- cells, we 
moved to the ex vivo GT experiments. Freshly-isolated lin- cells were transduced at low MOI and 
transplanted into lethally irradiated CD18HYP mice. After transplantation of transduced cells, hCD18+ 
cells could be detected in the PB of all the GT-treated animals. hCD18 was co-expressed with the three 
murine CD11 subunits (mCD11a, mCD11b, mCD11c; Figure 55). A similar proportion of hCD18+ mCD11a+ 
cells was observed in all the GT-treated mice at 1 and 3 mpt, in a range between 14 and 44%; (Figure 
56A). Interestingly, these animals expressed higher levels of mCD11a in comparison with mice 
transplanted with LV:SFFV.eGFP-transduced CD18HYP cells (Figure 57). This increment was very similar in 
all the groups and led to the recovery of 50% of the levels found in control mice transplanted with 
CD18WT cells. The increased expression of mCD11a resulted from the formation of new chimeric β2-
integrins composed by the association of hCD18 and mCD11a as observed in vitro. At the end of the 
experiment similar levels of hCD18+/mCD11a+ cells and a comparable upregulation of mCD11a 
expression was found in the BM of ex vivo GT-treated CD18HYP mice (Figure 59). 
 
hCD18 was expressed in T cells, B cells and neutrophils (Figure 58A), despite of the promoter 
used to drive the expression of the therapeutic transgene. As mentioned before, Chim and MIM have 
been proposed as myeloid-specific promoters. However, when the Chim promoter was first described 
by Santilli et al115, it was observed that this promoter was actived both in lymphoid and non-
hematopoietic cell lines, although at a lower level as compared to that observed in myeloid cells. A 
similar behaviour was observed for the MIM promoter, both in vitro and in vivo (Personal 
Communication). In our experiments, when PB cells were interrogated for hCD18 expression levels, it 
was possible to observe that neutrophils always showed higher hCD18 levels than B and T cells, as 
happens with the physiological mCD18 expression in these cells. This was observed in all GT-treated 
mice, no matter the nature of the promoter used to regulate the expression of hCD18. However, the 
ratio between the myeloid and lymphoid hCD18 expression was higher in cells that have been 
transduced with the LV:Chim.hCD18 group, which thus closely mimicked the physiological CD18 
expression pattern (Figure 58C). 
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CD18 is expressed in most leukocytes and play other roles outside the LAC. LFA-1 is essential in 
the immune synapse formation since it enables a maintained contact between T cells and APCs and 
initiates a signalling pathway leading to the decrease of the T cell activation threshold. In addition, LFA-
1  has been implicated in the cytolitic function of CD8+ T cells and NK cells24. Lymphocytes from LAD-I 
patients show impaired in vitro proliferation and blastogenesis. Nevertheless the role that CD18 
deficiency in lymphocytes plays in the pathogenesis of LAD-I is still unknown43. LAD-I symptomatology 
has been associated with defects on neutrophil function41. CD18-defficient neutrophils fail to 
extravasate from the blood flow while lymphocytes can take advantage of other adhesion molecules42. 
For that reason, we believe that a promoter driven expression of hCD18 in all haematopoietic lineages, 
though with high levels of expression in neutrophils would be ideal for the GT of LAD-I. 
 
Our results confirm for the first time that hCD18 can be expressed in vivo in CD18HYP 
hematopoietic cells after LV-mediated GT. Previous studies showed that hCD18 can be expressed after 
γRV-mediated ex vivo hematopoietic GT in C3H/HeJ mice (a general purpose mouse strain with WT 
mCD18 expression)133. A similar pattern of hCD18 expression was observed in this previous work, where 
neutrophils expressed higher hCD18 levels than lymphocytes.  
 
Safety is a major concern in the GT field. In the first GT clinical trials, several cases of T-ALL and 
MDS took place as a consequence of LTR-mediated insertional oncogenesis120,121,229,230. New SIN-LVs 
have a safer integration profile and have shown to be safer than classical γ-RVs. However, insertional 
oncogenesis is still possible, and safety has to be always evaluated for the new vectors. For that reason, 
secondary transplants are commonly performed in GT experiments as a powerful tool to detect 
possible leukemogenic events and, in addition, to study the long-term expression of the therapeutic 
transgene. 
 
In secondary recipients, hCD18+/mCD11a+ cells were observed in a range from 8 to 32% (Figure 
56B). In all the cases, this percentage was lower in comparison with primary recipients from the same 
group, except in the case of the MIM group. However, similar upregulation of mCD11a in hCD18+ cells 
of these animals was observed to that found in primary recipients (Figure 57). The reduction in cells 
expressing therapeutic or reporter transgenes in secondary recipients has been described in previous 
experiments115,231 in mice and it is more related to the exhaustion of hematopoietic reconstitution 
capacity of transduced cells after the secondary transplant than to a process of epigenetic silencing of 
the promoters. Actually, replication stress has been associated to the functional exhaustion of mouse 
HSCs232. The four different promoters that have been used in this work to drive the expression of hCD18 
are physiological and eukaryotic promoters that are less prone to be silenced167,233 in comparison with 
other viral promoters such as CMV or SFFV.  This fact was confirmed in the VCN determination (Table 
17), where it was possible to observe a reduction in the VCN of PBLs from primary recipients (0.9 – 0.4) 
in comparison with secondary recipients (0.6 – 0.3). No evidences of leukemia were noted in GT-treated 
mice since normal WBC counts (Figure 62) and normal multilineage distribution (Figure 61) were 
routinely observed even in secondary recipients. 
 
Different important aspects can be concluded from these results: First, hCD18-LVs are able to 
transduce true LT-HSCs as transgene expression was observed in secondary recipients even at 9 mpt. 
Second, manipulation of mouse hematopoietic stem cells with hCD18-LVs seemed to be a safe GT 
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approach, with no appearance of multicopy insertions or signs of malignant transformation. Despite of 
this preliminary safety analysis, other kind of studies remained to be performed, including the study of 
the integration pattern and the clonal distribution, the biodistribution of hCD18-LV-transduced cells or 
the absence of replicative competent lentiviral particles in the ex vivo GT-treated animals. 
 
In GT experiments, it is crucial not only to demonstrate that LVs are able to induce the 
expression of  the therapeutic transgene, but  also that this expression has a major impact on the 
phenotype of the disease. To evaluate the efficacy of the hCD18-LV-mediated GT in the correction of 
the LAD-I phenotype in CD18HYP mice, we analysed neutrophil migration capacity in the two 
inflammation scenarios used to characterise this mouse model; the TNFα-induced air pouch 
inflammation model and the LPS-induced pulmonary inflammation model(Figures 63 and 64). In both of 
them, ex vivo GT-treated animals showed similar neutrophil migration than WT controls indicating the 
recovery of the migration capacity of the donor neutrophils.  It is important to highlight that our data 
show for the first time that GT restores in vivo functional defects associated to CD18 deficiency. 
 
In summary, we have demonstrated in different in vitro human and in vivo mouse models the 
safety and the efficacy of the use of hCD18-LVs to correct different alterations in the leukocyte function 
associated to CD18 deficiency. These results, together with the on-going integration pattern analyses 
allow us to propose that a GT trial based on the use of LVs for the GT of human LAD-I patients would be 
reasonable. To our knowledge, there is only another group working in the GT of LAD-I in the Center for 
Cancer Research (Bethesda, USA). They had developed several LV and FVs containing different internal 
promoters to drive the expression of cCD18 and they have tested them in the CLAD model. While 
cCD18-FV expressing cCD18 from MSCV or PGK promoter succeeded in the correction of CLAD, more 
modest results were obtained with LVs expressing the therapeutic transgene from physiological 
promoters such as PGK or EF1a, or even when using fragments of the promoter regions of the human 
genes encoding for CD18 or CD11b. In these experiments, CD34+ cells were transduced at a very low 
MOI and animals received a RIC regimen145-147, which could explain the failure observed on these 
experiments.  
 
Although it has been shown that RIC is sufficient to allow the engraftment of corrected cells 
leading to the reversion of the phenotype in GT experiments conducted in CLAD-affected dogs64,66, we 
believe that the use of full-myeloablative conditioning will be required for the efficient LAD-I GT  due to 
the absence of selective advantage of corrected cells. This is the case of other myeloid 
immunodeficiencies such as X-CGD88.  
 
CLAD GT experiments pointed out that high CD18 expression levels are required to correct the 
disease phenotype. One way to achieve high levels of transgene expression is based on the use of a 
very strong promoter like the MSCV promoter/enhancer. Although no clonal dominance or malignant 
transformation has been observed in the long-term follow up of the MSCV-FV-treated CLAD dogs, the 
use of such a strong promoter would not be desirable according to the standards currently applied in 
human GT and it is not easily accepted by the regulatory agencies. Therefore, we believe that the use of 
moderate MOI of LVs (20 – 50 vp/cell) in which the expression of hCD18 is driven by a more 
physiological promoter would be desirable to achieve required transgene expression levels to correct 
the phenotype of the disease. Recent data from the MLD GT clinical trial, in which a PGK-LV was used to 
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achieve a supraphysiological expression of the therapeutic transgene, has shown that there is no 
increment in the genotoxic risk when LVs are used at a high MOI98. 
 
The use of large animal models for the preclinical evaluation of new GT vectors has been 
proposed by many authors234,235. It has been described that approximately 75% of mouse HSCs are 
outside G0 and that mouse HSCs divide every 2.5 weeks. In contrast, studies in non-humane primates 
indicate that HSCs from these animals are more quiescent and divide approximately every 36 weeks, 
more similar to human HSCs, which are estimated to divide every 45 weeks. As a next step in the 
preclinical development of our hCD18-LVs, the use of CLAD-affected dogs or humanised mice 
transplanted with LAD-I patient cells could de considered, although for many GT studies, mice are 
considered as good predictor of the efficacy and safety in humans and preclinical research in mouse 
model is currently enough for the approval by the regulatory agencies.   
 
FVs have several important advantages for GT. Foamyviruses are endemic in non-human 
primates and other mammals, but have not been observed in humans except in cases of benign 
zoonosis. FVs have a large packing capacity, broad host and cell-type tropism and an attractive safe 
integration profile relative to γRVs and LVs as it is considered almost random236. Moreover, 
transduction efficiencies of FV vectors in HSCs are comparable to those of LVs237. Despite all these 
characteristics that made FVs very good GT vectors, there is no clinical experience with FVs and the low 
titer of FV currently limits their utilization in large-scale GT238.  On the other hand, LVs are already used 
in the clinics, can be easily produced at a large scale under GMP conditions and have an enough safety 
profile, so the development of new hematopoietic GT strategies based on LVs will become more rapidly 
a reality for patients with severe diseases like LAD-I. 
 
The preclinical results obtained in this study allow us to propose the LV:Chim.hCD18 as a good 
candidate for LAD-I ex vivo hematopoietic GT. It is clear that a promoter driving a high expression of the 
therapeutic transgene in the myeloid lineage, but with some activity in the lymphoid lineage and in 
hematopoietic progenitors and stem cells, is a very good choice for LAD-I. In addition, the 
LV:Chim.hCD18 is the LV that had led to the best and more consistent results in different in vivo 
experiments. Pending from the integration profile study, we are currently drafting the application for 
orphan drug designation for which we fulfill all the criteria currently required to achieve this 
designation. We have many research and clinical European collaborators in the fields of GT and PIDs 
that would be interested in participate in a future LAD-I GT clinical trial. Although HSCT is nowadays the 
only curative therapy for LAD-I, GT may become a good alternative for those patients with the severe 
phenotype which, because of their low life expectancy, do not have enough time to find a compatible 
donor.  
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1. CD18HYP mice recapitulate the characteristics and symptoms of the moderate form of LAD-I 
disease in humans. 
 
2. CD18HYP mice show an increased content of quiescent HSCs in BM, in comparison with 
CD18WT mice.  
 
3. CD18HYP mice show an increased proportion of aged neutrophils in PB. However, this 
phenomenon does not account for the increment of BM HSCs in this animal model.  
 
4. Competitive repopulation experiments of CD18HYP and CD18WT BM cells demonstrate that 
CD18 deficiency leads to a self-autonomous expansion of mouse HSCs. 
 
5. We have generated new LVs expressing the hCD18 cDNA under the regulation of the PGK, 
UCOE, Chim and MIM promoters. 
 
6. All the hCD18-LVs generated in this study promote the ectopic expression of hCD18 and 
also the endogenous expression of hCD11a in the membrane of LAD-I lymphoblastoid cells and mediate 
the phenotypic correction of these cells. 
 
7. LAD-I like neutrophils have been generated by the transduction of human CD34+ cells with 
a LV expressing a specific anti-hCD18 shRNA, showing defects in a variety of CD18-dependent functions. 
 
8.  LAD-I like HSCs recover almost a 50% of WT hCD18 expression after transduction with  the 
LV:Chim.hCD18. Neutrophils generated from these corrected LAD-I like HSCs show improved ability to 
bind β2-integrin ligands and restored ability to undergo a respiratory burst. 
 
9. Haematopoietic cells from ex vivo GT-treated mice expressed with a concomitant 
increment of endogenous mCD11a expression in the membrane of these cells. In addition, these 
animals recover normal numbers of leukocytes in PB and neutrophil extravasation in response to 
inflammatory stimuli. 
 
10. Taken together, our work constitutes the first preclinical GT study conducted in a LAD-I 
mouse model with new therapeutic LVs designed for clinical application. Based on the results obtained 
in our study, the LV:Chim.hCD18 will be proposed for a future GT clinical trial of LAD-I patients.  
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1. Los ratones CD18 HYP recapitulan las características y síntomas del fenotipo moderado de la 
enfermedad denominada deficiencia de adhesión leucocitaria tipo I (DAL-I) en humanos. 
 
2. Los ratones CD18HYP muestran un incremento en el contenido de células madre 
hematopoyéticas (CMHs) quiescentes en la médula ósea en comparación con ratones CD18WT. 
 
3. Los ratones CD18HYP muestran una mayor proporción de neutrófilos envejecidos en sangre 
periférica. Sin embargo, este fenómeno no justifica el incremento de CMHs en la médula ósea de este 
modelo animal.  
 
4. Los experimentos de repoblación competitiva con células de médula ósea procedentes de 
ratones CD18HYP y CD18WT demuestran que la deficiencia en CD18 produce una expansión autónoma de 
las CMHs de ratón. 
 
5. Se han desarrollado cuatro vectores lentivirales (VLs) que expresan la proteína CD18 
humana bajo el control de los promotores PGK, UCOE, Chim y MIM. 
 
6. Los cuatro VLs-hCD18 generados en este estudio promueven la expresión ectópica de 
hCD18 así como la expresión endógena de hCD11a en la membrana de células linfoblastoides DAL-I, lo 
que resulta en la corrección del fenotipo característico de estas células.  
 
7. Se han generado neutrófilos “semejantes a DAL-I” mediante la transducción de células 
CD34+ humanas con un VL que expresa un ARNsh específico anti-hCD18, los cuales muestran defectos 
en diferentes funciones celulares dependientes de hCD18.  
 
8. Las CMHs “semejantes a DAL-I” recuperan el 50% de la expresión WT de hCD18 cuando son 
transducidas con el VL:Chim.hCD18. Los neutrófilos generados a partir de estas CMHs “semejantes a 
DAL-I” corregidas muestran una mejoría en la capacidad de unirse a ligandos de integrinas β2 y una 
recuperación de la capacidad para producir un estallido respiratorio normal. 
 
9. Las células hematopoyéticas de ratones CD18HYP tratados por terapia génica (TG) muestran 
expresión de hCD18 en la membrana con una concomitante recuperación de la expresión endógena en 
membrana de mCD11a. Además recuperan valores normales de leucocitos en sangre periférica y la 
capacidad de extravasación de los neutrófilos en respuesta a diferentes estímulos inflamatorios. 
 
10. En conjunto, nuestro trabajo constituye el primer estudio preclínico de TG en un modelo 
de ratón de DAL-I  con nuevos VLs terapéuticos diseñados para su aplicación clínica. Teniendo en cuenta  
los resultados obtenidos en este estudio, el VL:Chim.hCD18 será propuesto para un futuro ensayo 
clínico de TG para pacientes con DAL-I.  
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Table S1. List of monoclonal antibodies used for flow cytometry and cell sorting 
 
Purpose Reactivity Antigen Conjugation Vendor Catalog # Clone 
PB and BM murine β2 
integrin expression 
Mouse CD18 FITC BD Pharmingen 553292 C71/16 
Mouse CD11a PE-Cy7 BD Pharmingen 558191 2D7 
Mouse CD11b PE BD Pharmingen 553311 M1/70 
Mouse CD11c APC BD Pharmingen 550261 HL3 
Mouse CD3 PE BD Pharmingen 553064 145-2C11 
Mouse CD45R/B220 PE BD Pharmingen 553090 RA3-6B2 
Mouse GR1 FITC BD Pharmingen 553128 RB6-8C5 
Lin- sorting 
Mouse CD11b FITC BioLegend 101206 M1/70 
Mouse CD45R/B220 FITC Southern 1665-02 RA3-6B2 
Mouse CD3 FITC BD Pharmingen 553062 145-2C11 
Mouse GR1 FITC BD Pharmingen 553127 RB6-8C5 
Mouse Ter119 FITC eBioscience 11-5921 Ter119 
LSK content and 
sorting 
Mouse CD11b FITC BioLegend 101206 M1/70 
Mouse CD45R/B220 FITC Southern 1665-02 RA3-6B2 
Mouse CD3 FITC BD Pharmingen 553062 145-2C11 
Mouse GR1 FITC BD Pharmingen 553127 RB6-8C5 
Mouse Ter119 FITC eBioscience 11-5921 Ter119 
Mouse CD117/cKit PE-Cy7 BD Pharmingen 558163 2B8 
Mouse Sca1 PE BD Pharmingen 553336 E13-161.7 
LSK Cell Cycle status 
 
Mouse CD11b FITC BioLegend 101206 M1/70 
Mouse CD45R/B220 FITC Southern 1665-02 RA3-6B2 
Mouse CD3 FITC BD Pharmingen 553062 145-2C11 
Mouse Gr1 FITC BD Pharmingen 553127 RB6-8C5 
Mouse Ter119 FITC eBioscience 11-5921 Ter119 
Mouse CD117/cKit PE-Cy5 eBioscience 15-1171 2B8 
Mouse Sca1 PE BD Pharmingen 553336 E13-161.7 
Hematopoietic 
progenitors Analysis 
 
Mouse CD3 Biotin BD Pharmingen 553060 145-2C11 
Mouse Gr1 Biotin BD Pharmingen 553127 RB6-8C5 
Mouse CD11b Biotin BD Pharmingen 553309 M1/70 
Mouse CD45R/B220 Biotin BD Pharmingen 553086 RA3-6B2 
Mouse Ter119 Biotin BD Pharmingen 553672 Ter119 
- Biotin A350 Molecular Probes S11249 - 
Mouse CD117/cKit PE BD Pharmingen 553355 2B8 
Mouse Sca1 APC-Cy7 BioLegend 108125 D7 
Mouse CD34 FITC eBioscience 11-0341 RAM34 
Mouse CD150 APC BioLegend 115910 TC15-12F12.2 
Mouse CD135 PE BD Pharmingen 553842 ASF10.1 
Mouse CD16/32 
PerCP-
eFluor 710 
eBioscience 46-0161 93 
LSK Integrin Analysis 
 
Mouse CD3 Biotin BD Pharmingen 553060 145-2C11 
Mouse Gr1 Biotin BD Pharmingen 553127 RB6-8C5 
Mouse Mac1 Biotin BD Pharmingen 553309 M1/70 
Mouse CD45R/B220 Biotin BD Pharmingen 553086 RA3-6B2 
Mouse Ter119 Biotin BD Pharmingen 553672 Ter119 
- Biotin A350 Molecular Probes S11249 - 
Mouse CD117/cKit PE BD Pharmingen 553355 2B8 
Mouse CD117/cKit PE-Cy7 BD Pharmingen 558163 2B8 
Mouse Sca1 APC-Cy7 BioLegend 108125 D7 
Mouse CD18 FITC BD Pharmingen 553292 C71/16 
Mouse CD11a APC BD Pharmingen 550261 HL3 
Mouse CD29 A488 ABD Serotec MCA2298A488 HM BETA 1-1 
Mouse CD49d PE BD Pharmingen 557420 9C10(MFR4.B) 
PB aged neutrophils 
Analysis 
Mouse CD184/CXCR4 PE eBioscience 12-9991-81 2B11 
Mouse CD62L FITC BD Pharmingen 553150 MEL14 
Mouse Gr1 Biotin BD Pharmingen 553125 RB6-8C5 
CRA 
Human CD4 PE Miltenyi 130-098-134 MT-466 
Mouse CD45.1/Ly5.1 PE BioLegend 110708 A20 
Mouse CD45.2/Ly5.2 FITC BioLegend 109806 104 
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LDA 
Mouse CD45.2/Ly5.2 FITC BioLegend 109806 104 
Mouse CD3 PE-Cy5 BD Pharmingen 553065 145-2C11 
Mouse CD45R/B220 PE BD Pharmingen 553090 RA3-6B2 
Mouse Gr1 PE BD Pharmingen 553128 RB6-8C5 
Mouse CD11b Biotin BD Pharmingen 553309 M1/70 
- Biotin PECy7 Molecular Probes SA1012 - 
hCD18/hCD11a 
expression in LCLs 
Human CD18 APC BD Pharmingen 551060 6.7 
Human CD11a PE-Cy5 BD Pharmingen 551131 HI111 
sICAM-1 binding 
Assay 
Human Fc IgG PE eBioscience 12-4998-82 Polyclonal 
Ex vivo GT 
experiments: 
hCD18 and mCD11 
subunits co-
expression 
Human CD18 APC BD Pharmingen 551060 6.7 
Human CD18 FITC BioLegend 302106 TS1.18 
Mouse CD11a PE-Cy7 BD Pharmingen 558191 2D7 
Mouse CD11b PE BD Pharmingen 553311 M1/70 
Mouse CD11c APC BD Pharmingen 550261 HL3 
Ex vivo GT 
experiments: 
hCD18 expression in 
different leukocyte 
subpopulations 
Human CD18 APC BD Pharmingen 551060 6.7 
Mouse CD3 PE BD Pharmingen 553064 145-2C11 
Mouse CD3 FITC BD Pharmingen 553062 145-2C11 
Mouse CD45R/B220 PE BD Pharmingen 553090 RA3-6B2 
Mouse GR1 FITC BD Pharmingen 553128 RB6-8C5 
Mouse CD11b FITC BioLegend 101206 M1/70 
Ex vivo GT 
experiments: 
hCD18 expression in 
BM LSK cells 
Human CD18 APC BD Pharmingen 551060 6.7 
Mouse CD3 Biotin BD Pharmingen 553060 145-2C11 
Mouse Gr1 Biotin BD Pharmingen 553127 RB6-8C5 
Mouse Mac1 Biotin BD Pharmingen 553309 M1/70 
Mouse CD45R/B220 Biotin BD Pharmingen 553086 RA3-6B2 
Mouse Ter119 Biotin BD Pharmingen 553672 Ter119 
Mouse CD117/cKit     
Mouse Sca1     
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Figure S1. Cloning strategy followed to generate the pCCL.PGK.CD18.Wpre* plasmid. 
 
 
 
 
 
Figure S2. Cloning strategy followed to generate the pCCL.Chim.CD18.Wpre* plasmid. 
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Figure S3. Cloning strategy followed to generate the pCCL.MIM.CD18.Wpre* plasmid. 
 
 
Figure S4. Cloning strategy followed to generate the pCCL.A2UCOE.CD18.Wpre* plasmid. 
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Figure S5. Cloning strategy followed to construct the lentiviral backbones containing the shRNA expression cassette. 
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